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NOTES
1. All the temperatures are expressed in degree centigrade
(0C).
2. Melting Points of all the compounds are uncorrected and
have been recorded by open capillary method.
3. Room temperature, wherever mentioned, normally corresponds
to 280 to 33 0C.
4. Silica gel-G was used for preparing the TLC plates using
different solvent systems.
5. Infra Red spectrum  of all the compounds were scanned on
SHIMADZU-FOURIER TRANSFORM INFRA RED(FTIR) -
8400 SPECTROPHOTOMETER using KBr disc.
6. 1HNMR Spectra were recorded on BRUKER SPECTROPHO
TOMETER (400 MHz) using TMS as a internal standard and
CDCI3 and DMSO-d6 as solvents.
7. MASS spectrum were recorded on SHIMADZU-GCMS-QC-
2010.
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 A brief summary of the work to be incorporated in the thesis entitled 
“STUDIES ON BIOLOGICALLY ACTIVE SYNTHETIC COMPOUNDS” has 
been summarized as under. 
 
(I) STUDIES ON PYRIMIDINES 
 
(II) STUDIES ON QUINOLINES 
 
 
(I) STUDIES ON PYRIMIDINES 
 
PART - I :  STUDIES ON PYRIMIDINES 
 Pyrimidines represent one of the most active classes of compounds 
possessing a wide spectrum of biological activities viz., significant in vitro 
activity against unrelated DNA and RNA viruses including Polio and Herpes 
viruses, diuretics, antitubercular, antihypertensive. Some pyrimidines, which 
occurs as natural products like nucleic acids and vitamin-B  can be used as 
therapeutic agents for the treatment of AIDS and antitumor. In view of getting 
better theraputic agent of pyrimidines it was thought worthwhile to synthesize 
some newer pyrimidine derivatives which can be summarized as below. 
 
SECTION-I : Preparation and biological evaluation of 5-[N-(substituted-
phenyl)]-carboxamido-1,2,3,4-tetrahydro-6-methyl-2-oxo-4-(m-phenoxyp-
henyl)-pyrimidines. 
O
O
NH
N O
H
CH3
NH
R
 
              (Ia-j) 
R = Substituted Phenyl 
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 5-[N-(substitutedphenyl)]-carboxamido-1,2,3,4-tetrahydro-6-methyl-2-
oxo-(m-phenoxyphenyl)-pyrimidines (Ia-j) have been synthesized by the 
conden-sation of m-phenoxy benzaldehyde, substituted-N-phenylbutanamide-
3-ones and urea in the presence of catalytic amount of con. acid. 
 
SECTION-II : Preparation and biological evaluation of 5-[ N-(substituted-
phenyl)]-caboxamido-1,2,3,4-tetrahydro-6-methyl-4-(m-phenoxyphenyl)-
2-thioxopyrimidines. 
 
O
O
NH
N
H
SCH3
NH
R
 
(IIa-j) 
                                                    R=Substituted Phenyl 
5-[ N-(substitutedphenyl)]-caboxamido-1,2,3,4-tetrahydro-6-methyl-4-
(m-phenoxyphenyl)-2-thioxo-pyrimidines (IIa-j) have been synthesized by the 
conden-sation of m-phenoxy benzaldehyde, substituted-N-phenylbutanamide-
3-ones and thiourea in the presence of catalytic amount of con. acid. 
 
SECTION-III : Preparation and biological evaluation of 5-[ N-(substituted-
phenyl)]-caboxamido- 1,2,3,6-tetrahydro-1,4-dimethyl-2-oxo-6-(m-pheno-
xyphenyl)-pyrimidines. 
O
O
N
N
H
O
CH3
CH3
NH
R
 
                                                                (IIIa-j)           
     R = Substituted Phenyl 
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5-[ N-(substitutedphenyl)]-caboxamido- 1,2,3,6-tetrahydro-1,4-dimethyl-
2-oxo-6-(m-phenoxyphenyl)-pyrimidines (IIIa-j) have been synthesized by the 
condensation of m-phenoxy benzaldehyde, substituted-N-phenylbutanamide-
3-ones and N-methyl urea in the presence of catalytic amount of con. acid. 
 
SECTION-IV : Preparation and biological evaluation 5-[ N-(substitutedph-
enyl)]-carboxamido-1,2,3,4-tetrahydro-6-isopropyl-2-oxo-4-(m-phenoxyp-
henyl)-pyrimidines. 
O
O
NH
N
H
O
NH
CH3
CH3
R
                                               
(IVa-j) 
                                             R= Substituted Phenyl 
5-[N-(substitutedphenyl)]-carboxamido-1,2,3,4-tetrahydro-6-isopropyl-
2-oxo-4-(m-phenoxyphenyl)-pyrimidines (IVa-j) have been synthesized by the 
condensation of m-phenoxy benzaldehyde, 4-methyl-N-substitutedphenyl-3-
oxopentanamides and  urea in the presence of catalytic amount of con. acid. 
 
SECTION-V : Preparation and biological evaluation 5-[N-(substitutedph-
enyl)]-carboxamido-1,2,3,4-tetrahydro-6-isopropyl-4-(m-phenoxyphenyl)-
2-thioxopyrimidines. 
O
O
NH
N
H
S
CH3
CH3
NH
R
 
          (Va-j) 
              R= Substituted Phenyl 
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5-[ N-(substitutedphenyl)]-carboxamido-1,2,3,4-tetrahydro-6-isopropyl-
4-(m-phenoxyphenyl)-2-thioxopyrimidines (Va-j) have been synthesized by the 
condensation of m-phenoxy benzaldehyde, 4-methyl-N-substitutedphenyl-3-
oxopentanamides and  thiourea in the presence of catalytic amount of con. 
acid. 
 
SECTION-VI : Preparation and biological evaluation of 5-[N-(substituted-
phenyl)]-carboxamido -1,2,3,6-tetrahydro-4-isopropyl-1-methyl-2-oxo-6-
(m-phenoxyphenyl)pyrimidines. 
O
O
N
N
H
O
CH3
CH3
NH
CH3
R
 
(VIa-j) 
                                                      R=Substituted Phenyl 
5-[N-(substituted-phenyl)]-carboxamido-1,2,3,6-tetrahydro-4-isopropyl-
1-methyl-2-oxo-6-(m-phenoxyphenyl)-pyrimidines (VIa-j) have been synthesiz-
ed by the condensation of m-phenoxy benzaldehyde, 4-methyl-N-substituted-
phenyl-3-oxopentanamides and  N-methyl urea in the presence of catalytic 
amount of con. acid. 
 
(II) STUDIES ON QUINOLINES 
 
PART- II :  STUDIES ON QUINOLINES 
  
 Quinolines exhibit a wide spectrum of pharmacological profile such as 
antibacterial, antitubercular, antitumour, non-nucleoside inhibitors of human 
cytomeglao virus, new CB-2 cannabinoid receptors antagonists,antimalarials 
,antifungal, anti-inflammatory. Due to the various biological activities of 
quinolines, an attempt has been made to undertake the synthesis of 
quinolines as below 
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SECTION-I : Preparation and biological evaluation of 6-Chloro/fluoro/nit-
ro-N-cyclopropyl-2-(4-chloro/fluoro/methylphenyl)quinoline-4-carboxam-
ides. 
R
O
N
R1
NH
 
                                                (VIIa-i) 
                            R,R1 = Substituted Phenyl 
6-Chloro/fluoro/nitro-N-cyclopropyl-2-(4-chloro/fluoro/methylphenyl)qui-
noline-4-carboxamides (VIIa-j) have been synthesized by the condensation of 
6-chloro/fluoro/nitro-2-(4-chloro/fluoro/methylphenyl)quinoline-4-carbonyl 
chloride and cyclopropylamine in presense of basic medium. 
 
SECTION-II : Preparation and biological evaluation of 6-Chloro/fluoro/nit-
ro-N-pentyl-2-(4-chloro/fluoro/methylphenyl)quinoline-4-carboxamides. 
 
O
N
NH
CH3
R
R1
 
                                   (VIIIa-i) 
                        R,R1 = Substituted Phenyl 
6-Chloro/fluoro/nitro-N-pentyl-2-(4-chloro/fluoro/methylphenyl)quinolin-
e-4-carboxamides (VIIIa-j) have been synthesized by the condensation of 6-
chloro/fluoro/nitro-2-(4-chloro/fluoro/methylphenyl)quinoline-4-carbonyl chlori-
de and n-pentylamine in presence of basic medium. 
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SECTION-III : Preparation and biological evaluation of Di-(amino butyl)/ 
di-(aminopropynyl)/N,N-diethyl/ N-ethyl piperazinyl/ N-methyl piperaziny-
l/ morphonilyl/ piperidinyl/ N-phenyl piperizinyl/pyrolidinyl-6-fluro-2-(4-
fluorophenyl)-quinoline-4-carboxamides. 
 
N
F
O
F
R
 
                                                  (IXa-i) 
                                               R=Substituted phenyl 
 
 Di-(amino butyl)/ di-(aminopropynyl)/N,N-diethyl/ N-ethyl piperazinyl/ N-
methyl piperazinyl/ morphonilyl/ piperidinyl/ N-phenyl piperizinyl/pyrolidinyl-6-
fluro-2-(4-fluorophenyl)quinoline-4-carboxamides (IXa-i) have been synthesiz-
ed by the condensation of 6-fluoro-2-(4-fluoro)quinoline-4-carbonyl chloride 
and Di-n-propylamine/ Di butylamine/ N,N-diethyl amine/N-ethyl piperazine/ 
N-methyl piperazine/ morpholine/  piperadine/  N-benzyl piperazine/ pyrrol-
idine. 
SECTION-IV : Preparation and biological evaluation of 5-[6-Chloro/fluor-
o/nitro-2-(4-chloro/fluoro/methylphenyl)quinolin-4-yl]-1,3,4-oxadiazole-2-
thiols. 
N O
N
N
SH
R1
R
 
                                                 (Xa-i) 
                           R, R1 = Substituted Phenyl 
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5-[6-chloro/fluoro/nitro-2-(4-chloro/fluoro/methylphenyl)quinolin-4-yl]-
1,3,4-oxadiazole-2-thiols (Xa-i) have  been synthesized by the condensation of 
6-chloro/fluoro/nitro-2-(4-chloro/fluoro/methylphenyl)quinolin-4-carbohyd-
razides and a mixture of carbon disulphide and potassium hydroxide in 
presence of basic medium. 
 
SECTION-V : Preparation and biological evaluation of 4-Amino-5-[6-chlo-
ro/fluoro/nitro-2-(4-chloro/fluoro/methylphenyl)quinolin-4-yl]-4H-1,2,4-tr-
iazole-3-thiols. 
N N
N
N
SH
R1
NH2
R
 
(XIa-i) 
                                R, R1 = Substituted Phenyl 
 
4-Amino-5-[6-chloro/fluoro/nitro-2-(4-chloro/fluoro/methylphenyl)-quino-
lin-4-yl]-4H-1,2,4-triazole-3-thiols (XIa-j )have been synthesized by the cyclo-
condensation of 6-chloro/fluoro/nitro-2-(4-chloro/fluoro/methylphenyl)quinolin-
4-carbohydrazides, carbon disulphide and potassium hydroxide followed by 
the action of hydrazine hydrate. 
 
PURIFICATION AND STURCTURAL CHARACTRISATION: 
 
 The purity of all compounds (Ia-j - XIa-i) have been screened by thin 
layer chromatography using two different solvent systems (Rf1 & Rf2). The 
constitution of newly synthesized compounds have been delineated by 
elemental analysis, FT-IR, 1H NMR and Mass spectroscopy. 
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ANTIMICROBIAL ASSAY: 
 
 The purified organic compounds (Ia-j - XIa-i)  have been screened for 
their in vitro therapeutic assay like antibacterial activities towards Gram 
positive and Gram negative bacterial strain and antifungal activity towards 
fungal strain at different concentrations (Minimum Inhibitory Concentration). 
The biological activities of synthesized compounds have been compared with 
standard drugs like Ampicilline, Chloramphenicoal, Ciprofloxacin, Norfloxacin, 
Griseofulvin  at different concentrations. 
 
 
 
  
 
 
 
 

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STUDIES ON BIOLOGICALLY ACTIVE SYNTHETIC 
COMPOUNDS 
 
(A) Drug 
 
 The word drug is derived from the French word “drogue” which means 
‘a dry herb. It is the single active chemical entity present in a medicine that is 
used for diagnosis, prevention, treatment/ cure of a disease. This disease 
oriented definition of drug does not include contraceptives or use of drugs for 
improvement of health. According to “WHO” a drug may be defined as “Any 
substance or product which is used or intended to be used for modifying or 
exploring physiological system as pathological status for the benefit of the 
recipient”. 
 
(B)  Pharmacology 
 
 Pharmacology is the science of drugs. Ina broad sense, it deals with 
interaction of exogenously administered chemical molecules (drugs) with 
living system. It encompasses all aspects of knowledge about drugs, but most 
importantly those that are relevant to effective and safe use for medicinal 
purposes. For thousands of years most drugs were crude natural products of 
unknown composition and limited efficiency. Only the over effects of these 
substances on the body were rather imprecisely known, but how the same 
were produced was entirely unknown. Over the past 100 years or so, drugs 
have been purified, chemically characterized and a vast variety of highly 
potent and selective new drugs has been developed. The two main divisions 
of pharmacology are pharmacodynamics and pharmacokinetics. 
 
(a) Pharmecodynamics:   
It is derived from the Greek word “dynamic” means power. What the 
drugs do to the body? This includes physiological and biochemical effects of 
drugs and their mechanism of action at macromolecular/sub cellular organ 
systems. 
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(b) Pharmecokinetics:    
It is derived from the Greek word ‘Kinesis’ means movement. What the 
body does to the drug? This refers to movements of the drug in the alternation 
of the drug by the body; includes absorption, distribution, binding/ localization/ 
storage, biotransformation and excretion of the drug. 
 
Some other important aspects of pharmacology are given as under 
 
? Pharmacotherapeutics : It is the application of pharmacodynamic 
information together with knowledge of the disease for its prevention, 
mitigation or cure 
? Clinical Pharmacology: It is the scientific study of drug in man. It 
includes pharmacodynamic and pharmacokinetic investigation in 
healthy volunteers and in patients: evaluation of efficiency and safety of 
drugs and comparative trials with other forms of treatments; 
surveillance of patterns of drug uses, adverse effects, etc. 
? Chemotherapy: It is the treatment of systemic infection/ 
malignancy with specific drugs that have selective toxicity for the 
infecting organism/malignant cell with less effect on the host cells. 
 
Drugs in general, can thus be divided into: 
 
? Pharmacodynamic agents: These are chemical substances 
designed to have pharmacodynamic effect in the recipient. 
? Chemotherapeutic agents: These are chemical substances 
designed for the treatment of infectious diseases or by the proliferation 
of malignant cells. 
 
(c)  Essential Drug Concept:  
The ‘WHO’ has defined Essential Drugs as “those that satisfy the 
healthcare needs of majority of the population: they should therefore be 
available at all times in adequate amounts and in appropriate form”. 
 It has been realized that only a handful of drugs out of the multitude 
available can meet the health needs of majority of the people in any country, 
and that may be well tested and cheaper drugs are equally (or more) efficients 
General Introduction 
Department of Chemistry, Saurashtra University, Rajkot(Gujarat).             
11 
 
and safe as their newer more expensive congeners. For optimum utilization of 
resources, governments (especially in developing countries) should 
concentrate on these drugs by identifying them as Essential Drugs. The 
“WHO” has laid down criteria guide selection of an essential drug: 
(I) Adequate data on its efficiency and safety should be available from 
clinical studies. 
(II) It should be available in a form in which quality, including bioavailability 
and stability on storage can be assured. 
(III) Its choice should depend upon pattern of prevalent diseases; avail ability 
of facilities and trained personnel; financial resources; genetic, 
demographic and environmental factors. 
(IV) In case of two similar drugs, choice should be made on the basis of their 
relative efficiency, safety, quality, price, availability and cost benefit ration 
should be a major consideration. 
(V) Choice may also be influenced by comparative pharmacokinetic 
properties and local facilities for manufacture and storage. 
(VI) Most essential drug should be single compound. Fixed ration 
combination products should be included only when dosage of each 
ingredient meets the requirements of a defined population group, and 
when the combination has a proven advantage. 
(VII) Selection of essential drug should be a continuous process which should 
take into account the chaging priorities for public health action, 
epidemiological condition as well as availability of better drugs/ 
formulations and progress in pharmacological knowledge. 
 
(C)   Drug Development 
 Many natural products by trial and error, came into practise for 
combating human ailments existent during early human observation. With the 
advantage of modern scientific approach, various plant medicines came under 
chemical scrutiny, ultimately leading to the isolation of active principles since 
early. 
 Such compounds either in extract from or in pure form became a part 
of pharmacopoeias. For instance, though the Chinese drug, Mauhang was in 
use for over 5000 years for the treatment of various types of fever and 
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respiratory aliments, its active principle, Ephidrine was isolated in 1887. In 
1925 chemical investigations followed by pharmacological evaluation led this 
compound into the modern medicine. Similarly during this period, urea 
stibamine was introduced as the first drug in 1920 for the treatment of Kala-
azar. In 1930, De Rauwolifia preparation were first employed for sedative and 
hypotensive properties. 
 A drug is a substance having abnormal effect on certain body functions 
eg. Strychnine stimulates the action of heart and aspirin retards its action. 
Since both of them effects abnormally, the two substances are known as 
drugs. Chemical sciences contributed extensively new discoveries leading to 
useful drugs since after 1930. The moderns concept of drug discovery started 
in 1933 by Gerhand Domangk with his finding of “Pronstosil Red”, a 
compound responsible for the antibacterial activity. The advent of 
sulphonamides drew the attention for the different activites of various 
chemicals for bacterial and human cells, this important factor prompted Florey 
and Chain in 1939 to investigate penicillin which was discovered ten years 
earlier by Alexander Fleming. The spectacular chemotherapeutical properties 
of penicillin and its dramatic war-time development for the treatment of 
wounds made penicillin, a most commonly used inexpensive drug. 
 A large number of important drugs have been introduced during the 
period of 1940 to 1980. This period is known as “Golden period” of new drug 
discovery. Thus starting from 1933- the first antibacterial drug prontosil 
leading to various sulpha drugs; 1940- penicillin; 1945- chloroquine-
antimalarial ; 1958- adrenergic beta blocker coronary vasodilatory; 1960-
semi synthetic penicillin- antibacterial; 1965-trimethoprim-antimicrobial; 
1967- disodium chromoglycoate – antiallergic; 1972- cimetidine H2 – 
antagonist; 1975- verapamil – calciumantagonist and 1981- captopril- 
antihypertensive. There are some specific examples representing new 
therapeutic agent eg. Metormine glipizide – anti diabetic. 
 
(D) Latest Drug Development 
 
The current interest in the creation of large, searchable libraries of 
organic compounds has captured the imagination of organic chemists and the 
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drug discovery community. In numerous laboratories the Efforts are focused 
on the introduction of chemical diversity, which have been recently reviewed  
and pharmacologically interesting compounds have been identified from 
libraries of widely different compositions. 
Today, the chief sources of agents for the cure, the mitigation or the 
prevention of diseases are the organic compounds, natural or synthetic, 
together with so-called organometallics. Such agents have their origin in a 
number of ways (a) from naturally occurring materials - of both plant and 
animal origin, and (b) from the isolation of organic compounds synthesized in 
laboratory whose structures are closely related to those of naturally occurring 
compounds for eg. atropine, steroids, morphine, cocaine etc. that have been 
known to possess useful medicinal properties. 
The process of drug design is extensively driven by the instinct and 
experience of pharmaceutical research scientists. It is often instructive to 
attempt to “capture” these experiences by analyzing the historical record that 
are successful drug design projects of the past. From this analysis, the 
inferences are drawn which play an important role in shaping our current and 
future projects. Towards this region, we would like to analyse the structures of 
a large number of drugs - the ultimate product of a successful drug design 
effort. Our goal for this is to begin to deconvolute this information in order to 
apply it to design of new drugs. 
 Different kinds of drugs are developed for different types of diseases 
viz. which can be defined with their names of the modern drugs are as under. 
 
(a) Anticancer drugs 
The drugs, which stops the abnormal growth of cell tissues in human 
body, are termed as anticancer drug. Vinblastin and Busulphan are the 
novel anticancer drugs. 
 
(b) Hepatoprotective drugs 
Drugs, which gives vitality to liver and protects liver by giving immunity 
power against antibodies, are termed as Hepatoprotective drug. 
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(c)  Antimalarial drugs 
Drugs, which kills the plasmodium causing malaria are called 
antimalarial drug. Combination of Sulphamethoxazole with Pyrimethamine 
is a novel antimalarial drug. 
 
(d)  Drug for meningitis 
 Drugs, which cures the inflammation of meningitis, are termed as 
meningitis drugs Cifalexin is a novel meningitis drug.  
 
(e) Drug for typhoid 
Drugs, which kills the bacteria of Salmonella typhi causing typhoid are 
known as typhoid drugs. A novel drug for typhoid is Ciprofloxacin. 
 
(f)  Antidiabetic drugs 
Drugs, which converts the excess glucose of blood into glycogen, are 
termed as antidiabetic drugs. Novel antidiabetic drugs are Metformin, 
Glipizide and Gliclazide. 
 
(g)  Antitubercular drugs 
Drugs, which kills the bacteria of mycobacterium tuberculosis and thus 
cures lesions of pleural cavity. A novel antitubercular drug is Ethambutol. 
 
(h)  Antiasthamatic drugs 
Drugs, which prevents the attack of asthma and gives relax respiration 
are called antiasthamatic drugs. Novel antiasthamatic drugs are 
Ethophylline, Theophylline and Asmon. 
 
(i)  Antihypertensive drugs 
Drugs, which normalizes the blood pressure by dilating blood vessels, 
are called antihypertensive drugs. Novel antihypertensive drugs are Atenolol, 
Amlodipine and Nifedipine. 
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(j)  Anti-AIDS drugs 
Drugs, which kills the viruses of AIDS i.e., HIV-1 and HIV-2, are called 
Anti-AIDS drugs. Novel drugs are Zidovudine, Acyclovir and Didanosine. 
 
(k)  Antacid drugs 
Drugs, which neutralize the acid in stomach and stops excessive 
secretion of acid, are called antacid drugs. Novel antacid drugs are 
Omeprazole and Lansoprazole. 
 
(l)  Non steroidal anti-inflammatory drugs (NSAID) 
Drugs, which gives relief from fever, pain and inflammation are called 
NSAID. Novel NSAID are Pyroxicam, Meloxicam and Nimesulide. 
Different kind of drugs generally used are designed as anaesthetic, 
antituberculostatic, antihypertensive, anticonvulsant, anthelmintic, anti-
inflammatory, sedative and hypnotics which prompted us to synthesise drugs 
having pyrimidines and quinolines moieties as a better therapeutic activity. 
 
? Aims and objectives of the present investigation are 
 
(a) To generate several biologically active moieties such as          
pyrazolo[3,4- d]pyrimidines, quinazolines and pyrazoles. 
 
(b)  To characterize these products for their structural assignment using 
various spectroscopic techniques like IR, PMR and Mass spectroscopy. 
 
(c)  To screen these products (Ia-j –XIa-i) for their antimicrobial activity 
using different strains of bacteria and fungi and to compare antimicrobial 
activity with different known drugs at different concentrations for their MIC 
values. 
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In view of these facts, the research works presented in thesis are as 
follows. 
 
 (A) STUDIES ON PYRIMIDINES 
  
 (B) STUDIES ON QUINOLINES 
 
 
 
 
 
 
  
 
 
PA RT- I
STUDIES ON
 PYRIMID INES

 

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PART – I 
STUDIES ON PYRIMIDINES 
INTRODUCTION 
Pyrimidine (1) is a six membered heterocyclic compound consisting of 
two nitrogen atoms at one and three positions of heterocyclic ring. 
 
   (1) 
Generally pyrimidine derivatives such as 2-hydroxy-substituted-
pyrimidine, 2-mercapto-substituted-pyrimidine and 2-amino-substituted 
pyrimidine are studied. Pyrimidines have been isolated from the nucleic acid 
hydrolysates. 
Pyrimidines are among those molecules that make life possible, have 
been some of the building blocks of DNA and RNA. Several analogues of 
pyrimidines have been used as compounds that interfere with the synthesis 
and functioning of nucleic acids e.g. fluorouracil, which has been used in 
cancer treatment. Also there are some thiouracil derivatives, which produce 
adverse reduction in susceptible patients and found more potent and less 
likely to produce side effects and is being widely used7. There are several 
other important groups of pyrimidines with medicinal uses. 
Pyrimidine ring carrying various substituents may be built up from two 
or three aliphatic fragments by the principle synthesis or by a variety of other 
syntheses, which are complimentary rather than alternative to it. An 
alternative method of synthesis is the isomerisation or break down of another 
heterocyclic such as hydration of purine, but such methods are rarely used.  
 
 
                        (2)                 (2a)                  (2b)                (2c) 
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                        (2d)               (2e)                   (2f)                 (2g) 
 
Pyrimidine is best considered as a resonance hybrid to which the 
uncharged equivalent Kekule structures 2 and 2a and charged structures 2b 
and 2g contributes. The self consistent π (pi) electron densities required for 
the ground state of pyrimidine are 0.776, 0.825 and 1.103 for positions 2, 4 
and 5 respectively12. Despite considerable localization of π  (pi) electrons at 
nitrogen atoms of pyrimidines the ring system is still sufficiently aromatic to 
possess substantial stability. This has a great advantage in the primary 
synthesis of pyrimidines. 
 
The first primary synthesis from aliphatic fragments was carried out by 
Frankland et.al., in 1848. Since then a many distinct primary synthetic 
methods have been devised1, 3-5, 9, 11, 14, 16, 17, 20. It is also possible to prepare 
pyrimidines from other heterocyclic compounds such as pyrrole2, imidazole6, 
isoxazole and oxazole8, 10, pyridine18, pyrazine19, 1,3,5 triazine13, oxazine15, 
thiazine21 by different processes. 
 
SYNTHETIC METHODS FOR PYRIMIDINES 
 
Various methods for synthesis of pyrimidines which are reported in the 
literatures are as follows. 
 
(a) By the condensation of urea and malonic acid led to formation of    
           Pyrimidine24. 
 
(b) By the condensation of malonic ester and urea led to formation of 
           Pyrimidine25. 
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(c) By the condensation of formamidine with phenylazomalononitrile led to       
formation of 4, 5, 6-triaminopyrimidine23. 
(d) By the condensation of aromatic aldehydes, ß-ketoester or substituted 
ß-ketoester with urea or thiourea led to formation of pyrimidines22 .    
 
(e) By the condensation of thiourea and substituted ß-ketoester in          
presence of sodium ethoxide led to formation of mercapto-
pyrimidines26. 
 
(f) By the condensation of chalcones with dicyandiamide in presence of 
piperidine led to formation of pyrimidines27. 
 
(g) By thermal or microwave irridiation of thiourea and substituted ß-
ketoester in presence of dimethylformamide led to formation of 
substituted  tetrahydropyrimidines28. 
 
(h) One pot synthesis of aromatic aldehydes, ß-ketoester or substituted ß-
ketoester with urea or thiourea led to formation of substituted dihydro-
pyrimidin-2-ones catalysed by CuCl229. 
 
(i) One pot synthesis of aromatic aldehydes, ß-ketoester or substituted ß-
ketoester with urea or thiourea led to formation of 3,4-dihydro 
pyrimidin-2-(1H)-ones/thiones under microwave irradiation30. 
 
(j) One pot synthesis of aromatic aldehydes, ß-ketoester or substituted ß-
ketoester with urea or thiourea led to formation of dihydro pyrimidin 2-
(1H) - ones catalysed by Tin (II) chloride (SnCl2)30. 
 
(k) One pot synthesis of aromatic aldehydes, ß-ketoester or substituted ß-
ketoester with urea or thiourea led to formation of 3,4-dihydropyrimidin-
2-(1H)-ones by microwave induced eco-friendly solvent free biginelli 
reaction catalysed by calcium chloride31. 
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MECHANISM 
The reaction mechanism of pyrimidine formation can be depicted as under : 
  
PATH – A 
 
H+
+
+
NH2
NH2
X
H+
NH
XNH2
O
+
-H2O
H+
(a)
(b) (c)
(d) (e)
OH
O
NH
CH3
CH3
O
O
H
O
H
OH
O
NH
OH
H
NH2X
O
H
OH
X = O, S 
CH3 O
O
NH NH
XNH2
H
O
CH3
NH
N
H
X
HO
NH
O
CH3
CH3
 
 
The present work is explained by considering basic mechanism of 
multicomponents biginelli reaction. This includes the condensation of 
substituted m-phenoxybenzaldehyde (a) with either urea or thiourea or N-
methyl urea to form hemiaminal (b) with some similarities to the mannich 
condensation. Hemiaminal (b) undergoes dehydration in presence of acid 
catalyst to produce iminium cation (c) as an intermediate. The enamine 
(iminium cation) (c) generated acts as an electrophile for the nucleophilic 
addition of keto enol of 4-methyl-oxo-N phenylpentanamide with removal of 
proton to produce (d). 
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The intermediate (d) undergoes intramolecular condensation in presence of 
acid between oxygen of ketone and amino group of urea or thiourea or N-
methyl urea to give the cyclised targeted product (e). 
 
PATH – B 
The reaction mechanism of pyrimidine formation can be depicted as under : 
 
H+
+
H
+
-H2O
H
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O
+
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X
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H
X
H
CH3
CH3
O
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X = O, S  
 
This mechanism includes the condensation of m-phenoxy 
benzaldehydes (a) with keto enol of 4-methyl-3-oxo-N-phenylpentanamide (b) 
to formintermidiate (c) with some similarities to the aldol condensation. 
Intermidiate (c) undergoes dehydration in presence of acid catalyst to produce 
arylidine (d). The condensation of arylidine (d) with either urea or thiourea to 
form hemiaminal intermidiate (e). Hemiaminal intermidiate (e) undergoes 
intramolecular condensation in presence of acid between oxygen of ketone 
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and amino group of urea or thiourea or guanidine to give cyclised targeted 
product (f). 
 
PHARMACOLOGICAL IMPORTANCE OF PYRIMIDINES 
 
Numerous pyrimidines are well known drugs for variety of diseases. 
They may be placed in four categories viz. barbiturates, sulphonamides, 
antimicrobials and antitumor agents. Uracil, thymine, alloxan, vicine and 
divicine, cytosine, chroticacid, willardiline, tetradotoxine, becimethrian (3), 
blasticidine (4), cougerotin, amicetin, bamicetin and plicacetin, phleomicine, 
blemycin and related families (5). 
 
 
                   (3)                                     (4)                                     (5) 
 
Pyrimidine derivatives have wide varieties of usages. Pyrimidine ring 
system is also present in Vitamin B2 and folic acid. Pyrimidine ring system 
having a mercapto group occupy a unique position in medicinal chemistry48. 
These types of derivatives play a vital role in biological processes34-36 as well 
as synthetic drugs36. 
 
Some of the therapeutic activities of pyrimidine derivatives can be 
summarized as follows. 
 
  Antithyroid46-47              Antitumor39, 68-69 
           Antihypertensive49, 60-61      Antiinflammatory59, 95-96 
           Diuretic38 Antimalarial40, 42, 45 
           Antispasmodic41      Anticonvulsant70 
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 Antineoplastic50, 88,137,138  Anthelmintic54 
           Antimicrobial37, 51-55, 61, 71-94,135 Cardiovascular63-65             
           Antiviral56, 85-88,137                Platelet aggregation inhibitor43, 44 
           Antihistamine57-58,136  Anti-HIV66, 97,134 
           Antitubercular67 
 
The basis of any rational drug discovery programme is fundamently, 
the Medicinal Chemistry. Although the synthesis of modified nucleic acids has 
been a subject of interest for some time, the intense focus on the medicinal 
chemistry of oligonucleotides dates perhaps to not more than five years. As a 
result of this, the scope of medicinal chemistry has recently been expanded 
enormously, but the biological data of supporting the conclusions about 
synthetic strategies have just begun to emerge. 
 
Modifications in the base, sugar and phosphate moieties of 
oligonucleotides and oligonucleotide conjugates have been reported. The 
subjects of medicinal chemical programmes include approaches to create 
enhanced affinity and more selective affinity for RNA or duplex structures, the 
ability to cleave nucleic acid targets, enhanced nuclease stability, 
cellularuptake and distribution, in vivo tissue distribution, metabolism and 
clearance. Although substantial progress in the medicinal chemistry of 
oligonucleotides has been made in the past three years, it is not yet possible 
to reach the conclusion about the therapeutic ability of the novel 
modifications. Preliminary data on effects on nuclease stability and 
hybridization properties for a few modifications and activity in vitro suggest 
that the next generation of oligonucleotides may display substantially 
improved potencies and selectivity. 
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PYRIMIDINE MODIFICATIONS (Nucleotide) 
 
A relatively large number of modified pyrimidines have been 
synthesized and now incorporated into oligonucleotides and evaluated. The 
principle sites of modification are C-2, C-4, C-5 and C-6 (6). These and other 
nucleoside analogues have recently been thoroughly reviewed.123 
 
               
Sites of pyrimidine Modification 
                 (6) 
 
In as much as the C2 position is involved in Watson-Crick hybridization, 
oligonucleotides containing C2 alkyl modified pyrimidines have shown 
unattractive hybridization characters. However, an oligonucleotide containing 
2-thiothymidine (7) was found to hybridize well to DNA and, in fact even better 
to RNA with a thermal melting temperature ( Tm) value of 1.5°C/modification. 
In a different study, oligoribonucleotides with 2’-o-methyl-2-thiouridine (8) 
exhibited a thermal melting temperature ( Tm) value of +5.5°C/modification 
when hybridized against RNA resulting from a highly preoganized RNA-like 
C3’-endo conformation (attributed to the combination of 2-thio modification 
and 2’-o-Me substituent). Oligonucleotides with this modification also exhibit 
better hybridization discrimination for the wobble uracil-guanosine (U-G) base 
pair formation compared to the normal uracil-adenine (U-A) base pair. This 
selectivity is a result of weaker hydrogen bonding and increased steric bulk of 
the 2-thiocarbonyl group.121 
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(7)                                          (8) 
 
In contrast, the pyrimidine modifications in 4-position with interesting 
properties have been reported. 4-Thiopyrimidines (9,10) have been 
incorporated into oligonucleotides with no significant negative effect on 
hybridization. However, recent studies have shown destabilization in the 
normal uracil-adenine (U-A) base pair formation and stabilization of the 
wobble uracil-guanosine (U-G) base pair for 4-thiouridine. A bicyclic and an 4-
methoxy analog of cytosine were shown to hybridize with both purine bases in 
DNA with thermal melting temperature (Tm) values approximately equal to 
that of natural base pairs. Additionally, a fluorescent base has been 
incorporated into oligonucleotides and shown to enhance DNA-DNA duplex 
stability.122 
 
 
(9)     (10) 
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The pyrimidine modification at C5 position including halogenated 
nucleosides have been reported. Although the stability of duplexes may be 
enhanced by incorporation 5-halogenated uracil containing nucleosides, the 
occasional mispairing with guanidine and the potential that the oligonucleotide 
might degrade and release toxic nucleosides analogs cause concern. 
Oligonucleotides containing 5-propynylpyrimidine (11,12,13) modification 
have been shown to enhance the duplex stability thermal melting temperature 
(ΔTm= 1.6°C/modification), and support RNase H activity. The 5-heteroaryl 
pyrimidines were also shown to increase the stability of duplexes. A more 
dramatic influence was reported for the tricyclic 2’-deoxycytidine analoges, 
termed phenoxazine, exhibiting an enhancement of 2-5°C/modification, 
depending on the positioning of the modified bases.111 
 
 
                  (11)                              (12)                                  (13) 
 
 
As expected, modifications in the C6 position of pyrimidines are highly 
dupled destabilizing. Oligonucleotides containing 6-azapyrimidines (14) have 
been shown not only to reduce the thermal melting temperature (Tm) value by 
1-2°C per modification, but also to enhance the nuclease stability of 
oligonucleotides and to support E. coli RNase H-induced deradation of RNA 
targets.124 
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     (14) 
 
PYRIMIDINE MODIFICATIONS (Non-nucleotide) 
 
The increasing interest in the early 1970s in properties and use of 
interferon (IFN) together with the difficulty in producing useful amounts of 
interferon (IFN) led to the search for agents that would induce IFN in the host. 
Precedenced at that time for interferon (IFN) inducers included viruses and 
bacterial wall constituents and entities of large molecular weight such as 
thepolynucleotides.There were also several examples of low molecular weight 
substances such as certain antibiotics and the antiviral agent, tilorone.107 
In1976, it was reported that 6-methyl pyrimidinone (2-amino-5-bromo-6-
methyl-4-(3H)pyrimidinone, ABMP) induced circulating levels of interferon 
(IFN) in several animal specis upon oral or intraperitoneal administration.102 
Subsequent structure-activity studies yielded a more potent and less toxic 
6phenyl ananlog called ABPP or bropirimine(2-amino-5-bromo-6-phenyl 4-
(3H)pyrimidinone) (figure 1 and Table 1).100,106 Bropirimine and related 6-aryl 
analogs were examined extensively for efficacy in virus and tumor models, 
along with their immunomodulatory properties and overall pharmacological 
effects.112 
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Figure 1: Preliminary SAR of antiviral activity of pyrimidinones 
 
 
Anti viral activity spectrum of pyrimidines 
Monosubstituted Disubstituted Heterocyclic  
 
     Active 
2-F, OMe, Me,   
3-F,OMe, 2-Cl, 
NO2, Me, CF3, 
MeCH2CH2O, Br, 
I, 4-F, 4-Cl 
3,5-OMe, 2,5-Cl2, 
3,5-OMe, 3,4-Cl2 
3,5-Cl2 
1-Naphthyl,        
2-Furyl,                  
2,3-pyridyl,           
2-Pyrazyl 
 
 
  Inactive 
 
4-Me, CN, Butyl, 
OH, OCH2ph, 
OMe 
 
2,3-OMe 
 
2-Napthyl,           
1-Furyl,               
4-Pyridyl, 
2-Quinoline 
 
 
As with the polynucleotides, the pyrimidinones exhibited significant 
activity against interferon (IFN) sensitive viruses such as Semliki Forest virus 
in vivo. However, in addition, they exhibited prophylactic and therapeutic 
activity upon either local or systemic administration to rodents infected with a 
variety of DNA viruses, such as the herpes viruses (HSV-1, HSV-2 , CMV and 
pseudorabies), and when administered intranasally for upper respiratory  
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infections, such as infectious bovine rhinortacheites, influenza A and para 
influenza-3. Particularly interestion activity was noted with bropirimine on 
intravaginal administration in protection against HSV-2 intravaginal infection in 
guinea pigs, an important model for genital herpes in humans.113 Bropirimine 
also exhibited activity when given either intraperitoneally or orally to mice 
infected with Listera monocytogenes. The efficacy in this model was not 
abrogated by the addition of anti-interferon (IFN) antibody.108 
 
PYRIMIDINES AS ANTITUMOUR AGENTS 
A number of other pyrimidine antagonists displaying antitumour activity, 
in which the base is conjugated to a modified sugar ring have been reported. 
Although D-Arabinofuranosyl uridine (ara-uridine) shows no useful activity, 
and 5-bromo- and 5-iodo-D-arabinofuranosyl uridine inhibit the growth of 
sarcoma 180 and L1210 cells in culture.99 Other thymidine analogues with 
similar activity include 5-azidomethyl-,5-aminomethyl and 5 hydroxymethyl-2’-
deoxyuridine.101 3’-Amino-3’-deoxy thymidine103 and 3’-amino-2’,3’-dideoxycy 
tidine104 also posses strong activity against L1210 leukaemia 2’-Deoxy-2’ 
fluoro-5-methyl-1-B-D-arabinofuranosyluracil (FMAU; 15) is highly active 
against arabinofuranosyl cytidine (ara-C) resistant L1210 and P815 cell lines 
both in vitro and in vivo.110 2-B-D-Ribofuranosylthiazole4 carboxamide 
(Tiazofurin; 16) has aroused much interest recently for its activity against solid 
tumour such as lung carcinoma. It is metabolized to an analogue of NAD in 
which the thiazole-4-carboxamide moiety replaces the nicotinamide ring. 
However, it also depresses the synthesis of DNA and RNA, and thus merits 
inclusion as an antagonist of normal purine and pyrimidine metabolism.109 
 
                    (15)                     (16) 
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PYRIMIDINES AS ANTI-HIV AGENTS 
 
The strategy of designing nucleoside analogs that are selective for viral 
DNA polymerases is the most well-studied and successful approach to viral 
chemotherapy, and has led to the discovery of several clinically useful 
antiviral drugs. This strategy, however, has inherent limitations. Human DNA 
polymerases also required dNTP’s and the chemical mechanisms of 
polymerization by the viral and human enzymes are similar. Nucleoside 
analogs often have significant host toxicity that is probably related to inhibition 
of host cell DNA synthesis. Nevertheless, these compounds constitute the 
major class of antiviral drugs, and this approach is likely to yield additional 
active compounds in the near future. For the long term, however, other 
strategies may ultimately lead to more selective agent with lower toxicity. 
 
Obviously, the key to design analogue with a lower affinity for the host 
enzyme than the viral enzyme, which requires that there be structural 
differences between the enzyme active sites. For reverse transcriptase, the 
most well studied inhibitor is 3’-azido-3’-deoxythymidine (AZT; 17), which is 
currently used clinically to treat AIDS.132-133  
 
 
(17) 
 
3’-azido-3’-deoxythymidine (AZT) inhibits HIV reverse transcriptase 
with an IC50 of 40nM115, but is 100-300 times less active against mammalian 
DNA polymerase α and DNA polymerase γ. The reason for this selectivity is 
not clear since 3’-azido-3’-deoxythymidine (AZT) is a chain terminator for 
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mammalian DNA polymerases and inhibits normal cellular DNA 
synthesis.105Several other dideoxynucleoside analogs have been shown to be 
potent inhibitors of HIV replication in vitro.116,120 In general, these compounds 
have the same mechanism of action as 3’-azido-3’-deoxythymidine (AZT), that 
is, intracellular conversion to the triposphate derivative and subsequent 
inhibition of HIV reverse transcriptase. 
 
Some of these compounds are simply analogs of the natural 2’- deoxy-
nucleoside in which the 3’-OH group has been replaced with a hydrogen, such 
as 2’,3’-dideoxycytidine(18), 2’,3’-dideoxyadenosine(19) and 2’,3’-dideoxy 
thymidine(20). Other analogs contain a 2’-3’ double bond, such as 2’3’- 
didehydro-2’,3’-dideoxythymidine(21). Several related analogs with other 
modifications to the ribose ring or the heterocyclic base moiety have also 
been reported to have activity against HIV or HIV reverse transcriptase.117, 118 
 
                   (18)                    (19)                     (20)                     (21) 
 
R. A. Nugent et.al.125 have synthesized pyrimidine thioethers (22) and 
evaluated for inhibitory properties against wild-type HIV-1 reverse 
transcriptase. 
 
 (22) 
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A family of trisubstituted pyrimidines has been described as selective 
COX-2 inhibitors. To explore the usefulness of pyrimidine derivatives as 
potential NSAIDs. Aurelio Orjales et.al.,126 have synthesized novel pyrimidine 
derivatives (23) and (24). 
 
In vitro biological evaluation of these compounds has provided 
information to determine the structural features necessary for COX-2 
inhibitory activity. 
      
                  (23)  Y=CH; X, Z=N                              (24) Y, Z= N; X=CH 
 
F. Manetti et.al.127 have synthesized novel pyrimidines (25) with 
nanomolar activity toward recombinant HIV-1 and mutant HIV-1 strains. 
 
 
    (25) 
D.Rotili etal.128 have synthesized 6-substituted-[1-(2,6- difluorophenyl]-
pyrimidinones (26,27) and tested against endogenous, nontelomeric reverse 
transcriptase (endo-RT) in human differentiating cell systems to investigate 
their antiproliferative and cytodifferentiating activity. 
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                       (26)                                                        (27) 
 
R. Stoorer et al.,129 have synthesized 3-substituted-6-(3-ethyl-4- 
Methylanilino)uracils (28,29) screened for their capacity to inhibit the 
replication- specific bacterial DNA polymerase IIIC (pol IIIC) and the growth of 
Gram+bacteria in culture. 
 
 
  (28) n=2, 3, 4   (29) n=2,3,4 
 
A.Orjales etal., 130 have synthesized new series of 2-(4- methylsulfonyl-
phenyl) and 2-(4-sulfamoylphenyl)pyrimidines (30) and evaluated for their 
ability to inhibit cyclooxygenase-2 (COX-2). 
 
                                                         (30) 
Part-I                                                                                Introduction 
Department of Chemistry, Saurashtra University, Rajkot(Gujarat). 
 
34 
 
Recently, Y.Miyazaki et al., 131 have synthesized 4-amino-5, 6-furo [2, 
3-d] pyrimidines (31) and identified as inhibitors of glycogen synthase kinase-
3B (GSK-3B). 
 
                                     (31) 
In view of procuring highly potent biodynamic agents and after 
reviewing recent literature survey on oxo / thioxo / iminopyrimidines for their 
various methods of synthesis and different pharmacological activities, 
synthesis of pyrimidines have been undertaken which can be summarized in 
the following sections as follows: 
 
SECTION-I:  PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N- 
(SUBTITUTEDPHENYL)]-CARBOXIMIDO-1,2,3,4-TETRAHYD-
RO-6-METHYL-2-OXO-4-(m-PHENOXYPHENYL)-
PYRIMIDINES. 
 
SECTION-II:  PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N- 
           (SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAH-   
                      YDRO-6-METHYL-4-(m-PHENOXYPHENYL)-2- THIOXOPYRI-  
                      MIDINES. 
 
SECTION-III: PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N- 
SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,6- TETRAH-        
YDRO-1,4-DIMETHYL)-1,2,3,6-TETRAHYDRO-1,4-DIMETHY-
L-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINES. 
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SECTION-IV: PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N- 
(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRA-
HYDRO-6-ISOPROPYL-2-OXO-4-(m-PHENOXYPHENYL)-
PYRIMIDINES. 
 
SECTION-V: PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N- 
(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRA-
HYDRO-6-ISOPROPYL-4-(m-PHENOXYPHENYL)-2-THIOX-
OPYRIMIDINES.  
 
SECTION-VI: PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-
(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,6-TETRA-
HYDRO-4-ISOPROPYL-1-METHYL-2-OXO-6-(m-PHENOXY-
PHENYL)-PYRIMIDINES. 
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SECTION-I 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTED 
PHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-METHYL-2-OXO-4-
(m-PHENOXYPHENYL)-PYRIMIDINES. 
 
Keeping in view of wide spectrum biodynamic activities38-96 of 
pyrimidines and with a view to have potent therapeutic agents, the synthesis 
of 5-[N-(substitutedphenyl)-carboxamido-1,2,3,4-tetrahydro-6-methyl-2-
oxo-4-(m-phenoxyphenyl)pyrimidines (Ia-j) have been synthesized by the 
condensation of m-phenoxybenzaldehyde, N-(substitutedphenyl)-
oxobutanamides and urea in the presence of conc. acid. 
 
 
O
O
NH
N O
H
CH3
NH
R
 
 
              (Ia-j) 
                 R = Substituted Phenyl 
 
The constitutions of the products (Ia-j) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (Ia-j) 
were assayed for their in vitro biological assay. 
The products (Ia-j) were assayed for their in vitro biological assay like 
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96 
and P. aeruginosa MTCC-124 (Gram positive) and E. coli MTCC- 443 (Gram 
negative) bacterial strain and antifungal activity towards Aspergillus niger 
MTCC-282 and A. clavatus MTCC-1323 at different concentrations : i.e. 0 
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(control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory 
Concentration) values. The biological activities of the synthesized compounds 
(Ia-j) were compared with standard drugs viz., Ampicilline, Chloramphenicol, 
Ciprofloxacin, Norfloxacin, Griseofulvin and Nystatin. 
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REACTION SCHEME 
 
 
R
R
O
N
H
NH
O
NH
CH3
O
   (Ia-j)
R= Substituted Phenyl
NH2
O
NH2
+
O CHO
NH
O
CH3
O
H
+ /
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EXPERIMENTAL 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTED 
PHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-METHYL-2-OXO-4-
(m-PHENOXYPHENYL)-PYRIMIDINES. 
 
(A) Preparation of N-substituted-phenyl butanamide-3-ones. 
           For Preparation of N-substituted –phenyl butanamide-3-ones has been 
under taken according to literature132-133.   
 Similarly, other compounds (1a-j) were synthesized. The physical data 
are recorded in Table No. 1A.    
   
(B) Preparation of 5-[N-(p-chlorophenyl)]-carboxamido-1,2,3,4-tetrahy-
dro-6-methyl-2-oxo-4-(m-phenoxyphenyl)-pyrimidine (Ig). 
 
           A mixture of N-(p-chlorophenyl)-3-Oxobutanamide (2.11 gm, 0.01M), 
m-phenoxybenzaldehyde (1.98 ml, 0.01M), urea (0.90 gm, 0.015 M) and 
catalytic amount of conc. acid in ethanol (30 ml) was heated under reflux 
condition for 8 to 10 hrs. The reaction mixture was kept at room temperature 
for 24 hrs. The yellow crystalline product obtained was isolated and 
recrystallized from ethanol. Yield: 60%, M.P.: 2200 C, (Required: C, 66.44%; 
H, 4.65%; N, 9.68%; for C24H20ClN3O3 Found: C, 66.38%; H, 4.56%; N, 
9.63%). 
 
TLC solvent system Rf1: Ethyl acetate: Hexane (3.0:7.0) = 0.60 
TLC solvent system Rf2: Methanol       : Chloroform (0.5:9.5) = 0.75 
 
 Similarly other compound (Ia-j) were synthesized. The physical data are 
recorded in Table- 1. 
 
(C) Antimicrobial activity of 5-[N-(substitutedphenyl)]-carboxamido-
1,2,3,4-tetrahydro-6-methyl-2-oxo-4-(m-phenoxyphenyl)-pyrimidines (Ia-j). 
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         Antimicrobial activity testing was carried out by using cup-plate 
method77, which has been described as under. 
* Antibacterial activity 
 
Evaluation Techniques:- 
 The following conditions must be met for the screening of antimicrobial 
activity: 
- There should be intimate contact between the test organisms  
and substance to be evaluated. 
- Required conditions should be provided for the growth microorg- 
anisms. 
- Conditions should be same through the study. 
- Aseptic/sterile environment should be maintained. 
Various methods have been used for time to time by 
several workers to evaluate the antimicrobial activity. The evaluation can be 
done by the following methods: 
 
 - Turbidometric method. 
            -           Agar steak dilution method. 
 - Serial dilution method. 
 - Agar diffusion method. 
 Following Techniques are used as agar diffusion method: 
- Agar cup method. 
- Agar ditch method. 
- Paper disc method. 
We have used the Agar cup method to evaluate the antibacterial 
activity. 
It is one of the non automated invitro bacterial susceptibility tests. 
This classic method yields a zone of inhibition in mm results for the 
amount of antimicrobial agents that is needed to inhibit growth of specific 
microorganisms. It is carried out in petriplates. 
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DETERMINATION OF MINIMAL BACTERICIDAL CONCENTRATION BY 
AGAR CUP METHOD. 
MATERIALS AND METHOD:- 
1. All the Synthesized Drugs were used for antibacterial test  
procedures. 
2. All necessary controls like : 
- Drug Control 
- Vehicle control 
- Agar control 
- Organism control 
- Known antibacterial drugs control 
- All MTCC cultures were tested against above mentioned known 
and unknown drugs. 
- Mueller hinton broth was used as nutrient medium to grow and 
dilute the drug suspension for the test. 
- Inoculum size for the test strain was adjust to 108 cfu [colony 
forming unit] per milliliter by comparing the turbidity. 
- Following common standards strains were used for screening of 
antibacterial and antifungal activities: 
The strains were procured from Institute of microbial technology, 
Chandigarh. 
 
- Escherichia coli [Gram negative] MTCC-442 
- Pseudomonas aeruginosa [Gram negative] MTCC-441 
- Staphylococcus aureus    [Gram Positive] MTCC-96 
- Streptococcus pyogenes    [Gram Positive] MTCC-443 
  - Aspergillus niger     [Fungus]  MTCC-282 
           - Aspergillus clavatus    [Fungus]  MTCC-1323 
 
 (DMSO) was used as diluents/vehicle to get desired concentration of 
drugs to test upon standard bacterial strains. 
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 ANTIBIOTIC ASSAY AS PER BRITISH PHARMOCOPEIAS (BP) 
 
[Eur. method 2.7.] The potency of an antibiotic is estimated by comparing 
the inhibition of growth of sensitive micro-organisms produced by known 
concentrations of the antibiotic being examined and a reference substance. 
 The reference substances used in the assays are substances whose 
activity has been precisely determined with reference to the corresponding 
international standard or international reference preparation. 
 The assay must be designed in a way that will permit examination of 
the validity of the mathematical model on which the potency equation is 
based. If a parallel-line model is chosen, the two log dose-response (or 
transformed response) lines of the preparation being examined and the 
reference preparation must be parallel; they must be linear over the range of 
doses used in the calculation. These conditions must be verified by validity 
tests for a given probability, usually P = 0.05. Other mathematical models, 
such as the slope ratio model, may be used provided that proof of validity is 
demonstrated. Unless otherwise stated in the monograph, the fiducial limit of 
error (P=0.95) of the assay for potency are not less than 95 % and not more 
than 105 % of the estimated potency. 
 
Carry out the assay by method A or method B unless otherwise specified in 
the monograph. 
 
A. DIFFUSION METHOD 
 
1) Liquefy a medium suitable for the conditions of the assay and 
2) Inoculate it at a suitable temperature, for example 48oC to 50oC for 
vegetative forms, with a known quantity of a suspension of micro-organisms 
sensitive to the antibiotic being examined such that clearly defined zones of 
inhibition of suitable diameter are provided with the concentrations of the 
antibiotic used for the assay. 
 3) Immediately pour into petri dishes or large rectangular dishes a 
quantity of the inoculated medium to form a uniform layer 2 mm to 5 m thick. 
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Alternatively, the medium may consist of two layers, only the upper layer 
being inoculated.  
4) Store the dishes so that no appreciable growth or death of the micro-
organisms occurs before the dishes are used and so that the surface of the 
medium is dry at the time of use. 
 5) Using the solvent and the buffer solution indicated in Table A-1, 
prepare solutions of the reference substance and of the antibiotic being 
examined having known concentrations and presumed to be of equal activity. 
6) Apply the solutions to the surface of the medium, for example, in 
cavities prepared in agar. The same volume of solution must be added to 
each cylinder or cavity. 
OR  
7) Alternatively, use sterile absorbent paper of suitable quality; 
impregnate the discs with the solutions of the reference substance or the 
solutions of the antibiotic being examined and place on the surface of the 
agar.  
8) In order to assess the validity of the assay, use not fever the doses of 
the reference substance and three doses of the antibiotic being examined 
having the same presumed activity as the doses of the reference substance. 
9) It is preferable to use a series of doses in geometric progression. In 
routine assays when the linearity of the some system has been demonstrated 
over an adequate number of experiments using a three-point assay, a two-
point assay may be sufficient, subject to agreement by the component 
authority. However, in all cases of dispute, a three point assay as described 
above must be applied.   
10) Arrange the solutions on each petri dish on each rectangular dish 
according to a statistically suitable design, except for small petri dishes that 
cannot accommodate more than six solutions, arrange the solutions of the 
antibiotic being examined and the solutions of the reference substance in the 
alternate manner to avoid interaction of the more concentrated solutions. 
11) Incubate at a suitable temperature for about 18 hours. A period of 
diffusion prior to incubation, usually 1 to 4 hours, at  room temperature or at 
about 40C, as appropriate, may be used to minimize the effects of the 
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variation in time between the application of the solutions and to improve the 
regression slope. 
12) Measure the diameters with a precision of at least 0.1 mm. or the areas 
of the circular inhibition zones with a corresponding precision and calculate 
the potency using appropriate statistical methods. 
13) Use in each assay the number of replications per doses sufficient to 
ensure the required precision. 
14) The assay may be repeated and the results combined statistically to 
obtain the required precision and to ascertain whether the potency of the 
antibiotic being examined is not less than the minimum required. 
 
BUFFER SOLUTION 
Weight / 1000 ml. 
Adjust the pH by using 8 M phosphoric acid or 10 M potassium hydroxide.  
 
Buffer No. K2HPO4 KH2PO4 pH 
B1 02.00 08.000 6.0 
B2 16.73 00.523 8.0 
B3 - 13.610 4.5 
B4 20.00 80.000 6.0 
B5 35.00 - 10.5 
B6 13.60 04.000 7.0 
 
Result and Discussion:- 
 
 The products (Ia-j) have been subjected to antibacterial activity 
towards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTC-
C-441 (Gram positive) and E. coli MTCC- 443 and (Gram negative) bacterial 
strain and antifungal activity towards Aspergillus niger MTCC-282 and 
Candida albicans MTCC-227 at same concentration . The results of antimicr-
obial activity have been depicted on Page No. 51-53 .   
  
 
 
 
 
         TABLE NO. 1A: PHYSICAL CONSTANTS OF N-SUBSTITUTED-PHENYL BUTANAMIDE-3-ONES (1a-j). 
 
 Rf Value %  of  Nitrogen Comp. 
No. 
R 
 
Molecular 
Formula 
M.W. 
Yield 
% 
M.P. 
0C Rf1 /Rf2 Calcd./Found 
1a 4-CH3-C6H4 C11H13NO2 191 47    1130 0.60/0.48 7.32/7.28 
1b 2,3-(CH3)2-C6H3 C12H15NO2 205 56 1030 0.57/0.47 6.82/6.77 
1c 2,5-(CH3)2-C6H3 C12H15NO2 205 61 1200 0.38/0.49 6.82/6.79 
1d 3-NO2-C6H4 C10H10N2O4 222 58 1570 0.41/0.43 12.61/12.56 
1e 4-NO2-C6H4 C10H10N2O4 222 53    1610 0.45/0.47 12.61/12.57 
1f 3-Cl-C6H4 C10H10NO2Cl 211 57 1070 0.53/0.58 6.63/6.58 
1g 4-Cl-C6H4 C10H10NO2Cl 211 58 1330 0.64/0.51 6.63/6.57 
1h 3,4-Cl2-C6H3 C10H9NO2Cl2 246 64 1320 0.41/0.43 5.69/5.64 
1i 4-F-C6H4 C10H10NO2F 195 61 920 0.69/0.52 7.18/7.15 
1j 3-Cl-4-F-C6H3 C10H9NO2ClF 229 45 1230 0.51/0.54 6.11/6.07 
 
 
TABLE NO. 1: PHYSICAL CONSTANTS OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-    
METHYL-2-OXO-4-(3-PHENOXYPHENYL)PYRIMIDINES (Ia-j).  
 
Rf Value %  of  Nitrogen Comp.
No. 
R Molecular 
Formula 
M.W. 
 
Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
Ia 4-CH3-C6H4 C25H23N3O3 413 58 2320 0.57/0.70 10.16/10.11 
Ib 2,3-(CH3)2-C6H4 C26H25N3O3 427 57 2480 0.61/0.81 9.83/9.79 
Ic 2,5-(CH3)2-C6H4 C26H25N3O3 427 64 2590 0.63/0.77 9.83/9.81 
Id 3-NO2-C6H4 C24H20N4O4 444 56 2260 0.62/0.73 12.61/12.57 
Ie 4-NO2-C6H4 C24H23N3O3 444 65 2610 0.53/0.67 12.61/12.55 
If 3-Cl-C6H4 C24H20ClN3O3 434 49 2250 0.63/0.75 9.68/9.65 
Ig 4-Cl-C6H4 C24H20ClN3O3 434 60 2200 0.60/0.75 9.68/9.63 
Ih 3,4-Cl2-C6H3 C24H19ClN3O3 468 51 2750 0.58/0.71 8.97/8.92 
Ii 4-F-C6H4 C24H20FN3O3 417 51 2420 0.68/0.80 10.07/10.02 
Ij 3-Cl-4-F-C6H3 C24H19ClFN3O3 452 62 2800 0.55/0.65 9.30/9.25 
 
   TLC solvent system Rf1: Ethyl acetate: Hexane (3.0:7.0)  
   TLC solvent system Rf2: Methanol       : Chloroform (0.5:9.5)  
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IR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-
1,2,3,4-TETRAHYDRO-6-METHYL-2-OXO-4-(m-PHENOXYPHENYL)PYRI-
MIDINE (Ig). 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference 
Alkane 
-CH3 
 
 
 
Aromatic and  
ring skeleton 
vibration 
 
 
Pyrimidine  
Moiety 
 
Ketone 
(Amide) 
(Cyclic) 
 
 Amide 
 
Substitution 
 
Para(-4-) 
substituted 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
 
C-N-C (str., v) 
C-N (str., v) 
N-H (def., s,m) 
 
C=O (str., s) 
C=O (str., s) 
 
N-H (str., m) 
 
C-Cl (str., s) 
 
C-H (def., v,s) 
3072.71 
2847.03 
1425.44 
1342.50 
 
3072.71 
1510.31 
1116.82 
 840.99 
 
1313.57 
1247.99 
1600.97 
 
1691.63 
1676.20 
 
3450.77 
 
675.11-
769.22 
840.99 
2950-2875 
2900-2800 
1460-1400 
1385-1300 
 
3080-3010 
1600-1450 
1150-1050 
 825-800 
 
1360-1310 
1340-1250 
1650-1550 
 
1740-1650 
1740-1650 
 
3310-3500 
 
800-600 
 
800-850 
235 
235 
235 
235 
 
236 
236 
236 
236 
 
236 
236 
237 
 
237 
237 
 
237 
 
238 
 
238 
 
 
O
O
NH
N
H
OCH3
NH
Cl
(Ig)
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NMR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-
1,2,3,4-TETRAHYDRO-6-METHYL-2-OXO-4-(m-PHENOXYPHENYL)PYRI-
MIDINE (Ig).  
 
Signal No. Signal Position 
(δ ppm) 
 
Relative No. 
of Protons 
Multiplicity Inference 
1. 
 
1.5988 3H singlet -CH3(a) 
2. 
 
5.4609 1H singlet -CH(c) 
3. 
 
6.0090 2H singlet -NH(b) 
4. 
 
7.0136-7.0231 3H multiplet -Ar-H(e,e’,e’’) 
5. 
 
7.0462-7.0482 3H multiplet -Ar-H(f,f’,f’’) 
6. 
 
6.8368-6.8586 4H triplet -Ar-H(h,h’,I,j) 
7. 
 
7.5535-7.5583 2H doublet -Ar-H(g,g’) 
8. 6.9033-6.9243 
 
1H multiplet -Ar-H(k) 
9. 9.3000 1H singlet -NH(d) 
(Ia)
O
NH
N
H
NH
O
Cl
CH3 O
c
b
d
e
e'e''
f
f'f''g
g'
h
h'
i
jk
a
b
(Ig)
 
 
MASS SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-METHYL-2-OXO-4-
(m-PHENOXYPHENYL)-PYRIMIDINE (Ig).  
 
 
O
O
NH
N
H
OCH3
NH
Cl
(Ig)
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O
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O
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B.P.
 
 
TABLE NO. 1B: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TET-
RAHYDRO- 6-METHYL-2-OXO- 4-(m-PHENOXYPHENYL)-PYRIMIDINES (Ia-j). (Different Inhibition Concentration in µg/ml). 
 
 
Antibactrial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Comp.  No. R 5 25 50 100 250 5 25 50 100 250 
Ia 4-CH3-C6H4 - 12 14 17 19 - 12 15 17 17 
Ib 2,3-(CH3)2-C6H3 - 12 15 15 18 - 12 13 15 16 
Ic 2,5-(CH3)2-C6H3 - 12 14 17 19 - 11 13 14 16 
Id 3-NO2-C6H4 - 11 13 15 18 - 12 15 16 18 
Ie 4-NO2-C6H4 - 10 13 15 18 - 11 14 15 19 
If 3-Cl-C6H4 - 13 15 16 19 - 10 14 15 17 
Ig 4-Cl-C6H4 - 12 13 16 17 - 11 14 17 19 
Ih 3, 4-(Cl)2-C6H3 - 12 13 18 21 - 10 15 17 19 
Ii 4-F-C6H4 - 10     15  16 20 - 12 14 15 18 
Ij 3-Cl-4-F-C6H3 - 10 13 15 18 - 13 14 15 16 
Comparative activity of (Ia-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
     Ih 
Ia, Ic, If, Ih, 
Ii 
 Ij 
Ia, Id, If, 
Ig, Ih,Ie, Ii 
Ia, Id, Ig, 
Ih, 
Ia, Ih, Id, 
Ie, Ig, Ii 
Amplicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
  
TABLE NO. 1C: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TET-
RAHYDRO- 6-METHYL-2-OXO- 4-(m-PHENOXYPHENYL)-PYRIMIDINES (Ia-j). (Different Inhibition Concentration in µg/ml). 
 
Antibactrial activity (Zones of inhibition in m.m.) 
E.Coli MTCC- 443 P. Aeruginosa  MTCC- 441 Comp.  No. R 5 25 50 100 250 5 25 50 100 250 
Ia 4-CH3-C6H4 - 14 15 16 17 - 11 15 17 18 
Ib 2,3-(CH3)2-C6H3 - 15 16 19 21 - 12 15 18 19 
Ic 2,5-(CH3)2-C6H3 - 14 16 19 20 - 10 11 13 15 
Id 3-NO2-C6H4 - 14 16 17 20 - 13 15 16 20 
Ie 4-NO2-C6H4 - 15 16 18 20 - 13 15 18 20 
If 3-Cl-C6H4 - 13 15 17 19 - 11 13 14 18 
Ig 4-Cl-C6H4 - 15 16 16 19 - 14 15 17 19 
Ih 3, 4-(Cl)2-C6H3 - 14 17 18 19 - 12 15 17 19 
Ii 4-F-C6H4 - 15 16 18 20 - 13 15 17 18 
Ij 3-Cl-4-F-C6H3 - 13 14 16 19 - 10 12 15 17 
Comparative activity of (Ia-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
  Ib, Ie, Ig, Ii 
 Ib, Ic, Id, 
Ie, Ig, Ii 
Ib ,  Ic 
Ib, Ic, Id, 
Ie, Ii 
  Ia, Ib, Ih, Id, Ie, Ig, Ii
Ib, Ie Id, Ie 
Amplicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
 
 
TABLE NO. 1D: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TET-
RAHYDRO- 6-METHYL-2-OXO- 4-(m-PHENOXYPHENYL)-PYRIMIDINES (Ia-j). (Different Inhibition Concentration in µg/ml). 
 
Antifungal activity (Zones of inhibition in m.m.) 
A. niger MTCC- 282 A. Clavatus  MTCC- 1323 Comp. No. R 5 25 50 100 250 5 25 50 100 250 
Ia 4-CH3-C6H4 - 16 20 23 23 - 21 21 22 24 
Ib 2,3-(CH3)2-C6H3 - 20 21 25 25 - 21 22 22 25 
Ic 2,5-(CH3)2-C6H3 - 19 20 21 24 - 21 22 22 25 
Id 3-NO2-C6H4 - 17 19 22 24 - 18 19 20 22 
Ie 4-NO2-C6H4 - 18 21 24 24 - 20 21 23 24 
If 3-Cl-C6H4 - 21 22 22 23 - 18 19 21 22 
Ig 4-Cl-C6H4 - 16 18 22 22 - 18 19 21 24 
Ih 3, 4-(Cl)2-C6H3 - 20 24 25 25 - 18 20 21 23 
Ii 4-F-C6H4 - 20 21 22 23 - 18 20 22 22 
Ij 3-Cl-4-F-C6H3 - 21 22 23 24 - 20 22 22 24 
Comparative activity of (Ia-j) with known chosen standard drugs 
Standard drug                             Antifungal activity 
  Ic Ih Ib, Ih   Ia, Ib, Ic Ib, Ic, Ij 
Ia, Ib, Ic, 
Ie, Ii, Ij 
Ia,Ib, Ic, 
Ie, Ig, Ij 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
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SECTION - II 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTED 
PHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-METHYL-4-(m-PHEN-
OXYPHENYL)-2-THIOXOPYRIMIDINES. 
  
 Keeping in view of wide spectrum biodynamic activities38-96 of 
pyrimidines and with a view to have potent therapeutic agents, the synthesis 
of 5-[N-(substitutedphenyl)-carboxamido-1,2,3,4-tetrahydro-6-methyl-4-
(m-phenoxyphenyl)-2-thioxopyrimidines (IIa-j) have been synthesized by 
the condensation of m-phenoxybenzaldehyde, N-(4-substitutedphenyl)-
oxobutanamides and thiourea in the presence of catalytic amount of conc. 
acid. 
 
   
O
O
NH
N
H
SCH3
NH
R
 
       
(IIa-j) 
                                                    R=Substituted Phenyl 
 
The constitutions of the products (IIa-j) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (IIa-j) 
were assayed for their in vitro biological assay.  
 
The products (IIa-j) were assayed for their in vitro biological assay like 
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96 
and P. aeruginosa MTCC-124 (Gram positive) and E. coli MTCC- 443 (Gram 
negative) bacterial strain and antifungal activity towards Aspergillus niger 
MTCC-282 and A. clavatus MTCC-1323 at different concentrations : i.e. 0 
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(control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory 
Concentration) values. The biological activities of the synthesized compounds 
(IIa-j) were compared with standard drugs viz., Ampicilline, 
Chloramphenicol, Norfloxacin, Ciprofloxacin, Griseofulvin and Nystatin. 
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REACTION SCHEME 
 
 
NH2CSNH2
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R= Substituted Phenyl
+
(IIa-j)
H
+ /
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EXPERIMENTAL 
 
PREPARATION AND BILOGICAL EVALUATION OF 5-[N-(SUBSTITUTED 
PHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-METHYL-4-(m-PHEN-
OXYPHENYL)-2-THIOXOPYRIMIDINES. 
 
(A) Preparation of N-substituted-phenyl butanamide-3-ones. 
     
 For preparation, refer Part-I, Section-I, Page No. 39. 
 
(B) Preparation of 5-[N-(p-chlorophenyl)]-carboxamido-1,2,3,4- tetrah-
ydro-6-methyl-4-(m-phenoxyphenyl)-2-thioxopyrimidine (IIg). 
 
A mixture of N-(p-chlorophenyl)-3-oxobutanamide (2.11 gm, 0.01M), 
m-phenoxybenzaldehyde (1.98 ml, 0.01), thiourea (1.14 gm, 0.015 M) and 
catalytic amount of con. acid in ethanol (30 ml) was heated under reflux 
condition for 8 to 10 hrs. The reaction mixture was kept at room temperature 
for 24 hrs. The yellow crystalline product obtained was isolated and 
recrystallized from ethanol. Yield 58%, M.P.: 2300 C, (Required C, 64.06%; H, 
4.48%; N, 9.34%; for C24H20ClN3O3S Found: C, 64.01%; H, 4.43%; N, 9.29%). 
 
TLC solvent system Rf1: Ethyl acetate: Hexane (4.0:6.0) =0.55 
TLC solvent system Rf2: Methanol: Chloroform (1.0:9.0) =0.61 
 
 Similarly, other compounds (IIa-j) were synthesized. The physical data 
are recorded in Table No. 2. 
 
(C) Antimicrobial activity of 5-[N-(p-chlorophenyl)]-carboxamido-1,2,-
3,4-tetrahydro-6-methyl-4-(m-phenoxyphenyl)-2-thioxopyrimidines (IIa-j). 
  
 Antimicrobial activity testing was carried out as described in Part-I, 
Section-I, page no. 40. The MIC values of test solution are recorded in Table 
no. 2A, 2B, and 2C. 
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Result and Discussion:- 
 
 The products (IIa-j) have been subjected to antibacterial activity 
towards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTC-
C-441 (Gram positive) and E. coli MTCC- 443 and (Gram negative) bacterial 
strain and antifungal activity towards Aspergillus niger MTCC-282 and 
Candida albicans MTCC-227 at same concentration . The results of antimicr-
obial activity have been depicted on Page No. 64-66 .   
 
 
 
TABLE NO. 2: PHYSICAL CONSTANTS OF 5-[N-(SUBSTITUTED PHENYL)]-CARBOXAMIDO -1,2,3,4-TETRAHYDRO-6-
METHYL-4-(m-PHENOXYPHENYL)-2-THIOXOPYRIMIDINES (IIa-j). 
 
Rf Value %  of  Nitrogen Comp.
No. 
R Molecular 
Formula 
M.W. 
 
Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
IIa 4-CH3-C6H4 C25H23N3O2S 430 59 2400 0.52/0.60 9.78/9.73 
IIb 2,3-(CH3)2-C6H3 C26H25N3O2S 444 53 2380 0.49/0.68 9.47/9.42 
IIc 2,5-(CH3)2-C6H3 C26H25N3O2S 444 63 2480 0.45/0.64 9.47/9.44 
IId 3-NO2-C6H4 C24H20N4O4S 460 55 2200 0.53/0.63 12.71/12.66 
IIe 4-NO2-C6H4 C24H20N4O4S 460 63 2600 0.57/0.65 12.17/12.13 
IIf 3-Cl-C6H4 C24H20ClN3O2S 450 45 2350 0.65/0.70 9.34/9.30 
IIg 4-Cl-C6H4 C24H20ClN3O2S 450 58 2300 0.55/0.61 9.34/9.29 
IIh 3,4-Cl2-C6H3 C24H19Cl2N3O2S 484 54 2800 0.60/0.69 8.67/8.62 
IIi 4-F-C6H4 C24H20FN3O2S 433 49 2450 0.59/0.63 9.69/9.65 
IIj 3-Cl-4-F-C6H3 C24H19ClFN3O2S 468 60 2650 0.55/0.60 8.98/8.94 
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IR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-
1,2,3,4-TETRAHYDRO-6-METHYL-4-(m-PHENOXYPHENYL)-2-THIOXOPY-
RIMIDINE (IIg). 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference 
Alkane 
-CH3 
 
 
 
Aromatic and  
ring skeleton 
vibration 
 
 
Pyrimidine 
Moiety 
 
 
 
Ketone 
(Amide) 
Thio 
 
 
Substitution 
 
Para(-4-) 
substituted 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
 
C-N-C (str., v) 
C-N (str., v) 
N-H (str., b) 
N-H (def., s,m) 
 
C=O (str., b) 
 
C=S (str.,  s) 
 
 
C-Cl (str., s) 
 
C-H (def., v,s) 
2938.65 
2862.46 
1426.21 
1321.28 
 
2938.65 
1592.29 
1088.50 
818.81 
 
1338.64 
1285.60 
3356.25 
 1626.05 
 
 1688.73 
 
 1140.93 
 
 
    713.69 
 
    818.81 
2975-2850 
2900-2800 
1460-1400 
1385-1300 
 
3080-3010 
1600-1450 
1150-1050 
825-800 
 
1360-1310 
1340-1250 
3310-3500 
1650-1550 
 
1740-1650 
 
1200-1050 
 
 
800-600 
 
800-850 
235 
235 
235 
235 
 
236 
236 
236 
      236 
 
236 
236 
237 
237 
 
237 
 
237 
 
 
238 
 
238 
 
O
O
NH
N
H
SCH3
NH
Cl
(IIg)
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NMR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-
1,2,3,4-TETRAHYDRO-6-METHYL-4-(m-PHENOXYPHENYL)-2-THIOXOPY-
RIMIDINE (IIg). 
 
Signal No. Signal Position 
(δ ppm) 
 
Relative No. 
of Protons 
Multiplicity Inference 
1. 
 
1.6579 3H singlet -CH3(a) 
2. 
 
2.1279 2H singlet -NH(b) 
3. 
 
5.4704 1H singlet -CH(c) 
4. 
 
7.0188-7.0415 3H multiplet -Ar-H(d,d’,d’’) 
5. 
 
7.0482-7.0782 3H multiplet -Ar-H(e,e’,e’’) 
6. 
 
6.9115-6.9314 1H multiplet -Ar-H(f) 
7. 
 
6.8383-6.9003 4H triplet -Ar-H(g,g”,h,h”) 
8. 7.5514-7.5568 
 
2H doublet -Ar-H(i,i”) 
9. 9.3000 1H singlet -NH(j) 
O
O
NH
N
H
SCH3
NH
Cl
a
b
b
c
d
d'd''
e
e'e"
f g
g"
h
h''
i
i''
j
(IIa)
O
O
NH
N
H
SCH3
NH
Cl
a
b
b
c
d
d'd''
e
e'e"
f g
g"
h
h''
i
i''
j
(IIg)
 
MASS SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-METHYL-4-(m-PHENOX-
YPHENYL)-2-THIOXOPYRIMIDINE (IIg). 
 
O
O
NH
N
H
SCH3
NH
Cl
(IIg)
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TABLE NO. 2B: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TET-
RAHYDRO-6-METHYL-4-(m-PHENOXYPHENYL)-2-THIOXOPYRIMIDINES (IIa-j). (Different Inhibition Concentration in µg/ml). 
 
Antibactrial activity (Zones of inhibition in m.m.) 
 
E.Coli MTCC- 443 P. Aeruginosa  MTCC- 441 
Comp. 
 No. R 
5 25 50 100 250 5 25 50 100 250 
IIa 4-CH3-C6H4 - 14 17 18 21 - 11 12 15 17 
IIb 2,3-(CH3)2-C6H3 - 15 17 16 17 - 10 14 16 18 
IIc 2,5-(CH3)2-C6H3 - 15 18 20 21 - 13 17 18 21 
IId 3-NO2-C6H4 - 15 17 18 20 - 12 14 15 17 
IIe 4-NO2-C6H4 - 13 14 16 19 - 14 15 17 20 
IIf 3-Cl-C6H4 - 13 15 17 18 - 10 12 15 18 
IIg 4-Cl-C6H4 - 12 14 15 17 - 11 12 15 18 
IIh 3, 4-(Cl)2-C6H3 - 12 12 14 17 - 13 15 19 21 
IIi 4-F-C6H4 - 12 15 15 17 - 10 13 15 17 
IIj 3-Cl-4-F-C6H3 - 13 15 16 17 - 11 13 17 19 
Comparative activity of (IIa-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
  IIb, IIc, IId 
 IIa, IIb, 
IIc, IId, 
IIc  IIa, IIc, IId,   
IIc, IIe, 
IIh,  
IIc, IIh 
IIc, IIe, 
IIh 
Amplicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
 
 
TABLE NO. 2A: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TET-
RAHYDRO-6-METHYL-4-(m-PHENOXYPHENYL)-2-THIOXOPYRIMIDINES (IIa-j). (Different Inhibition Concentration in µg/ml). 
 
Antibactrial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Comp.  No. R 5 25 50 100 250 5 25 50 100 250 
IIa 4-CH3-C6H4 - 10 14 16 20 - 12 13 15 16 
IIb 2,3-(CH3)2-C6H3 - 12 13 16 19 - 14 15 17 19 
IIc 2,5-(CH3)2-C6H3 - 12 14 15 18 - 15 15 16 17 
IId 3-NO2-C6H4 - 12 13 16 19 - 10 13 14 17 
IIe 4-NO2-C6H4 - 12 13 14 17 - 13 13 14 16 
IIf 3-Cl-C6H4 - 12 14 17 18 - 10 13 14 17 
IIg 4-Cl-C6H4 - 14 15 17 21 - 12 11 13 15 
IIh 3, 4-(Cl)2-C6H3 - 10 12 15 19 - 11 12 15 17 
IIi 4-F-C6H4 - 12 13 15 18 - 13 14 15 18 
IIj 3-Cl-4-F-C6H3 - 13 15 16 17 - 12 13 14 16 
Comparative activity of (IIa-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
      IIa, IIb, IId, IIg, IIh, 
 IIb,IIc IIb, IIc, IIi IIb, IIc, IIb, IIi 
Ampicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
 
 
TABLE NO. 2C: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TET-
RAHYDRO-6-METHYL-4-(m-PHENOXYPHENYL)-2-THIOXOPYRIMIDINES (IIa-j). (Different Inhibition Concentration in µg/ml). 
 
Antifungal activity (Zones of inhibition in m.m.) 
A. niger MTCC- 282 A. Clavatus  MTCC- 1323 Comp. No. R 5 25 50 100 250 5 25 50 100 250 
IIa 4-CH3-C6H4 - 21 21 23 24 - 19 21 24 25 
IIb 2,3-(CH3)2-C6H3 - 21 23 24 25 - 18 20 22 23 
IIc 2,5-(CH3)2-C6H3 - 20 22 25 25 - 18 19 22 24 
IId 3-NO2-C6H4 - 20 21 21 22 - 20 22 22 24 
IIe 4-NO2-C6H4 - 20 20 19 22 - 18 20 23 25 
IIf 3-Cl-C6H4 - 18 21 22 22 - 19 22 23 24 
IIg 4-Cl-C6H4 - 22 22 24 25 - 18 20 25 25 
IIh 3, 4-(Cl)2-C6H3 - 19 20 21 22 - 20 22 23 25 
IIi 4-F-C6H4 - 20 21 23 25 - 20 21 24 25 
IIj 3-Cl-4-F-C6H3 - 21 22 22 25 - 20 23 24 25 
Comparative activity of (IIa-j) with known chosen standard drugs 
Standard drug                             Antifungal activity 
    IIc    IId, IIf, IIh 
IIa, IIb, 
IIc, IId, 
IIe, IIf, IIg, 
IIh, IIi, IIj 
IIa, IIb, 
IIc, IId, 
IIe, IIf, IIg, 
IIh,  IIj 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
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SECTION - III 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTE-
DPHENYL)]-CARBOXAMIDO-1,2,3,6-TETRAHYDRO-1,4-DIMETHYL-2-OX-
O-6-(m-PHENOXYPHENYL)-PYRIMIDINES. 
 
 Keeping in view of wide spectrum biodynamic activities38-96 of 
pyrimidines and with a view to have potent therapeutic agents, the synthesis 
of 5-[N-(substitutedphenyl)]-carboxamido-1,2,3,6-tetrahydro-1,4-dimethy-
l-2-oxo-6-(m-phenoxyphenyl)-pyrimidines (IIIa-j) have been synthesised by 
the condensation of m-phenoxy benzaldehyade, N-(4-substitutedphenyl)-
oxobutanamides and N-methyl urea in presence of catalytic amount of 
conc. Acid. 
 
 
O
O
N
N
H
O
CH3
CH3
NH
R
 
       
               (IIIa-j) 
                                                 R = Substituted Phenyl 
 
The constitutions of the products (IIIa-j) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (IIIa-j) 
were assayed for their in vitro biological assay. 
 
The products (IIIa-j) were assayed for their in vitro biological assay like 
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96 
and P. aeruginosa MTCC-124 (Gram positive) and E. coli MTCC- 443 (Gram 
negative) bacterial strain and antifungal activity towards Aspergillus niger 
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MTCC-282 and A. clavatus MTCC-1323 at different concentrations : i.e. 0 
(control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory 
Concentration) values. The biological activities of the synthesized compounds 
(IIa-j) were compared with standard drugs viz., Ampicilline, 
Chloramphenicol, Norfloxacin, Ciprofloxacin, Griseofulvin and Nystatin. 
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REACTION SCHEME 
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EXPERIMENTAL 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTE-
DPHENYL)]-CARBOXAMIDO-1,2,3,6-TETRAHYDRO-1,4-DIMETHYL-2-OX-
O-6-(m-PHENOXYPHENYL)-PYRIMIDINES. 
 
(A) Preparation of N-substituted-phenyl butanamide-3-ones. 
For preparation, refer Part-I , Section-I, Page No. 39. 
 
(B) Preparation of 5-[N-(p-Chlorophenyl)]-carboxamido-1,2,3,6-tetrah-
ydro-1,4-dimethyl-2-oxo-6-(m-phenoxyphenyl)-pyrimidine (IIIg). 
 
 A mixture of N-(p-chlorophenyl)-3-Oxobutanamide (2.11 gm, 0.01M), 
m-phenoxy benzaldehyde (1.98 ml, 0.01M), N-methyl urea (1.11 gm, 0.015 
M) and catalytic amount of conc. acid in ethanol (30 ml) was heated under 
reflux condition for 8-10 hrs. The reaction mixture was kept at room 
temperature for 24 hrs. The yellow crystalline product obtained was isolated 
and recrystallized from ethanol. Yield: 58%, M.P.: 2400 C, (Required: C, 
67.04%; H, 4.95%; N, 9.38%; for C25H22ClN3O3 Found: C, 66.99%; H, 4.91%; 
N, 9.34%). 
 
TLC solvent system Rf1: Ethyl acetate: Hexane (4.0:6.0) = 0.48 
TLC solvent system Rf2: Methanol: Chloroform (1.0:9.0) = 0.57 
 
 Similarly other compounds (IIIa-j) were synthesized. The physical data 
are recorded in Table-3. 
 
(C) Antimicrobial activity of 5-[N-(substitutedphenyl)]-carboxamido-
1,2,3,6-tetrahydro-1,4-dimethyl-2-oxo-6-(m-phenoxyphenyl)-pyrimidines 
(IIIa-j). 
 Antimicrobial activity testing was carried out as described in Part-I, 
Section-I, page no. 40. The MIC values of test solution are recorded in Table 
no. 3A, 3B, and 3C. 
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Result and Discussion:- 
 
 The products (IIIa-j) have been subjected to antibacterial activity 
towards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTC-
C-441 (Gram positive) and E. coli MTCC- 443 and (Gram negative) bacterial 
strain and antifungal activity towards Aspergillus niger MTCC-282 and 
Candida albicans MTCC-227 at same concentration . The results of antimicr-
obial activity have been depicted on Page No. 77-79.   
 
 
 
TABLE NO. 3: PHYSICAL CONSTANTS OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,6-TETRAHYDRO-1,4-
DIMETHYL-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINES (IIIa-j). 
 
Rf Value %  of  Nitrogen Comp.
No. 
R Molecular 
Formula 
M.W. 
 
Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
IIIa 4-CH3-C6H4 C26H25N3O3 427 60 2470 0.58/0.64 9.83/9.80 
IIIb 2,3-(CH3)2-C6H3 C27H27N3O3 441 62 2380 0.49/0.55 9.52/9.47 
IIIc 2,5-(CH3)2-C6H3 C27H27N3O3 441 57 2490 0.53/0.62 9.52/9.48 
IIId 3-NO2-C6H4 C24H22N4O5 458 55 2250 0.54/0.59 12.22/12.17 
IIIe 4-NO2-C6H4 C24H22N4O5 458 61 2640 0.49/0.54 12.22/12.18 
IIIf 3-Cl-C6H4 C25H22ClN3O3 448 59 2480 0.60/0.69 9.38/9.35 
IIIg 4-Cl-C6H4 C24H20ClN3O2S 450 58 2300 0.48/0.57 9.34/9.29 
IIIh 3,4-Cl2-C6H3 C24H19Cl2N3O2S 484 54 2800 0.60/0.69 8.67/8.62 
IIIi 4-F-C6H4 C25H22FN3O3 431 49 2360 0.57/0.62 9.74/9.70 
IIIj 3-Cl-4-F-C6H3 C25H21ClFN3O3 466 51 2650 0.53/0.58 9.02/8.98 
 
   TLC solvent system Rf1: Ethyl acetate: Hexane (4.0:6.0)  
   TLC solvent system Rf2: Methanol: Chloroform (1.0:9.0)           
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IR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-
1,2,3,4-TETRAHYDRO-6-METHYL-2-OXO-4-(m-PHENOXYPHENYL)PYRI-
MIDINES (IIIg). 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference 
Alkane 
-CH3 
 
 
 
Aromatic and  
ring skeleton 
vibration 
 
m-phenoxy 
benzaldehyde
(alkyl-aryl) 
 
Pyrimidine  
Moiety 
 
 
 
Ketone 
(Amide) 
(Cyclic) 
 
Substitution 
 
Para(-4-) 
Substituted 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
 
C-O-C (asym.str., s) 
C-O-C (sym.str., s) 
 
 
C-N-C (str., v) 
C-N (str., v) 
N-H (str., m) 
N-H (def., s,m) 
 
C=O (str., s) 
C=O (str., s) 
 
C-Cl (str., s) 
 
C-H (def., v,s) 
2933.83 
2864.74 
1442.80 
1338.64 
 
3127.07 
1531.53 
1126.47 
  773.48 
 
1238.34 
1126.47 
 
 
1338.57 
1292.35 
3284.88 
1622.19 
 
1693.63 
1666.55 
 
686.11 
 
773.48 
2950-2875 
2900-2800 
1460-1400 
1385-1300 
 
3080-3010 
1600-1450 
1150-1050 
 825-800 
 
1275-1200 
1075-1000 
 
 
1360-1310 
1340-1250 
3310-3500 
1650-1550 
 
1740-1650 
1740-1650 
 
800-600 
 
800-850 
235 
235 
235 
      235 
 
236 
236 
236 
      236 
 
236 
      236 
 
 
      236 
236 
237 
237 
 
237 
237 
 
238 
 
238 
 
O
O
N
N
H
OCH3
NH
Cl
CH3
(IIIg)
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NMR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-
1,2,3,6-TETRAHYDRO-1,4-DIMETHYL-2-OXO-6-(m-PHENOXYPHENYL)-
PYRIMIDINE (IIIg). 
 
 
Signal No. Signal Position 
(δ ppm) 
 
Relative No. 
of Protons 
Multiplicity Inference 
1. 1.6594 3H singlet -CH3(a) 
2. 2.8583 3H singlet -CH3(b) 
3. 5.4746 1H singlet -CH(c) 
4. 7.0438-7.0622 3H multiplet -Ar-H(e,e’,e’’) 
5. 7.2274-7.2380 3H multiplet -Ar-H(f,f’,f’’) 
6. 6.8378-6.8532 1H multiplet -Ar-H(g) 
7. 6.8562-6.9236 4H triplet -Ar-H(h,h’,i,i’) 
8. 7.5504-7.5588 2H doublet -Ar-H(j,j’) 
9. 9.3000 1H singlet -NH(k) 
O
N
N
H
O
OCH3
NH
Cl
CH3
a
b
c
d
e
e'e"
f
f'f"
g h
h''
i
i'
j
j' k
(IIIg)
 
MASS SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-1,2,3,6-TETRAHYDRO-1,4-DIMETHYL-2-OXO-6-
(m-PHENOXYPHENYL)-PYRIMIDINES (IIIg). 
 
O
O
N
N
H
OCH3
NH
Cl
CH3
(IIIg)
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O
O
NH
N
H
O
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O
NH
N
H
OCH3
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O
N
N
H
O
CH3
NH2
m/z= 231
NH2
CH2
m/z=133
O
O
N
N
H
OCH3
NH
O
CH3
m/z= 198
m/z= 397
m/z=447
(IIIg)
B.P.
 
TABLE NO. 3A: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,6-TET-
RAHYDRO-1,4-DIMETHYL-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINES (IIIa-j). (Different Inhibition Concentration in 
µg/ml). 
 
Antibactrial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Comp.  No. R 5 25 50 100 250 5 25 50 100 250 
IIIa 4-CH3-C6H4 - 12 13 15 20 - 12 14 15 17 
IIIb 2,3-(CH3)2-C6H3 - 10 13 15 19 - 11 13 14 16 
IIIc 2,5-(CH3)2-C6H3 - 12 14 17 21 - 10 15 16 18 
IIId 3-NO2-C6H4 - 10 12      15 18 - 14 16 18 20 
IIIe 4-NO2-C6H4 - 10 14 16 19 - 14 14 16 19 
IIIf 3-Cl-C6H4 - 10 14 17 19 - 13 14 16 19 
IIIg 4-Cl-C6H4 - 10 13 15 17 - 14 15 17 21 
IIIh 3, 4-(Cl)2-C6H3 - 12 15 17 17 - 12 13 15 17 
IIIi 4-F-C6H4 - 12 14 15 18 - 12 15 17 19 
IIIj 3-Cl-4-F-C6H3 - 12 14 18 21 - 12 14 15 17 
Comparative activity of (IIIa-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
     IIIj 
IIIa, IIIb, 
IIIc, IIIe, 
IIIf, IIIj 
 IIId, IIIe, IIIg, IIIf 
IIIa, IIIc, 
IIId, IIIe, 
IIIf, IIIg, 
IIIi 
IIIc, IIId, 
IIIe, IIIf, 
IIIg, IIIi 
IIIc, IIId, 
IIIe, IIIf, 
IIIg, IIIi 
Ampicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
 
TABLE NO. 3B: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,6-
TETRAHYDRO-1,4-DIMETHYL-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINES (IIIa-j). (Different Inhibition Concentration in 
µg/ml). 
 
Antibactrial activity (Zones of inhibition in m.m.) 
 
E.Coli MTCC- 443 P. Aeruginosa  MTCC- 441 
Comp. 
 No. R 
5 25 50 100 250 5 25 50 100 250 
IIIa 4-CH3-C6H4 - 11 14 17 19 - 11 12 13 15 
IIIb 2,3-(CH3)2-C6H3 - 12 15 19 21 - 12 14 17 19 
IIIc 2,5-(CH3)2-C6H3 - 12 12 15 18 - 13 15 16 18 
IIId 3-NO2-C6H4 - 13 14 15 16 - 10 14 17 18 
IIIe 4-NO2-C6H4 - 15 17 18 18 - 14 16 17 19 
IIIf 3-Cl-C6H4 - 15 15 18 19 - 10 12 16 17 
IIIg 4-Cl-C6H4 - 12 16 18 21 - 11 15 18 20 
IIIh 3, 4-(Cl)2-C6H3 - 12 15 19 23 - 11 13 18 20 
IIIi 4-F-C6H4 - 14 16 18 21 - 10 12 15 19 
IIIj 3-Cl-4-F-C6H3 - 15 16 18 20 - 10 11 13 14 
Comparative activity of (IIIa-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
  IIIe, IIIf, IIIj 
IIIe, IIIi, 
IIIg, IIIj 
IIIb, IIIh 
IIIb, IIIf, 
IIIg, IIIh, 
IIIi, IIIj 
  IIIc, IIIe, IIIg 
IIIg, IIIh IIIg, IIIh 
Amplicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
TABLE NO. 3C: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,6-
TETRAHYDRO-1,4-DIMETHYL-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINES (IIIa-j). (Different Inhibition Concentration in 
µg/ml). 
 
Antifungal activity (Zones of inhibition in m.m.) 
A. niger MTCC- 282 A. Clavatus  MTCC- 1323 Comp. No. R 5 25 50 100 250 5 25 50 100 250 
IIIa 4-CH3-C6H4 - 18 20 23 25 - 18 21 23 25 
IIIb 2,3-(CH3)2-C6H3 - 18 20 22 25 - 18 20 22 24 
IIIc 2,5-(CH3)2-C6H3 - 21 22 23 25 - 21 22 23 25 
IIId 3-NO2-C6H4 - 20 22 24 25 - 19 20 23 24 
IIIe 4-NO2-C6H4 - 20 21 23 25 - 22 22 23 25 
IIIf 3-Cl-C6H4 - 20 22 23 25 - 19 21 22 24 
IIIg 4-Cl-C6H4 - 19 20 22 22 - 21 22 23 25 
IIIh 3, 4-(Cl)2-C6H3 - 21 22 23 25 - 18 20 21 22 
IIIi 4-F-C6H4 - 22 24 24 25 - 18 18 20 22 
IIIj 3-Cl-4-F-C6H3 - 20 23 22 23 - 19 20 21 24 
Comparative activity of (IIIa-j) with known chosen standard drugs 
Standard drug                             Antifungal activity 
  
IIIc,IIId 
IIIe,IIIf, 
IIIg,IIIh 
IIIi, IIIj 
    IIIc, IIIe, IIIg 
IIIa, IIId, 
IIIj 
IIIa, IIIb, 
IIIc, IIId, 
IIIe, IIIg, 
IIIf 
IIIa, IIIb, 
IIIc, IIId, 
IIIe, IIIf, 
IIIg, IIIi 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
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SECTION-IV 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTED 
PHENYL)]-CARBOXAMIDO -1,2,3,4-TETRAHYDRO-6-ISOPROPYL-2-OXO-
4-(m-PHENOXYPHENYL)-PYRIMIDINES. 
 
Keeping in view of wide spectrum biodynamic activities38-96 of 
pyrimidines and with a view to have potent therapeutic agents, the synthesis 
of 5-[N-(substitutedphenyl)]-carboxamido-1,2,3,4-tetrahydro-6-isopropyl-
2-oxo-4-(m-phenoxyphenyl)-pyrimidines (IVa-j) have been synthesized by 
the condensation of m-phenoxy benzaldehyde, N-(substitutedphenyl)-4 
meth-yl-3-oxopentamide  and urea in the presence of conc. acid. 
 
O
O
NH
N
H
O
NH
CH3
CH3
R
 
 
                                                                 (IVa-j) 
                                                    R= Substituted Phenyl 
 
The constitutions of the products (IVa-j) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (IVa-j) 
were assayed for their in vitro biological assay. 
 
The products (IVa-j) were assayed for their in vitro biological assay like 
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96 
and P. aeruginosa MTCC-124 (Gram positive) and E. coli MTCC- 443 (Gram 
negative) bacterial strain and antifungal activity towards Aspergillus niger 
MTCC-282 and A. clavatus MTCC-1323 at different concentrations : i.e. 0 
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(control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory 
Concentration) values. The biological activities of the synthesized compounds 
(IVa-j) were compared with standard drugs viz., Ampicilline, 
Chloramphenicol, Norfloxacin, Ciprofloxacin, Griseofulvin and Nystatin. 
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REACTION SCHEME 
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EXPERIMENTAL 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTED 
PHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-ISOPROPYL-2-OXO-
4-(m-PHENOXYPHENYL)-PYRIMIDINES. 
 
(A)  Preparation of N-(substitutedphenyl)-4 methyl-3-oxopentamide210-211. 
For Preparation, of N-substituted –phenyl butanamide-3-ones has been 
under taken according to literature210-211.   
 Similarly, other compounds (4a-j) were synthesized. The physical data 
are recorded in Table No. 4A. 
 
(B) Preparation of 5-[N-(p-chlorophenyl)]-carboxamido-1,2,3,4-tetrah-
ydro-6-isopropyl-2-oxo-4-(m-phenoxyphenyl)-pyrimidine (IVg). 
           A mixture of N-(p-chlorophenyl)-4methyl-3-oxopentanamide (2.40 
gm, 0.01M), m-phenoxy benzaldehyde (1.98 ml, 0.01M), urea (0.90 gm, 
0.015 M) and catalytic amount of conc. acid in ethanol (30 ml) was heated 
under reflux condition for 8 to 10 hrs. The reaction mixture was kept at room 
temperature for 24 hrs. The yellow crystalline product obtained was isolated 
and recrystallized from ethanol. Yield: 62%, M.P.: 2200 C, (Required: C, 
67.06%; H, 5.24%; N, 9.10%; for C26H24ClN3O3 Found: C, 67.02%; H, 5.19%; 
N, 9.05%). 
TLC solvent system Rf1: Ethyl acetate: Hexane (4.0:6.0) = 0.59 
TLC solvent system Rf2: Methanol       : Chloroform (1.0:9.0) = 0.43 
Similarly other compounds (IVa-j) were synthesized. The physical data 
are recorded in Table- 4. 
 
(C) Antimicrobial activity of 5-[N-(substitutedphenyl)]-carboxamido-
1,2,3,4-tetrahydro-6-isopropyl-2-oxo-4-(m-phenoxyphenyl)-pyrimidines 
(IVa-j). 
Antimicrobial activity testing was carried out as described in Part-I, 
Section-I, page no.40. The MIC values of test solution are recorded in Table 
no.4B, 4C, and 4D.
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Result and Discussion:- 
 
 The products (IVa-j) have been subjected to antibacterial activity 
towards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTC-
C-441 (Gram positive) and E. coli MTCC- 443 and (Gram negative) bacterial 
strain and antifungal activity towards Aspergillus niger MTCC-282 and 
Candida albicans MTCC-227 at same concentration . The results of antimicr-
obial activity have been depicted on Page No. 91-93 .   
 
 
 
   TABLE NO. 4A: PHYSICAL CONSTANTS OF N-(SUBSTITUTEDPHENYL)-4 METHYL-3-OXOPENTAMIDES (4a-j). 
 
   
 
Rf Value %  of  Nitrogen Comp.
No. 
R Molecular 
Formula 
M.W. 
 
Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
4a 4-CH3-C6H4 C13H17NO2 191 60 1280 0.64/0.52 6.39/6.33 
4b 2,3-(CH3)2-C6H3 C14H19NO2 233 58 1070 0.61/0.51 6.00/5.95 
4c 2,5-(CH3)2-C6H3 C14H19NO2 233 63 1170 0.43/0.54 6.00/5.96 
4d 3-NO2-C6H4 C12H14N2O4 250 52 1580 0.45/0.48 11.19/11.12 
4e 4-NO2-C6H4 C12H14N2O4 250 59 1670 0.49/0.51 11.19/11.14 
4f 3-Cl-C6H4 C12H14NO2Cl 240 53 1480 0.58/0.53 5.84/5.78 
4g 4-Cl-C6H4 C12H14NO2Cl 240 57 1380 0.67/0.54 5.84/5.79 
4h 3,4-Cl2-C6H3 C12H13NO2Cl2 274 66 1420 0.45/0.47 5.11/5.08 
4i 4-F-C6H4 C12H14NO2F 205 60 980 0.65/0.48 6.27/6.22 
4j 3-Cl-4-F-C6H3 C12H13NO2ClF 258 47 1130 0.55/0.58 5.44/5.40 
 
TABLE NO. 4: PHYSICAL CONSTANTS OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-ISOPR-
OPYL-2-OXO-4-(m-PHENOXYPHENYL)-PYRIMIDINES (IVa-j).  
 
  
 TLC solvent system Rf1: Ethyl acetate: Hexane (4.0:6.0)  
 TLC solvent system Rf2: Methanol       : Chloroform (1.0:9.0) 
Rf Value %  of  Nitrogen Comp. 
No. 
R Molecular 
Formula 
M.W. 
 
Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
IVa 4-CH3-C6H4 C27H27N3O3 442 53 2170 0.64/0.51 9.52/9.46 
IVb 2,3-(CH3)2-C6H3 C28H29N3O3 456 59 2780 0.60/0.48 9.22/9.17 
IVc 2,5-(CH3)2-C6H3 C28H29N3O3 456 61 2600 0.57/0.47 9.22/9.19 
IVd 3-NO2-C6H4 C26H24N4O5 473 49 2350 0.53/0.58 11.86/11.81 
IVe 4-NO2-C6H4 C26H24N4O5 473 63 2650 0.51/0.54 11.86/11.80 
IVf 3-Cl-C6H4 C24H20ClN3O3 462 47 2160 0.41/0.43 9.10/9.06 
IVg 4-Cl-C6H4 C26H24ClN3O3 462 62 2200 0.59/0.43 9.10/9.05 
IVh 3,4-Cl2-C6H3 C24H19ClN3O3 496 56 2380 0.59/0.49 8.47/8.42 
IVi 4-F-C6H4 C26H24FN3O3 417 54 2400 0.45/0.47 9.43/9.38 
IVj 3-Cl-4-F-C6H3 C24H19ClFN3O3 480 57 2670 0.38/0.49 8.76/8.71 
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 IR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO -
1,2,3,4-TETRAHYDRO-6-ISOPROPYL-2-OXO-4-(m-PHENOXYPHENYL)-
PYRIMIDINES (IVg). 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference 
Alkane 
-CH3 
 
 
 
Aromatic and  
ring skeleton 
vibration 
 
 
Pyrimidine  
Moiety 
 
 
 
m-phenoxy 
benzaldehyde
(alkyl-aryl) 
 
Ketone 
(Amide) 
(Cyclic) 
 
Substitution 
 
Para(-4-) 
substituted 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
 
C-N-C (str., v) 
C-N (str., v) 
N-H (str., m) 
N-H (def., s,m) 
 
C-O-C (asym. str.,s) 
C-O-C (sym.str., s) 
 
 
C=O (str., s) 
C=O (str., s) 
 
 
C-Cl (str., s) 
 
 
C-H (def., v,s) 
2938.65 
2860.53 
1432.19 
1392.65 
 
3038.95 
1542.14 
1093.67 
 832.31 
 
1343.46 
1276.92 
3333.10 
1639.55 
 
1238.94 
1093.67 
 
 
1674.27 
1668.84 
 
 
692.47-
716.58 
 
832.31 
2950-2875 
2900-2800 
1460-1400 
1385-1300 
 
3080-3010 
1600-1450 
1150-1050 
 825-800 
 
1360-1310 
1340-1250 
3310-3500 
1650-1550 
 
1275-1200 
1075-1000 
 
 
1740-1650 
1740-1650 
 
 
800-600 
 
 
800-850 
235 
235 
235 
      235 
 
236 
236 
236 
      236 
 
      236 
      236 
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      237 
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237 
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NMR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO 
-1,2,3,4-TETRAHYDRO-6-ISOPROPYL-2-OXO-4-(m-PHENOXYPHENYL)-
PYRIMIDINE (IVg). 
 
Signal No. Signal Position 
(δ ppm) 
 
Relative No. of 
Protons 
Multiplicity Inference 
1. 1.6123-1.6155 6H doublet -CH3(a) 
2. 2.6511-2.6689 1H multiplet -CH(b) 
3. 5.4272 1H singlet -CH(c) 
4. 5.9535 2H singlet -CH2(d) 
5. 7.0112-7.0733 3H multiplet -Ar-H(e,e’,e’’) 
6. 7.1411-7.1942 3H multiplet -Ar-H(f,f’,f’’) 
7. 7.2520-7.2997 4H triplet -Ar-H(h,h’,i,i’) 
8. 7.5994-7.8276 2H doublet -Ar-H(j,j’) 
9. 9.5000 1H singlet -Ar-NH(k) 
 
O
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N
H
O
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Cl
CH3
CH3
a b
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e
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f
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g h
h'
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j
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MASS SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-ISOPROPYL-2-OXO-4-
(m-PHENOXYPHENYL)-PYRIMIDINE (IVg). 
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TABLE NO. 4B: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-
TETRAHYDRO- 6-ISOPROPYL-2-OXO-4-(m-PHENOXYPHENYL)-PYRIMIDINES (IVa-j). (Different Inhibition Concentration in 
µg/ml).            
 
Antibactrial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Comp.  No. R 5 25 50 100 250 5 25 50 100 250 
IVa 4-CH3-C6H4 - 10 15 16 17 - 12 13 15 16 
IVb 2,3-(CH3)2-C6H3 - 12 14 15 18 - 9 13 14 16 
IVc 2,5-(CH3)2-C6H3 - 12 13 15 17 - 10 13 15 18 
IVd 3-NO2-C6H4 - 12 15 17 18 - 10 12 14 15 
IVe 4-NO2-C6H4 - 11 13 15 18 - 10 11 16 17 
IVf 3-Cl-C6H4 - 10 14 18 20 - 12 16 17 18 
IVg 4-Cl-C6H4 - 11 14 15 19 - 10 13 15 16 
IVh 3, 4-(Cl)2-C6H3 - 10 14 17 20 - 9 11 14 17 
IVi 4-F-C6H4 - 12 13 14 17 - 11 13 15 16 
IVj 3-Cl-4-F-C6H3 - 10 12 13 18 - 10 12 15 16 
Comparative activity of (IVa-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
    IVf 
    IVg,     
IVh, IVf, 
  IVf IVe, IVf IVc, IVf 
Ampicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
 
TABLE NO. 4C: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-
TETRAHYDRO- 6-ISOPROPYL-2-OXO-4-(m-PHENOXYPHENYL)-PYRIMIDINES (IVa-j). (Different Inhibition Concentration in 
µg/ml).            
Antibactrial activity (Zones of inhibition in m.m.) 
 
E.Coli MTCC- 443 P. Aeruginosa  MTCC- 441 
Comp. 
 No. R 
5 25 50 100 250 5 25 50 100 250 
IVa 4-CH3-C6H4 - 14 16 17 21 - 11 12 13 15 
IVb 2,3-(CH3)2-C6H3 - 15 17 18 22 - 12 14 16 17 
IVc 2,5-(CH3)2-C6H3 - 10 13 15 17 - 13 14 17 19 
IVd 3-NO2-C6H4 - 12 13 17 19 - 13 15 18 19 
IVe 4-NO2-C6H4 - 12 13 15 17 - 11 14 16 17 
IVf 3-Cl-C6H4 - 13 13 15 17 - 11 12 16 18 
IVg 4-Cl-C6H4 - 15 17 20 21 - 10 11 14 15 
IVh 3, 4-(Cl)2-C6H3 - 15 17 18 20 - 15 17 19 22 
IVi 4-F-C6H4 - 11 14 16 18 - 12 14 17 19 
IVj 3-Cl-4-F-C6H3 - 11 14 15 18 - 10 14 15 16 
Comparative activity of (IVa-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
  
IVb, 
IVg, 
IVh 
IVa, IVb, 
IVc, IVh 
IVg 
IVa, IVb, 
IVg, IVh 
 IVh IVd, IVh IVd, IVh IVg 
Ampicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
TABLE NO. 4D: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-
TETRAHYDRO- 6-ISOPROPYL-2-OXO-4-(m-PHENOXYPHENYL)-PYRIMIDINES (IVa-j). (Different Inhibition Concentration in 
µg/ml).            
Antifungal activity (Zones of inhibition in m.m.) 
A. niger MTCC- 282 A. Clavatus  MTCC- 1323 Comp. No. R 5 25 50 100 250 5 25 50 100 250 
IVa 4-CH3-C6H4 - 22 22 24 24 - 18 19 22 24 
IVb 2,3-(CH3)2-C6H3 - 20 22 23 25 - 21 21 23 24 
IVc 2,5-(CH3)2-C6H3 - 19 20 22 25 - 18 18 19 22 
IVd 3-NO2-C6H4 - 18 21 21 22 - 18 20 22 23 
IVe 4-NO2-C6H4 - 19 20 21 22 - 21 22 23 25 
IVf 3-Cl-C6H4 - 19 20 19 21 - 18 18 21 22 
IVg 4-Cl-C6H4 - 20 24 24 25 - 19 21 22 24 
IVh 3, 4-(Cl)2-C6H3 - 21 22 23 24 - 19 20 22 24 
IVi 4-F-C6H4 - 18 21 21 22 - 19 22 23 25 
IVj 3-Cl-4-F-C6H3 - 18 21 22 22 - 18 20 21 22 
Comparative activity of (IVa-j) with known chosen standard drugs 
Standard drug                             Antifungal activity 
  
IVa, 
IVb, 
IVc, 
IVe,  
IVf,  
IVg,  
IVh,   
IVg    IVb,  IVe IVe,  IVi 
IVa,  IVb,  
IVd,  IVe,  
IVg,  IVh,  
IVi 
IVa,  IVb,  
IVh,  IVe,  
IVg,  IVi 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
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SECTION-V 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTE-
DPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-ISOPROPYL-4-(m-
PHENOXYPHENYL)-2-THIOXOPYRIMIDINES. 
 
Keeping in view of wide spectrum biodynamic activities38-96 of 
pyrimidines and with a view to have potent therapeutic agents, the synthesis 
of 5-[N-(substitutedphenyl)-carboxamido-1,2,3,4-tetrahydro-6-isopropyl-
4-(m-phenoxyphenyl)-2-thioxopyrimidines (Va-j) have been synthesized by 
the condensation of m-phenoxybenzaldehyde, N-(substitutedphenyl)-4-
methyl-3-oxopentamide  and  thiourea in the presence of conc. acid. 
 
O
O
NH
N
H
S
CH3
CH3
NH
R
 
 
              (Va-j) 
                    R= Substituted Phenyl 
 
The constitutions of the products (Va-j) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (Va-j) 
were assayed for their in vitro biological assay. 
 
The products (Va-j) were assayed for their in vitro biological assay like 
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96 
and P. aeruginosa MTCC-124 (Gram positive) and E. coli MTCC- 443 (Gram 
negative) bacterial strain and antifungal activity towards Aspergillus niger 
MTCC-282 and A. clavatus MTCC-1323 at different concentrations : i.e. 0 
Section-V                                                                 Studies on Pyrimidines 
 
Department of Chemistry, Saurashtra University, Rajkot (Gujarat). 
 
 
95 
(control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory 
Concentration) values. The biological activities of the synthesized compounds 
(Va-j) were compared with standard drugs viz., Ampicilline, 
Chloramphenicol, Norfloxacin, Ciprofloxacin, Griseofulvin and Nystatin. 
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REACTION SCHEME 
 
 
R
NH
O
CH3
O
CH3
R
O CHO
   (Va-j)
R= Substituted Phenyl
NH2
S
NH2
CH3
O
N
H
NH
S
NH
O
CH3
+
H
+ /
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EXPERIMENTAL 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTE-
DPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-ISOPROPYL-4-(m-
PHENOXYPHENYL)-2-THIOXOPYRIMIDINES. 
 
(A) Preparation of N-(substitutedphenyl)-4 methyl-3-oxopentamide. 
 
For preparation, refer Part-I , Section-IV, Page No. 83. 
 
(B) Preparation of 5-[N-(p-chlorophenyl)]-carboxamido-1,2,3,4-tetrahy-
dro-6-isopropyl-4-(m-phenoxyphenyl)-2-thioxopyrimidine (Vg). 
  A mixture of N-(p-chlorophenyl)-4methyl-3-oxopentanamide (2.40 
gm, 0.01M), m-phenoxy benzaldehyde (1.98 ml, 0.01M), thiourea (1.14 gm, 
0.015 M) and catalytic amount of conc. acid in ethanol (30 ml) was heated 
under reflux condition for 8 to 10 hrs. The reaction mixture was kept at room 
temperature for 24 hrs. The yellow crystalline product obtained was isolated 
and recrystallized from ethanol. Yield: 60%, M.P.: 2250 C, (Required: C, 
65.33%; H, 5.06%; N, 8.79%; for C26H24ClN3O2S Found: C, 65.28%; H, 
5.01%; N, 8.74%). 
 
TLC solvent system Rf1: Ethyl acetate: Hexane (4.0:6.0) =0.53 
TLC solvent system Rf2: Methanol: Chloroform (1.0:9.0) =0.56 
 
Similarly, other compounds (Va-j) were synthesized. The physical data 
are recorded in Table-5. 
 
(C) Antimicrobial activity of N-(substitutedphenyl)-1,2,3,4-tetrahydro-
6-isopropyl-4-(m-phenoxyphenyl)-2-thioxopyrimidine-5-carboxamides  
(Va-j). 
  Antimicrobial activity testing was carried out as described in 
Part-I, Section-I, page no. 40. The MIC values of test solution are recorded 
in Table no. 5A, 5B, and 5C. 
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Result and Discussion:- 
 
 The products (Va-j) have been subjected to antibacterial activity 
towards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTC-
C-441 (Gram positive) and E. coli MTCC- 443 and (Gram negative) bacterial 
strain and antifungal activity towards Aspergillus niger MTCC-282 and 
Candida albicans MTCC-227 at same concentration . The results of antimicr-
obial activity have been depicted on Page No. 104-106 .  
  
 
TABLE NO. 5: PHYSICAL CONSTANTS OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-TETRAHYDRO-6-ISOPR-
OPYL-4-(m-PHENOXYPHENYL)-2-THIOXOPYRIMIDINES (Va-j).  
 
Rf Value %  of  Nitrogen Comp.
No. 
R Molecular 
Formula 
M.W. 
 
Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
Va 4-CH3-C6H4 C27H27N3O2S 458 56 2610 0.58/0.53 9.18/9.12 
Vb 2,3-(CH3)2-C6H3 C28H29N3O2S 472 62 2590 0.47/0.49 8.91/8.86 
Vc 2,5-(CH3)2-C6H3 C28H29N3O2S 472 57 2480 0.44/0.50 8.91/8.85 
Vd 3-NO2-C6H4 C26H24N4O4S 489 57 2440 0.53/0.52 11.47/11.41 
Ve 4-NO2-C6H4 C26H24N4O5 489 61 2590 0.48/0.43 11.47/11.43 
Vf 3-Cl-C6H4 C26H24ClN3O2S 478 59 2530 0.48/0.46 8.79/8.73 
Vg 4-Cl-C6H4 C26H24ClN3O2S 478 60 2250 0.53/0.56 8.79/8.74 
Vh 3,4-Cl2-C6H3 C26H23Cl2N3O3S 512 65 2120 0.42/0.48 8.20/8.15 
Vi 4-F-C6H4 C26H24FN3O2S 462 49 2730 0.52/0.50 9.10/9.04 
Vj 3-Cl-4-F-C6H3 C26H23ClFN3O2S 480 51 2670 0.53/0.48 8.47/8.42 
     
    TLC solvent system Rf1: Ethyl acetate: Hexane (4.0:6.0)  
    TLC solvent system Rf2: Methanol: Chloroform (1.0:9.0)  
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IR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-
1,2,3,4-TETRAHYDRO-6-ISOPROPYL-4-(m-PHENOXYPHENYL)-2-THIOX-
OPYRIMIDINE (Vg). 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference 
Alkane 
-CH3 
 
 
 
Aromatic and  
ring skeleton 
vibration 
 
 
Pyrimidine  
Moiety 
 
 
m-phenoxy 
benzaldehyde
(alkyl-aryl) 
Ketone 
Thio 
 
Substitution 
 
Para(-4-) 
substituted 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
 
C-N-C (str., v) 
C-N (str., v) 
N-H (str., m) 
N-H (def., s,m) 
C-O-C (asym. str.,s) 
C-O-C (sym.str., s) 
 
C=O (str., s) 
C=S (str., b) 
 
C-Cl (str., s) 
 
C-H (def., v,s) 
2912.61 
2864.39 
1435.09 
1348.29 
 
3066.92 
1519.96 
1105.25 
 802.41 
 
1313.57 
1244.13 
3450.77 
1600.97 
1244.13 
1028.09 
 
1691.63 
1170.83 
 
675.11-
769.22 
840.99 
2950-2875 
2900-2800 
1460-1400 
1385-1300 
 
3080-3010 
1600-1450 
1150-1050 
 825-800 
 
1360-1310 
1340-1250 
3310-3500 
1650-1550 
1275-1200 
1075-1000 
 
1740-1650 
1200-1050 
 
800-600 
 
800-850 
235 
235 
235 
      235 
 
236 
236 
236 
      236 
 
236 
236 
237 
237 
236 
      236 
 
237 
237 
 
238 
 
238 
 
O
O
NH
N
H
S
CH3
CH3
NH
Cl
(Vg)
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NMR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO 
-1,2,3,4-TETRAHYDRO-6-ISOPROPYL-4-(m-PHENOXYPHENYL)-2-THIOX-
OPYRIMIDINE (Vg). 
  
 
Signal No. Signal Position 
(δ ppm) 
 
Relative No. 
of Protons 
Multiplicity Inference 
1. 1.4522-1.4561 6H doublet -CH3(a) 
2. 2.1346 2H singlet -NH(b) 
3. 2.5413-2.5588 1H multiplet -CH(c) 
4. 5.4395 1H      singlet -CH(d) 
        5. 7.0561-7.1316 3H multiplet -Ar-H(e,e’,e’’) 
6. 7.1361-7.1942 3H multiplet -Ar-H(f, f’,f’’) 
7. 7.2529-7.3021 4H triplet -Ar-H(h,h’,i,i’) 
8. 7.5964-7.5280 2H doublet -Ar-H(j,j’) 
9. 9.4000 1H singlet -Ar-NH(k) 
O
O
NH
N
H
S
NH
Cl
CH3
CH3
a
b
a
c
d
e
e'e"
f
f'f"
g h
h'
i
i'
j
j' k b
(Vg)
MASS SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO -1,2,3,4-TETRAHYDRO-6-ISOPROPYL-4-(m-PHE-
NOXYPHENYL)-2-THIOXOPYRIMIDINE (Vg). 
O
O
NH
N
H
S
NH
Cl
CH3
CH3
(Vg)
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CH3
O
O
NH
N
H
S
NH
Cl
CH3
CH3
m/z = 477
m/z = 350
m/z = 307
m/z = 323
m/z = 281
m/z = 279
m/z = 264
m/z = 249
m/z = 222
m/z = 281
O
O
N
N
H
S
NH2
CH3
O
N
N
H
S
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CH3
CH3
O
O
N
N
H
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O
N
N
H
S
O
N
N
H
CH3
O
N
N
H
CH3
OH
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N
H
S
CH3
CH3
O
CH3
O
OH
CH3
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NH
m/z = 477
(Vg)
B.P.
 
TABLE NO. 5B: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-
TETRAHYDRO-6-ISOPROPYL-4-(m-PHENOXYPHENYL)-2-THIOXOPYRIMIDINES (Va-j). (Different Inhibition Concentration in 
µg/ml).                                                     
 
 
Antibactrial activity (Zones of inhibition in m.m.) 
 
E.Coli MTCC- 443 P. Aeruginosa  MTCC- 441 
Comp. 
 No. R 
5 25 50 100 250 5 25 50 100 250 
Va 4-CH3-C6H4 - 12 13 19 20 - 11 14 15 17 
Vb 2,3-(CH3)2-C6H3 - 11 14 16 16 - 11 13 14 17 
Vc 2,5-(CH3)2-C6H3 - 10 14 17 19 - 14 15 18 19 
Vd 3-NO2-C6H4 - 14 15 17 20 - 13 14 16 17 
Ve 4-NO2-C6H4 - 16 17 19 22 - 9 10 13 14 
Vf 3-Cl-C6H4 - 11 15 17 19 - 10 12 14 17 
Vg 4-Cl-C6H4 - 14 15 15 16 - 12 15 15 19 
Vh 3, 4-(Cl)2-C6H3 - 14 17 18 20 - 12 14 19 23 
Vi 4-F-C6H4 - 12 13 16 18 - 12 13 15 17 
Vj 3-Cl-4-F-C6H3 - 17 18 19 21 - 10 11 16 18 
Comparative activity of (Va-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
  Ve, Vj 
Ve, Vh, 
Vj 
Va, Ve, 
Vj 
Va, Vj, Vd, 
Ve, Vh 
  Vc, Vg Vc, Vh Vh 
Amplicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
 
TABLE NO. 5C: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-
TETRAHYDRO-6-ISOPROPYL-4-(m-PHENOXYPHENYL)-2-THIOXOPYRIMIDINES (Va-j). (Different Inhibition Concentration in 
µg/ml).                                                     
 
 
Antifungal activity (Zones of inhibition in m.m.) 
A. niger MTCC- 282 A. Clavatus  MTCC- 1323 Comp. No. R 5 25 50 100 250 5 25 50 100 250 
Va 4-CH3-C6H4 - 19 21 23 25 - 21 21 23 24 
Vb 2,3-(CH3)2-C6H3 - 18 19 19 20 - 18 20 22 25 
Vc 2,5-(CH3)2-C6H3 - 20 21 21 22 - 21 23 25 25 
Vd 3-NO2-C6H4 - 18 20 22 25 - 18 20 21 22 
Ve 4-NO2-C6H4 - 18 21 22 24 - 18 18 21 22 
Vf 3-Cl-C6H4 - 20 22 23 24 - 18 20 22 22 
Vg 4-Cl-C6H4 - 18 20 22 23 - 18 19 21 22 
Vh 3, 4-(Cl)2-C6H3 - 19 20 21 22 - 18 19 21 21 
Vi 4-F-C6H4 - 18 19 21 22 - 21 22 23 25 
Vj 3-Cl-4-F-C6H3 - 20 21 21 22 - 19 21 22 25 
Comparative activity of (Va-j) with known chosen standard drugs 
Standard drug                             Antifungal activity 
  
Va, Vc, 
Vf, Vh, 
Vj 
    Va, Vc, Vi Vc, Vi 
Va, Vb, 
Vc, Vf, Vi, 
Vj 
Va, Vb, 
Vc, Vi, Vj 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
TABLE NO. 5A: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,4-
TETRAHYDRO-6-ISOPROPYL-4-(m-PHENOXYPHENYL)-2-THIOXOPYRIMIDINES (Va-j). (Different Inhibition Concentration in 
µg/ml).                                                     
 
Antibactrial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Comp.  No. R 5 25 50 100 250 5 25 50 100 250 
Va 4-CH3-C6H4 - 10 12 15 17 - 12 12 15 17 
Vb 2,3-(CH3)2-C6H3 - 10 15 17 18 - 11 14 17 17 
Vc 2,5-(CH3)2-C6H3 - 12 14 15 17 - 12 14 16 19 
Vd 3-NO2-C6H4 - 12 13 15 18 - 14 16 17 18 
Ve 4-NO2-C6H4 - 11 15 16 19 - 13 15 17 21 
Vf 3-Cl-C6H4 - 12 14 15 19 - 10 14 16 17 
Vg 4-Cl-C6H4 - 11 13 14 17 - 12 14 15 17 
Vh 3, 4-(Cl)2-C6H3 - 13 14 15 18 - 14 17 18 20 
Vi 4-F-C6H4 - 12 15 16 19 - 14 15 17 19 
Vj 3-Cl-4-F-C6H3 - 12 14 15 18 - 12 13 15 18 
Comparative activity of (Va-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
     
Ve,  Vf,  
 Vi 
 
 Vd,  Vh,  Vi 
Vb,  Vc,  
Vd,  Ve,  
Vg,  Vf,  
Vh 
Vb, Vd, 
Ve, Vf, 
Vh, Vi, Vj 
Vc, Vd, 
Ve, Vi, 
Vh, Vj 
Ampicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
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SECTION-VI 
 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTE-
DPHENYL)]-CARBOXAMIDO -1,2,3,6-TETRAHYDRO-4-ISOPROPYL-1-ME-
THYL-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINES. 
 
Keeping in view of wide spectrum biodynamic activities38-96 of 
pyrimidines and with a view to have potent therapeutic agents, the synthesis 
of 5-[N-(p-chlorophenyl)]-carboxamido-1,2,3,6-tetrahydro-4-isopropyl-1-
methyl-6-(m-phenoxyphenyl)-2-thioxopyrimidines (VIa-j) have been synth-
esized by the condensation of m-phenoxy benzaldehyde, N-
(substitutedphenyl)-4-methyl-3-oxopentamide  and  N-methyl urea in the 
presence of conc. acid. 
 
O
O
N
N
H
O
CH3
CH3
NH
CH3
R
 
       
         (VIa-j) 
                                                      R=Substituted Phenyl 
 
The constitutions of the products (VIa-j) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (VIa-j) 
were assayed for their in vitro biological assay. 
The products (VIa-j) were assayed for their in vitro biological assay like 
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96 
and P. aeruginosa MTCC-124 (Gram positive) and E. coli MTCC- 443 (Gram 
negative) bacterial strain and antifungal activity towards Aspergillus niger 
MTCC-282 and A. clavatus MTCC-1323 at different concentrations : i.e. 0 
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(control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory 
Concentration) values. The biological activities of the synthesized compounds 
(VIa-j) were compared with standard drugs viz., Ampicilline, 
Chloramphenicol, Norfloxacin, Ciprofloxacin, Griseofulvin and Nystatin. 
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 REACTION SCHEME 
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R= Substituted Phenyl
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EXPERIMENTAL 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[N-(SUBSTITUTE-
DPHENYL)]-CARBOXAMIDO -1,2,3,6-TETRAHYDRO-4-ISOPROPYL-1-
METHYL-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINES. 
 
(A) Preparation of N-(substitutedphenyl)-4-methyl-3-oxopentamide. 
 
For preparation, refer Part-I , Section-IV, Page No. 83. 
 
(B) Preparation of 5-[N-(p-chlorophenyl)]-carboxamido-1,2,3,6-tetrahy-
dro-4-isopropyl-1-methyl-2-oxo-(m-phenoxyphenyl)-pyrimidine (VIg). 
 
  A mixture of N-(p-chlorophenyl)-4methyl-3-oxopentanamide (2.40 
gm, 0.01M), m-phenoxy benzaldehyde (1.98 ml, 0.01M), N-methyl urea 
(1.11 gm, 0.015 M) and catalytic amount of conc. acid in ethanol (30 ml) was 
heated under reflux condition for 8-10 hrs. The reaction mixture was kept at 
room temperature for 24 hrs. The yellow crystalline product obtained was 
isolated and recrystallized from ethanol. Yield: 54%, M.P.: 2140 C, (Required: 
C, 68.13%; H, 5.51%; N, 8.83%; for C27H26ClN3O3 Found: C, 68.07%; H, 
5.46%; N, 8.78%). 
 
TLC solvent system Rf1: Ethyl acetate: Hexane (4.0:6.0) =0.48 
TLC solvent system Rf2: Methanol: Chloroform (1.0:9.0) =0.51 
 Similarly, other compounds (VIa-j) were synthesized. The 
physical data are recorded in Table-6. 
 
(C) Antimicrobial activity of N-(substitutedphenyl)-1,2,3,6-tetrahydro-
4-isopropyl-1-methyl-6-(m-phenoxyphenyl)-2-thioxopyrimidine-5-carbox-
amides (VIa-j). 
Antimicrobial activity testing was carried out as described in Part-I, 
Section-I, page no. 40. The MIC values of test solution are recorded in Table 
no. 5A, 5B, and 5C. 
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Result and Discussion:- 
 
 The products (VIa-j) have been subjected to antibacterial activity 
towards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTC-
C-441 (Gram positive) and E. coli MTCC- 443 (Gram negative) bacterial 
strain and antifungal activity towards Aspergillus niger MTCC-282 and 
Candida albicans MTCC-227 at same concentration . The results of 
antimicrobial activity have been depicted on Page No. 117-119 .  
 
TABLE NO. 6: PHYSICAL CONSTANTS OF 5-[N-(SUBSTITUTE-DPHENYL)]-CARBOXAMIDO-1,2,3,6-TETRAHYDRO-4-
ISOPROPYL-1-METHYL-6-(m-PHENOXYPHENYL)-2-THIOXOPYRIMIDINES (VIa-j).  
 
Rf Value %  of  Nitrogen Comp.
No. 
R Molecular 
Formula 
M.W. 
 
Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
VIa 4-CH3-C6H4 C28H29N3O3 456 56 2530 0.52/0.56 9.22/9.16 
VIb 2,3-(CH3)2-C6H3 C29H31N3O3 470 53 2390 0.49/0.54 8.95/8.90 
VIc 2,5-(CH3)2-C6H3 C28H29N3O2S 470 48 2270 0.51/0.55 8.95/8.91 
VId 3-NO2-C6H4 C27H26N4O5 487 49 2370 0.48/0.53 11.52/11.46 
VIe 4-NO2-C6H4 C27H26N4O5 487 50 2390 0.57/0.61 11.52/11.48 
VIf 3-Cl-C6H4 C27H26ClN3O3 475 59 2330 0.49/0.57 8.83/8.77 
VIg 4-Cl-C6H4 C27H26ClN3O3 475 54 2140 0.48/0.51 8.83/8.78 
VIh 3,4-Cl2-C6H3 C27H25Cl2N3O3 510 57 2120 0.43/0.53 8.23/8.18 
VIi 4-F-C6H4 C27H26FN3O3 460 48 2420 0.52/0.59 9.14/9.08 
VIj 3-Cl-4-F-C6H3 C27H25ClFN3O3 494 49 2620 0.53/0.58 8.51/8.46 
 
   TLC solvent system Rf1: Ethyl acetate: Hexane (4.0:6.0)  
   TLC solvent system Rf2: Methanol: Chloroform (1.0:9.0)  
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IR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO-
1,2,3,6-TETRAHYDRO-4-ISOPROPYL-1-METHYL-6-(m-PHENOXYPHENY-
L)-PYRIMIDINE (VIg). 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference 
Alkane 
-CH3 
 
 
 
Aromatic and  
ring skeleton 
vibration 
 
 
m-phenoxy 
benzaldehyde
(alkyl-aryl) 
 
Pyrimidine  
Moiety 
 
 
 
Ketone 
(Amide) 
(Cyclic) 
 
Substitution 
 
Para(-4-) 
Substituted 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
 
C-O-C (asym.str., s) 
C-O-C (sym.str., s) 
 
 
C-N-C (str., v) 
C-N (str., v) 
N-H (str., m) 
N-H (def., s,m) 
 
C=O (str., s) 
C=O (str., s) 
 
 
C-Cl (str., s) 
 
C-H (def., v,s) 
2900.07 
2852.81 
1446.66 
1342.50 
 
3064.03 
1527.67 
1056.08 
  818.81 
 
1214.23 
1056.06 
 
 
1328.03 
1278.85 
3374.58 
1615.44 
 
1658.84 
1654.01 
 
 
681.86- 
754.19 
818.81 
2950-2875 
2900-2800 
1460-1400 
1385-1300 
 
3080-3010 
1600-1450 
1150-1050 
 825-800 
 
1275-1200 
1075-1000 
 
 
1360-1310 
1340-1250 
3310-3500 
1650-1550 
 
1740-1650 
1740-1650 
 
 
800-600 
 
800-850 
235 
235 
235 
      235 
 
236 
236 
236 
      236 
 
236 
      236 
 
 
      236 
236 
237 
237 
 
237 
237 
 
 
238 
 
      238 
 
O
O
N
N
H
O
CH3
CH3
NH
Cl
CH3
(VIg)
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NMR SPECTRAL STUDY OF 5-[N-(p-CHLOROPHENYL)]-CARBOXAMIDO 
-1,2,3,6-TETRAHYDRO-4-ISOPROPYL-1-METHYL-2-OXO-6-(m-PHENOXY-
PHENYL)PYRIMIDINE (VIg).  
 
Signal No. Signal Position 
(δ ppm) 
Relative No. of 
Protons 
Multiplicity Inference 
1. 
 
1.1127-1.1174 6H doublet -CH3(a) 
2. 
 
2.5507-2.5673 1H multiplet -CH(b) 
3. 
 
2.9661 3H singlet -CH3(c) 
4. 
 
5.1934 1H Singlet -CH(d) 
5. 
 
5.4933 1H singlet -NH(e) 
6. 
 
6.9490-6.9539 2H doublet -Ar-H(i,i’) 
7. 
 
6.3407-6.3518 2H doublet -Ar-H(j,j’) 
8. 6.9661-6.9784 3H multiplet -Ar-H(g,g’,g’’) 
9. 7.2812-7.2875 3H multiplet -Ar-H(h,h’,h’’) 
10. 7.0444-7.1525 1H multiplet -Ar-H(k) 
11. 7.3640-7.3707 1H multiplet -Ar-H(l) 
12. 7.4653-7.5044 1H doublet -Ar-H(m) 
13. 5.4933 1H singlet -Ar-H(e) 
14. 8.0000 1H singlet -Ar-NH(f) 
 
O
N
N
H
NH
O
Cl
O
CH3
CH3
CH3
a
a b
c
d
e
f
g
g'g''
h
h'h''i
i'
j
j'
k
lm
(VIIa)
MASS SPECTRAL STUDY OF 5-[N-(4-CHLOROPHENYL)]-CARBOXAMIDO -1,2,3,6-TETRAHYDRO-4-ISOPROPYL-1-METHY- 
L-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINE (VIg). 
 
O
O
N
N
H
O
NH
Cl
CH3
CH3
CH3
(VIg)
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O
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N
H
CH3
O
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CH3
NHCl
O
O
N
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O
CH3
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NHCl
m/z = 475 m/z = 321
m/z = 322 (M+1)
m/z = 475
m/z = 279 (M+1)
m/z = 224
m/z = 278
m/z = 305
m/z = 196
m/z = 279 (M+1)
O
N
N
H
CH3
O
CH3
CH3
O
N
N
H
OCH3
m/z = 278
O
O
N
N
H
CH3
OCH3
O
CH3
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O
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CH3
O
N
N
H
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O
N
N
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O
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N
H
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TABLE NO. 6A: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,6-
TETRAHYDRO-4-ISOPROPYL-1-METHYL-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINES (VIa-j).(Different  Inhibition Conce-
ntration in µg/ml). 
 
 
Antibacterial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Comp.  No. R 5 25 50 100 250 5 25 50 100 250 
VIa 4-CH3-C6H4 - 12 14 15 20 - 13 15 16 18 
VIb 2,3-(CH3)2-C6H3 - 10 13 15 20 - 13 15 16 19 
VIc 2,5-(CH3)2-C6H3 - 11 12 15 18 - 12 13 15 17 
VId 3-NO2-C6H4 - 12 13 16 18 - 11 12 14 16 
VIe 4-NO2-C6H4 - 12 13 14 17 - 12 15 16 19 
VIf 3-Cl-C6H4 - 9 12 15 18 - 9 11 15 16 
VIg 4-Cl-C6H4 - 10 13 15 18 - 10 11 14 17 
VIh 3, 4-(Cl)2-C6H3 - 12 14 17 21 - 10 12 13 17 
VIi 4-F-C6H4 - 10 12 14 17 - 10 11 12 14 
VIj 3-Cl-4-F-C6H3 - 11 13 14 17 - 11 12 15 16 
Comparative activity of (VIa-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
     VIa,  VIb,  VIh 
 VIa,  VIb,  
VIa,  VIb,  
VIe,  
VIa, VIb, 
VIe,  
VIa, Vb, 
Ve 
Ampicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
 
TABLE NO. 6B: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,6-
TETRAHYDRO-4-ISOPROPYL-1-METHYL-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINES (VIa-j).(Different  Inhibition Conce-
ntration in µg/ml). 
 
Antibactrial activity (Zones of inhibition in m.m.) 
 
E.Coli MTCC- 443 P. Aeruginosa  MTCC- 441 
Comp. 
 No. R 
5 25 50 100 250 5 25 50 100 250 
VIa 4-CH3-C6H4 - 17 18 18 20 - 10 14 17 18 
VIb 2,3-(CH3)2-C6H3 - 13 15 17 19 - 11 13 13 15 
VIc 2,5-(CH3)2-C6H3 - 10 14 16 19 - 12 13 17 19 
VId 3-NO2-C6H4 - 11 14 17 18 - 13 15 17 20 
VIe 4-NO2-C6H4 - 13 14 15 17 - 11 13 15 16 
VIf 3-Cl-C6H4 - 11 15 17 18 - 10 12 14 15 
VIg 4-Cl-C6H4 - 11 15 16 17 - 12 13 15 18 
VIh 3, 4-(Cl)2-C6H3 - 10 13 14 15 - 12 14 15 17 
VIi 4-F-C6H4 - 9 13 17 19 - 13 15 18 21 
VIj 3-Cl-4-F-C6H3 - 10 13 15 18 - 10 11 14 15 
Comparative activity of (VIa-j) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
  VIa VIa  VIa   VId, VIi VIi VId 
Ampicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
 
TABLE NO. 6C: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[N-(SUBSTITUTEDPHENYL)]-CARBOXAMIDO-1,2,3,6-
TETRAHYDRO-4-ISOPROPYL-1-METHYL-2-OXO-6-(m-PHENOXYPHENYL)-PYRIMIDINES (VIa-j).(Different  Inhibition Conce-
ntration in µg/ml). 
 
 
Antifungal activity (Zones of inhibition in m.m.) 
A. niger MTCC- 282 A. Clavatus  MTCC- 1323 Comp. No. R 5 25 50 100 250 5 25 50 100 250 
VIa 4-CH3-C6H4 - 20 22 22 23 - 19 21 24 25 
VIb 2,3-(CH3)2-C6H3 - 18 22 22 23 - 18 20 22 23 
VIc 2,5-(CH3)2-C6H3 - 21 22 23 24 - 18 19 22 25 
VId 3-NO2-C6H4 - 21 22 22 24 - 20 20 23 24 
VIe 4-NO2-C6H4 - 18 20 21 22 - 18 20 23 25 
VIf 3-Cl-C6H4 - 20 22 23 24 - 19 21 23 25 
VIg 4-Cl-C6H4 - 18 21 21 24 - 23 23 24 25 
VIh 3, 4-(Cl)2-C6H3 - 18 21 22 23 - 20 22 23 24 
VIi 4-F-C6H4 - 19 21 23 25 - 18 21 23 25 
VIj 3-Cl-4-F-C6H3 - 20 22 22 24 - 20 21 23 23 
Comparative activity of (VIa-j) with known chosen standard drugs 
Standard drug                             Antifungal activity 
  VIa VIa  VIa   VIg, VIh VIa, VIb, 
VIa,  VIc, 
VId, VIe, 
VIf, VIg, 
VIh, VIi, 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
 

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PART-II 
STUDIES ON QUINOLINES 
INTRODUCTION 
Benzene ring when fused with two and three (2,3) positions of pyridine 
nucleus is known as quinoline. The structure of quinoline is depicted as under. 
 
N  
(32) 
 
 The discovery of quinoline in 1842 by Gerhardt as the result of the 
drastic decomposition of quinine and of cinchonine antedates Anderson’s 
discovery of pyridine by four year. It was not, however, until Weidel in 1878 
and later Ladenbarg studied the pyridine bases in detail that the foundations 
for the Chemistry of quinoline and isoquinoline were well and truly laid. The 
latter was discovered in the quinoline fraction of coal tar by Hoogewerff and 
Van Drop in 1885. It was largely due to the efforts of these chemists that 
subsequent work on the isoquinoline alkaloids proved so fruitful in the next 
century. The presence of quinoline or isoquinoline bases in petroleum 
distillates was demonstrated by Maberry et.al.,243. Later Bailey et.al., in a 
series of researches isolated and identified a number of quinolines, among 
which may be mentioned in the following 2,3,8-trimethyl quinoline244, 
quinoline and quinaldine245 ; 2,3,4,8-tetramethylquinoline246 and 2,3-dimethyl-
8-propylqinoline247 and 2,8-dimethylquinolines248. 
 
The medicinal use of quinoline derivatives dates back more than 350 
years. The first compound is a natural one known as Quinine139 which is still 
important drug for threating Chloroquine and multidrug resistant falciparum 
malaria. It is the chief alkaloid of the South American Cinchona tree’s bark. In 
the year 1633, an Augustiniam monk named Calancha; of Lima Peru; first 
wrote that a powder of Cinchona given as a beverage cures the fevers. It was 
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employed for medicine as a powder, extract or infusion for almost two 
centuries. 
The search for synthetic antimalarial other than Quinine derivatives 
initiated in Germany early in the twentieth century. It was based on the 
observation of Guttmann and Ehrlich140 made in 1891 that the dye methelene 
blue and some chemotherapeutic effect on malaria in patients. In 1920s the 
first synthetic antimalarial agent, Pamaquine was synthesized by Schulemann 
et.al.,141, which is 8-amino quinoline derivative. After that many 8-amino 
quinoline derivatives such as, Pentaquine142 and Primaquine143 were 
synthesized. 
 
The quinoline nucleus occurs in several natural compounds (cinchona 
alkaloids) and pharmacologically active substances displaying a broad range 
of biological activity.144-146 In addition to the medicinal applications, quinolines 
have been employed in the study of bioorganic and bioorganometallic 
processes.147-149The most important occurrence of quinoline derivative plant 
is that of the cinchona and angostura alkaloids. The alkaloid echinospsine239 
present in echinops ritro was shown by Spath240 and Kolbe to be identical 
with synthetic 1-methyl-4-methoxy-quinoline.Suzuki et. al.,241 isolated form 
rice bran several acids, one of which is regarded as dihydroxyquinoline-5-
carboxylic acid.242In animals the only quinoline derivative of important is 
Kynurenic acid (33). It occurs normally in the urine of dogs but not that of cats. 
It is a product of  the catabolism of tryptophan, the ultimate intermediate being 
o-aminobenzolypyruvic acid (34). 
 
OH
N COOH
O
NH2 O
COOH
 
 
               (33)                                                       (34) 
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 Ganguli et.al.,248 record the isolation of 5,8-dimethylquinoline. It was 
isolated as the picrate. Reactivity of 2 and 4 substituted quinoline as 
influenced by other groups. 
Buchmann et.al.,249 refluxed 2,4-dichloroquinoline(35) with a solution of 
potassium hydroxide in ethanol and obtained the mixture of the following 
compounds: 
Cl
N Cl
C2H5OK
O
N
CH3
Cl
+
CH3N
Cl
O
+
Cl
N OH
 
            (35)          (36)                   (37)                             (38) 
 
 These results might be interpreted as indicating a slightly greated 
activity of a 2-chloro in accordance with expectation because of greater 
proximity to the –C=N- group.According to Buchmann et.al.,249, the halogen in 
4- chloro-2-hydroxy quinoline is quite inactive, which the chlorine in 2-chloro-
4-hyrdroxyquinoline and both halogens in 2,4-dichloroquinoline are active. 
Koenings et.al.,250 have suggested that when 2,4-dimethylquinoline is heated 
with 1 mole of formaldehyde, gives 4-methyl-2-(3-dihydroxyisopropyl)-
quinoline. It indicates the more reactivity of 2-methyl group. Though, Eibner251 
had heated quinaldine and lepidine (5 g. of each) with equal weight of 
benzaldehyede, obtained 7.95 gm of 2-styryl quinoline and 1 gm of the 
hydrochloride of 4-styryl quinoline. Thus, in all of these experiments the 2-
methyl has consistently proved to be more reactive than the 4-methyl, which 
is more distant from the activating –C=N- group. 
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SYNTHETIC ASPECT 
 
 The literature survey reveals that several named organic reactions and 
publication and patents described the synthesis of quinolines as under. 
 
1. Quinoline from aniline, sulphuric acid and oxidizing agent.150 
 
 
 
2.    Quinoline synthesis from the condensation of o-aminobenzaldehyde with 
α-methylene carbonyl compound.151 
 
 
3.  Acid catalysed condensation of aniline and β-diketones to assemble 
quinolines.152 
 
 
4. Thermal or acid-catalysed condensation of aniline and β-ketoester leads 
to quinoline-4-one.153 
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5. Synthesis of 4-hydroxyquinoline by the action of carbonyl compound on 
anthranilic acid is referred as a Nimentowski Quinoline synthesis.154 
 
 
 
6.   The construction of 2-hydroxyquinoline or 2-quinolone by the treatment of 
β-ketoester with aryl amine above 1000C. is regarded as Knorr Quinoline 
synthesis. The intermediate anilide undergoes cyclodehydration with 
concentrated sulphuric acid.155 
 
 
7.  The preparation of substituted cinchonic acid by the condensation of an 
aryl amine, aliphatic or aromatic aldehyde and pyruvic acid is known as the 
Dobner reaction.156 
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8.   Synthesis of 4-hydroxyquinoline by the action of alkoxymethylenemalo-nic 
ester or acylmalonic ester on aryl amine is known as Gould-Jacobs 
reaction.157 
 
 
 
9.   Quinoline-4-carboxylic acid from the condensation of isatic acid and α-
methylene carbonyl compound using base.158 
 
 
10.   The α,β unsaturated aldehyde like crotonaldehyde reacts with aromatic 
amine to yield quinoline derivatives.159 
 
 
         Quinoline carboxylic acid in which quinoline ring is substituted by oxo 
and carboxylic acid group at different positions are well documented in 
literature. 
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Some of the important 4-quinolones which are used in chemical trial can 
be summarized as under with several structures.160 
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STRUCTURE- ACTIVITY RELATIONSHIP 
 
The quinolone carboxylic acids constitute a class of extremely potent 
and orally active broad spectrum antibacterial agents162-165. These compou-
nds have been shown to affect the bacterial growth by inhibiting the DNA 
gyrase, a key enzyme in bacterial DNA replication.166-167 
The substituiton of a piperazinyl ring at position 7 has rendered the 
molecule active against Pseudomonas and the presence of a fluorine atom at 
position 6 extends the activity of the molecule to some but not all gram 
positive bacteria169. Streptococcus can be resistant168. Additions of alkyl 
chains to the nitrogen at position 1, increase the activity of the compounds. 
The substitution of hydrogen atoms by fluorines at position 8 of the ring and 
on the methyl of the alkyl chain diminishes the rate of degradation and 
decreases the rate of elimination.It was widely believed that 3-carboxylic acid 
and 4-carbonyl were necessary for the antimicrobial activity of the 
compounds. However, Chu et.al.,170 a showed that the transformation of 
existing molecules in 2,3,4,9-tetrahydroisothiazolo[5,4-b] quinoline-3,4-diones 
produces a significant increase in their biological activity170. 
 
Overview of SAR of Fluoroquinolones antibacterial drugs,171-172. 
 
O
Y- N
R6
R5
R4
R3
COOH
R2
R1
(39)
Moderate Influence on
potency Cardiotoxicity
Essential For gyrase binding
and bacterial memdrane
transport
Limited changes
influences
Infuences potency and
Pk::. antigenicity.Controls Pk (oral abs).:
Phototoxicity
Infuences potency
spectrum, Pk
Controls gyrase and
anti bacterial potency
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1. Substituent at N-1 position: A compilation of active N-1 quinolone  
substituents is shown below with an emphasis on overall in vitro 
potency. 
                                                                                                                       
 
                                 against anarobes         
                                                                         (40) 
2.   The simple replacement of C-2 hydrogen has generally to be 
disadvantageous,e.g., C-2 methyl or hydroxyl groups. However, some 
derivatives containing a suitable C-1 and C-2 ring have been shown to 
possess notable activity, e.g., Prulifloxacin. 
 
                           
O
O
O O N
N
CH3
N
F COOH
S
CH3
 
                                                                   (41) 
3. Without doubt, the C-3 carboxylic acid moiety is most commonly 
encountered. Other acidic groups such as sulphonic acid, phosponic 
acid, tetrazole as well as derivatisation as an ester results in a loss of 
antibacterial activity. 
4. The C-4-oxo group of the quinolone nucleous appears to be essential 
for antibacterial activity. Replacement with 4-thioxo or sulphonyl group 
leads to a loss of activity. 
5. The incorporation of an amino group at the C-5 position has proven to 
be beneficial in terms of antibacterial activity. The order of activity at 
R3: NH2, CH3>F, H>OH, OR, SH, SR. 
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6.  The incorporation of a fluorine atom at the C-6 position of the quinolone 
is monumental, the order of activity at R4: F.>Cl, Br, CH3 >CN. 
7.  The introduction of a piperazine moiety at C-7 was a landmark 
devlopment. Other aminopyrrolidines also are compatible for activity. 
   
                               R                                              (42) 
8. A hydrogen atom at the C-8 or a nitrogen atom (a napthyridone) is the 
most common. In general, a C-8 fluoro substitutent offers good potency 
against gram-negative pathogens, while a C-8 methoxy moiety is active 
against grampositive bacteria. The order of activity at R6; F, Cl, OCH3, 
>H, CF3> methyl,vinyl, propagyl. 
9. A halogen (F or Cl) at the 8-position improves oral absorption. 
10. The joining of N-1 group to the C-8 position will oxazine ring leads to 
active ofloxacine. 
 
MEDICINAL INTEREST OF QUINOLINES 
 
The research on Quinoline system is of current interest due to their 
valuable activities as Antibiotic, DNA gyrase inhibitors, Antibacterial etc. 
Besides the currently established drugs like Norfloxacin ,Ciprofloxacin. Many 
quinoline derivatives have been synthesized world wide and have led to 
numerous second generation commercial product such as Ofloxacin, 
Gatifloxacin, Pipemidic acid. By the literature survey, it was found that 
quinolines possess wide variety of biodynamic activity, which can be put 
forward as under. 
 
[A] Analgesic activity173-176  [B] Antiallergic activity177-181 
[C] Antiasthmatic activity182-183  [D] Antibacterial activity184-202,253 
[E] Anticancer activity203,254-255  [F] Anticocidialactivity175,188,204-205 
[G] Antiinflammatory activity206-207 [H] Antinaphylatetic activity208 
[I] Antipyretic activity173   [J] Antirheumatism activity173 
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[K] Antispasmolytic activity209  [L] Antitumor activity210-212,258 
[M] Antiulcer activity213   [N] Bacteriostatic activity216 
[O] CNS depressant activity174,216 [P] Diuretic activity216-217 
[Q] Hypnotic activity218   [R] Hypotensive activity174 
[S] Pressure lowering activity219 [T] Tranquilizer activity217 
[U] Tuberculosis activity219-220,257 [V] Antimalarials221 
[W] Topoisomerase inhibitors222-223  
[X] CB2 cannabinoid receptors agonists224 
 
 
Recently, K.S.Aithal et.al.,225 have reported uses of norfloxacin for 
bone joint urinary tract, respiratory tract infection and also for maningitis. 
Antimicrobial and antifungal activity of 4-quinolones have been reported by 
M.B.Deshmukh et.al.,226-227 Antiallergic activity studies of quinolone (43) and 
imidazoquinolinones (44) have been reported by N. P. Peet et.al.,180 which 
established the SAR conclusion that amine and ester functions at the position 
8 and 3 respectively were necessary for the significant antiallergic activity. 
 
 
(43)            (44) 
 
 
H. Takayama et.al.,228 have isolated new alkaloid (45) from leaves of 
Gardnerianutans having a novel 4-quinolone ring skeleton. 
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                                                          (45) 
The alkaloid was obtained from crude basic fraction of the leaves of 
gardneria nutans in its unique structure having a 4-quinolone moiety. 
R. Singh et. al.,229 have reported the synthesis and antibacterial activity 
of 7-hydrazinoquinolones (46). 
 
                     (46) 
           
 
G. Gruver et. al.,171 have designed the synthesis of 1,3,4-oxadiazoles 
and 1,3,4-oxadiazole-2-thione derivatives of nalidixic acid (47) and (48) as 
potent antibacterial and fungicidal agents. 
 
(47)                                                             (48) 
          R1= p-Cl, p-OH, o,m-di nitro, phenyl 
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C. Zhi et. al.,223 have reported the synthesis of a novel hybrid 
antibacterial agent (49) of 6-(3-ethyl-4-methylanilino)uracils (EMAU) and 
fluoroquinolones moiety (FQ) as potent DNA polymerase- topoisomerase 
inhibitors and showed that the resulting AU-FQ hybrid compounds were 
significantly more potent than the parent ‘EMAU’ compounds. 
     
      (49) 
 
Recently, synthesis antimicrobial activity studies of novel amide 
derivatives of 4-quinolone (50) and (51) have been reported by H. I. Chauhan 
et.al.,252 
 
(50)                                                        (51)    
R=H,-OCH3,O-Cl,m-CH3,o-NO2----etc  R1=N-methyl piperazine,N-ethyl, 
                                                                             morpholine.etc 
 
A. Carta et.al.,230 have studied the antitubercular activity of some new 
(1,2,3)- triazolo (4,5-h) quinolones (52) aganist the multidrug resistant Mycob-
acterium tuberculosis strains (H37Rv). 
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          (52)   
                                                           R and R1= Substituted phenyl 
 
Recently, antimycobacterial and toxicological evaluation of novel 
ofloxacin derivatives (53) have been reported by M. Dinakaran et.al.,231 
 
(53) 
                                            R and R1=substituted phenyl 
 
 
 
In our further studies and in order to evaluate the biodynamic activities, 
synthesis of quinoline derivatives was undertaken, which can be summarised 
in the following sections. 
 
 
SECTION-I : PREARATION AND BIOLOGICAL EVALUATION OF 6-CHL-
ORO/FLUORO/NITRO/-N-CYCLOPROPYL-2-(p-CHLORO/FL-
UORO/METHYLPHENYL)-QUINOLINE-4-CARBOXAMIDES. 
 
SECTION-II : PREPARATION AND BIOLOGICAL EVALUATION OF 6-CH-
LORO/FLUORO/NITRO-N-PENTYL-2-(p-CHLORO/FLUORO/-
METHYLPHENYL)-QUINOLINE-4-CARBOXAMIDES. 
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SECTION-III : PREPARATION AND BIOLOGICAL EVALUATION OF DI-
(AMINO PROPYNYL)/ DI-(AMINOBUTYL)/ N,N-DIETHYL/  N-
ETHYL PIPERAZINYL/ N-METHYL PIPERAZINYL/ MORPHO-
NILYL/ PIPERIDINYL / N-PHENYL PIPERIZINYL/PYROLIDIN-
YL-6-FLUORO-2-(p-FLUOROPHENYL)-QUINOLINE-4-
CARBOXAMIDES. 
 
SECTION-IV : PREPARATION AND BIOLOGICAL EVALUATION OF 5-(6-
CHLORO/FLU-ORO/NITRO-2-(p-CHLORO/FLUORO/METHYL-
PHENYL)-QUINOLIN-4-YL)-1,3,4-OXADIAZOLE-2-THIOLS. 
 
SECTION-V : PREPARATION AND BIOLOGICAL EVALUATION 4-AMINO-
5-[6-CHLORO/FLUORO/NITRO-2-(p-CHLORO/FLUORO/MET-
HYLPHENYL)-QUINOLIN-4-YL]-4H-1,2,4-TRIAZOLE-3-
THIOLS. 
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SECTION-I 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 6-CHLORO/FLUO-
RO/NITRO-N-CYCLOPROPYL-2-(p-CHLORO/FLUORO/METHYLPHENYL)-
QUINOLINE-4-CARBOXAMIDES. 
Keeping in view of wide spectrum biodynamic activities173-224 of 
Quinolines and with a view to have potent therapeutic agents, the synthesis 
of 6-Chloro/fluoro/nitro-N-cyclopropyl-2-(p-chloro/fluoro/methyl)-quinoli-
ne-4-carboxamides has been synthesized by the condensation of 6-
Chloro/fluoro/nitro-N-cyclopropyl-2-(p-chloro/fluoro/methyl)-quinoline-4-
carbonyl chlorides and cyclopropylamine. 
 
R
O
N
R1
NH
 
                                                      (VIIa-i) 
                               R,R1 = Substituted Phenyl 
The constitutions of the products (VIIa-i) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (VIIa-i) 
were assayed for their in vitro biological assay. 
The products (VIIa-i) were assayed for their in vitro biological assay 
like antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 and B. subtillis MTCC-441 (Gram positive) and E. coli MTCC- 443 and 
(Gram negative) bacterial strain and antifungal activity towards Aspergillus 
niger MTCC-282 and Candida albicans MTCC-227 at different concentrati- 
ons: i.e. 0 (control), 5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum 
Inhibitory Concentration) values. The biological activities of the synthesized 
compounds (VIIa-i) were compared with standard drugs viz., Ampicilline, 
Chloramphenicol, Ciprofloxacin, Norfloxacin, Griseofulvin and Nystatin.  
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REACTION SCHEME 
 
 
NH2
R1 + CH3
O
COOH +
R1
COOH
N R
SOCl2
COCl
N R
R1
NH2
3 hrs.
-HCl
R-CHO
R1
O
N R
NH
/
 
                                                (VIIa-i) 
                            R, R1= Substituted Phenyl 
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EXPERIMENTAL 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 6-CHLORO/FLUOR-
O/NITRO-N-CYCLOPROPYL-2-(p-CHLORO/FLUORO/METHYLPHENYL)-
QUINOLINE-4-CARBOXAMIDES. 
 
(A) Preparation of 6-fluro-2-(p-flurophenyl)-quinoline-4-carboxylic 
acid (7d). 
A mixture of 4-flurobenzaldehyde (0.01mole), freshly distilled pyruvic 
acid (0.01 mole; 0.88 g) and absolute ethyl alcohol (25 ml) was refluxed to the 
boiling point on a water bath and a solution of  4-fluroaniline (0.01 mole) in 
absolute ethyl alcohol (25 ml) was added slowly with frequent shaking. The  
content was refluxed for 3 hours and allowed to stand overnight. The product 
was filtered and recrystallised from ethanol. Yield: 70%, M.P.: 1480C, 
(Required: C, 67.37%; H, 3.18%; N, 4.91% for C16H9F2O2, Found: C, 67.32%; 
H, 3.11%; N, 4.86%). 
TLC solvent system Rf1: Ethyl acetate: Hexane       (3.0:7.0) = 0.58 
TLC solvent system Rf2: Methanol      : Toluene       (0.5:9.5) = 0.47 
Similarly other compounds (7a-j) were synthesized. The physical data 
are record in Table No. 7A 
 
(B) Preparation of 6-Fluro-N-cyclopropyl-2-(p-flurophenyl)-quinoline-
4-carboxamide (VIId). 
 
A mixture of 6-fluro-2-(p-flurophenyl)-quinoline-4-carboxylic acid 
(0.001 mole; 2.84 g) in dioxan (40 ml) and thionyl chloride (10 ml) was 
refluxed at 60-700 C for 3 hours. Excess of thionyl chloride was removed by 
distillation and product obtained was kept at 00C and 2-3 drops of pyridine 
and refluxed with cyclopropyl amine (0.01 mole; 0.57 ml) using dioxan (15 
ml) as solvent for further 6 hours. The resulting mixture was poured on to ice, 
filtered, washed with water and dried at 40 to 450C. The product was 
crystallized from ethanol. Yield: 65%, M.P.: 1650C, (Required: C, 70.36%; H, 
4.35%; N, 8.64% for C19H14F2N2O Found: C, 70.30%; H, 4.29%; N, 8.58%). 
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TLC solvent system Rf1: Ethyl acetate: Hexane (3.5:6.5) = 0.60 
TLC solvent system Rf2: Methanol      : Toluene (1.0:9.0) = 0.48 
 
 Similarly other compounds (VIIa-i) were synthesized. The physical data 
are recorded in Table No.7. 
 
(C) Antimicrobial activity of 6-Chloro/fluoro/nitro-N-cyclopropyl-2-(p-
chloro/fluoro/methylphenyl)-quinoline-4-carboxamides (VIIa-i). 
 
Antimicrobial activity testing was carried out as described in Part-I,  
Section-I, Page No. 40. The MIC values of test solution are recorded in 
Table No. 7B, 7C and 7D.  
 
Result and Discussion :- 
 
 The products (VIIa-i) have been subjected to antibacterial activity tow-
ards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTCC-
441 (Gram positive) and E. coli MTCC- 443  (Gram negative) bacterial strain 
and antifungal activity towards Aspergillus niger MTCC-282 and Candida 
albicans MTCC-227 at same concentration . The results of antimicrobial acti-
vity have been depicted on Page No.151-153.  
 
 
TABLE NO. 7A: PHYSICAL CONSTANTS OF 6-CHLORO/FLUORO/NITRO-2-(p-CHLORO/FLUORO/METHYLPHENYL)-
QUINOLINE-4-CARBOXYLICACID (7a-i). 
 
        Rf Value %  of  Nitrogen Comp. 
No. 
 
R 
 
R1 
Molecular 
Formula 
 M.W.   Yield     M.P. 
     0C Rf1/Rf2 Calcd./Found 
7a 4-Cl-C6H4 4-F C16H9ClFNO2 301 60 130 0.55/0.42 4.64/4.59 
7b 4-Cl-C6H4 4-Cl C16H9Cl2NO2 318 65 147 0.52/0.45 4.40/4.35 
7c 4-Cl-C6H4 4-NO2 C16H9ClN2O4 329 67 122 0.58/0.40 8.52/8.48 
7d 4-F-C6H4 4-F C16H9F2NO2 285 70 148 0.58/0.47 4.91/4.86 
7e 4-F-C6H4 4-Cl C16H9ClFNO2 301 55 147 0.50/0.40 4.64/4.60 
7f 4-F-C6H4 4-NO2 C16H9FN2O4 312 60 133 0.52/0.46 8.97/8.92 
7g 4-CH3-C6H4 4-F C17H12FNO2 281 57 160 0.55/0.40 4.98/4.94 
7h 4-CH3-C6H4 4-Cl C17H12ClNO2 298 62 149 0.53/0.41 4.70/4.65 
7i 4-CH3-C6H4 4-NO2 C17H12N2O4 308 60 156 0.57/0.42 9.09/9.05 
 
  TLC solvent system Rf1: Ethyl acetate: Hexane (3.0:7.0)  
  TLC solvent system Rf2: Methanol      : Toluene (0.5:9.5)  
 
 
 
TABLE NO. 7: PHYSICAL CONSTANTS OF 6-CHLORO/FLUORO/NITRO-N-CYCLOPROPYL-2-(p-CHLORO/FLUORO/METHY-
LPHENYL)-QUINOLINE-4-CARBOXAMIDES (VIIa-i). 
 
        Rf Value %  of  Nitrogen Comp. 
No. 
 
R 
 
R1 
Molecular 
Formula 
 M.W.   Yield     M.P. 
     0C Rf1/Rf2 Calcd./Found 
VIIa 4-Cl-C6H4 4-F C19H14ClFN2O 340 59 187 0.53/0.41 8.22/8.17 
VIIb 4-Cl-C6H4 4-Cl C19H14Cl2N2O 357 56 158 0.50/0.43 7.84/7.79 
VIIc 4-Cl-C6H4 4-NO2 C19H14ClN3O3 368 62 172 0.51/0.42 11.43/11.37 
VIId 4-F-C6H4 4-F C19H14F2NO 324 65 165 0.60/0.48 8.64/8.58 
VIIe 4-F-C6H4 4-Cl C19H14ClFN2O 340 53 178 0.57/0.43 8.22/8.16 
VIIf 4-F-C6H4 4-NO2 C19H14FN3O3 351 60 189 0.54/0.40 11.96/11.91 
VIIg 4-CH3-C6H4 4-F C20H17FN2O 320 55 183 0.49/0.47 8.74/8.68 
VIIh 4-CH3-C6H4 4-Cl C20H17ClN2O 337 57 171 0.52/0.44 8.32/8.27 
VIIi 4-CH3-C6H4 4-NO2 C20H17N3O3 347 64 183 0.55/0.45 12.10/12.05 
 
  TLC solvent system Rf1: Ethyl acetate: Hexane (3.5:6.5)  
  TLC solvent system Rf2: Methanol      : Toluene (1.0:9.0)  
 
Section-I                                                                  Studies on Quinolines 
 
Department of Chemistry, Saurashtra University, Rajkot(Gujarat). 
 147 
IR SPECTRAL STUDY OF 6-FLUORO-N-CYCLOPROPYL-2-(p-FLUROPH-
ENYL)-QUINOLINE-4-CARBOXAMIDE (VIId). 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference 
Alkane 
(Methyl and  
 Methylene) 
 
 
Aromatic and  
ring skeleton 
vibration 
 
 
 
Amine 
 
 
Ketone 
(Amide) 
 
Halogen  
Substitution 
 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
C-N (str., v) 
 
N-H (str., b) 
 
N-H (def., s,m) 
 
C=O (str., s) 
 
C-F (str., b) 
2956.97 
2852.81 
1423.51 
1363.72 
 
3178.79 
1462.09 
1124.54 
 846.78 
1336.71 
 
3417.98-
3178.79 
1600.97 
 
1656.91 
 
1363.72-
1099.46 
2950-2875 
2900-2800 
1460-1400 
1385-1300 
 
3080-3010 
1600-1450 
1150-1050 
 825-800 
1340-1250 
 
3400-3000 
 
1650-1550 
 
1740-1650 
 
1400-1080 
235 
235 
235 
235 
 
236 
236 
236 
236 
      236 
 
237 
 
237 
 
237 
 
238 
 
O
N
F
F
NH
VIId
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NMR SPECTRAL STUDY OF 6-FLURO-N-CYCLOPROPYL-2-(p-FLUROPH-
ENYL)-QUINOLINE-4-CARBOXAMIDE (VIId). 
 
 
Signal No. Signal Position 
(δ ppm) 
 
Relative No. 
of Protons 
Multiplicity Inference 
1. 0.3505-0.3611 2H multiplet -CH2(a) 
2. 0.6108-0.6519 2H multiplet -CH2(b) 
3. 1.9107-1.9219 1H multiplet -CH(c) 
4. 6.9663-7.0149 2H doublet Ar-H(d) 
5. 7.4993 1H multiplet Ar-H(e) 
6. 7.6108-7.6519 2H singlet Ar-H(f) 
7. 8.0319-8.0339 1H doublet -NH(g) 
8. 8.1371-8.1797 2H doublet Ar-H(h) 
9. 8.2731 1H multiplet Ar-H(i) 
10. 8.8497 1H multiplet Ar-H(j) 
 
O
N
F
F
NH
a b
c
d
de
f
h
h
g
i
j
VIId
 
 
  MASS  SPECTRAL STUDY OF 6-FLUORO-N-CYCLOPROPYL-2-(4-FLUOROPHENYL)QUINOLIN-4-CARBOXAMIDE (VIId). 
 
 
O
N
F
F
NH
(VIId)
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TABLE NO. 7A: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 6-HALO/NITRO-N-CYCLOPROPYL-2-(p-CHLORO/FLUORO/-
METHYLPHENYL)-QUINOLINE-4-CARBOXAMIDES (VIIa-i). (Different Inhibition Concentration in µg/ml).              
Antibacterial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Com.  No. R R
1 
5 25 50 100 250 5 25 50 100 250 
VIIa 4-Cl-C6H4 4-F - 12 13 15 17 - 10 14 16 19 
VIIb 4-Cl-C6H4 4-Cl - 10 11 14 18 - 12 13 17 18 
VIIc 4-Cl-C6H4 4-NO2 - 11 12 13 16 - 11 12 14 17 
VIId 4-F-C6H4 4-F - 11 12 14 17 - 10 12 16 18 
VIIe 4-F-C6H4 4-Cl - 10 13 15 19 - 12 14 18 19 
VIIf 4-F-C6H4 4-NO2 - 12 13 15 16 - 11 16 17 18 
VIIg 4-CH3-C6H4 4-F - 10 12 13 17 - 12 13 15 18 
VIIh 4-CH3-C6H4 4-Cl - 12 13 15 20 - 13 14 15 19 
VIIi 4-CH3-C6H4 4-NO2 - 10 12 15 18 - 12 13 14 17 
Comparative activity of (VIIa-i) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
     VIIe, VIIh  VIIh 
VIIa,  
VIIe, 
VIIh 
VIId, 
VIIe, 
VIIa, 
VIIb, 
VIIf, 
VIId, 
VIIe, 
VIIg, 
VIIh 
Ampicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
 
TABLE NO. 7B: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 6-HALO/NITRO-N-CYCLOPROPYL-2-(p-CHLORO/FLUORO/-
METHYLPHENYL)-QUINOLINE-4-CARBOXAMIDES (VIIa-i). (Different Inhibition Concentration in µg/ml). 
 
Antibacterial activity (Zones of inhibition in m.m.) 
E.coli MTCC-443 P.aeruginosa MTCC-424 
Comp
. 
 No. 
R R1 
5 25 50 100 250 5 25 50 100 250 
VIIa 4-Cl-C6H4 4-F - 15 17 18 20 - 12 13 16 17 
VIIb 4-Cl-C6H4 4-Cl - 13 17 19 20 - 15 17 18 20 
VIIc 4-Cl-C6H4 4-NO2 - 13 15 17 19 - 13 16 17 20 
VIId 4-F-C6H4 4-F - 13 14 16 19 - 12 13 15 17 
VIIe 4-F-C6H4 4-Cl - 14 16 17 18 - 11 13 16 18 
VIIf 4-F-C6H4 4-NO2 - 12 14 15 17 - 13 14 17 18 
VIIg 4-CH3-C6H4 4-F - 14 16 17 18 - 13 15 17 19 
VIIh 4-CH3-C6H4 4-Cl - 12 13 15 18 - 14 16 17 18 
VIIi 4-CH3-C6H4 4-NO2 - 14 17 18 20 - 12 13 15 18 
Comparative activity of (VIIa-i) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
  VIIa 
VIIa, 
VIIb, 
VIIe, 
VIIg, 
VIIi 
VIIb 
VIIa, 
VIIb, 
VIIi 
 VIIb 
VIIb, 
VIIc, 
VIIg, 
VIIh 
VIIb VIIb, VIIc 
Ampicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
 
 
TABLE NO. 7C: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 6-HALO/NITRO-N-CYCLOPROPYL-2-(p-CHLORO/FLUORO/-
METHYLPHENYL)-QUINOLINE-4-CARBOXAMIDES (VIIa-i). (Different Inhibition Concentration in µg/ml). 
 
 
 
Antifungal activity (Zones of inhibition in m.m.) 
A.niger MTCC-282 A.clavatus MTCC-1323 Com.  No. R R
1 
5 25 50 100 250 5 25 50 100 250 
VIIa 4-Cl-C6H4 4-F - 17 18 20 21 - 20 21 23 24 
VIIb 4-Cl-C6H4 4-Cl - 18 21 23 24 - 18 20 21 23 
VIIc 4-Cl-C6H4 4-NO2 - 15 17 18 22 - 18 19 21 22 
VIId 4-F-C6H4 4-F - 14 15 19 21 - 15 17 20 22 
VIIe 4-F-C6H4 4-Cl - 15 18 19 22 - 18 19 20 22 
VIIf 4-F-C6H4 4-NO2 - 15 19 21 22 - 21 21 22 24 
VIIg 4-CH3-C6H4 4-F - 16 17 19 23 - 18 20 22 22 
VIIh 4-CH3-C6H4 4-Cl - 18 19 20 22 - 20 22 22 24 
VIIi 4-CH3-C6H4 4-NO2 - 17 19 21 23 - 20 21 22 24 
Comparative activity of (VIIa-i) with known chosen standard drugs 
Standard drug                             Antifungal activity 
       VIIf VIIh VIIa, VIIf 
VIIa, VIIf, 
VIIh, VIIi 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
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SECTION-II 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 6-CHLORO/FLUOR-
O/NITRO-N-PENTYL-2-(p-CHLORO/FLUORO/METHYL)-QUINOLINE-4-
CARBOXAMIDES. 
 
Keeping in view of wide spectrum biodynamic activities173-224 of 
Quinolines and with a view to have potent therapeutic agents, the synthesis 
of 6-Chloro/fluoro/nitro-N-pentyl-2-(p-chloro/fluoro/methylphenyl)-quinol-
ine-4-carboxamides have been synthesized by the condensation of 6-
Chloro/fluoro/nitro-2-(p-chloro/fluoro/methyl)-quinoline-4-carbonyl chlor-
ides and N-pentyl amine. 
 
O
N
NH
CH3
R
R1
 
                                                      (VIIIa-i) 
                                R,R1 = Substituted Phenyl 
 
The constitutions of the products (VIIIa-i) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (VIIIa-i) 
were assayed for their in vitro biological assay. 
The products (VIIIa-i) were assayed for their in vitro biological assay 
like antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-
96 (Gram positive) and E. coli MTCC- 443 , P. aeruginosa MTCC-424 (Gram 
negative) bacterial strain and antifungal activity towards A. niger MTCC-282 
and A. clavatus  MTCC-1323 at different concentrations: i.e. 0 (control), 5, 
25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory Concentration) 
values. The biological activities of the synthesized compounds (VIIIa-i) were 
compared with standard drugs viz., Ampicilline, Chloramphenicol, 
Ciprofloxacin, Norfloxacin, Griseofulvin and Nystatin.  
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                                           REACTION SCHEME 
 
 
 
NH2
R1 + CH3
O
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N R
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                                                                  (VIIIa-i) 
                                              R,R1 = Substituted Phenyl 
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EXPERIMENTAL 
PREPARATION AND BIOLOGICAL EVALUATION OF 6-CHLORO/FLUOR-
O/NITRO-N-PENTYL-2-(p-CHLORO/FLUORO/METHYLPHENYL)-QUINOLI-
NE-4-CARBOXAMIDES. 
 
(A) Preparation of 6-Fluoro-2-(p-flurophenyl)-quinoline-4-carboxylic 
acid. 
For preparation, refer Part-II, Section-I, Page No. 143. 
 
(B) Preparation of 6-Fluoro-N-pentyl-2-(p-flurophenyl)-quinoline-4-
carboxamide (VIIId). 
 
A mixture of 6-Fluoro-2-(p-flurophenyl)-quinoline-4-carboxylic acid 
(0.001 mole; 3.01 g) in dioxan (40 ml) and thionyl chloride (10 ml) was 
refluxed on waterbath at 60 to 700 C for 3 hours. Excess of thionyl chloride 
was removed by distillation and product obtained was kept at 00C and add 2 
to 3 drops of pyridine further refluxed with n-pentyl amine (0.01 mole; 0.87 
ml) using dioxan (15 ml) as solvent for further 6 hours. The resulting mixture 
was poured on to ice, filtered, washed with water and dried at 40-450C. The 
product was crystallized from ethanol. Yield: 59%, M.P.: 1690C, (Required: C, 
71.17%; H, 5.69%; N, 7.90% for C21H20F2N2O Found: C, 71.13%; H, 5.65%; 
N, 7.85%). 
TLC solvent system Rf1: Ethyl acetate: Hexane       (5.0:5.0) = 0.53. 
TLC solvent system Rf2: Methanol      : Chloroform (1.0:9.0) = 0.55. 
 Similarly other compounds (VIIIa-i) were synthesized. The physical data 
are recorded in Table No. 8. 
 
(C) Antimicrobial activity of 6-Chloro/fluoro/nitro-N-pentyl-2-(p-
chloro/fluoro/methyl)-quinoline-4-carboxamides (VIIIa-i). 
Antimicrobial activity testing was carried out as described in Part-I ,  
Section-I, Page No. 40. The MIC values of test solutions are recorded in 
Table No. 8A, 8B and 8C. 
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Result and Discussion :- 
 
 The products (VIIIa-i) have been subjected to antibacterial activity 
towards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTC-
C-441 (Gram positive) and E. coli MTCC- 443 and (Gram negative) bacterial 
strain and antifungal activity towards Aspergillus niger MTCC-282 and 
Candida albicans MTCC-227 at same concentration . The results of antimicr-
obial activity have been depicted on Page No. 163-165.  
 
 
TABLE NO. 8: PHYSICAL CONSTANTS OF 6-CHLORO/FLUORO/NITRO-N-PENTYL-2-(CHLORO/FLUORO/METHYL)-
QUINOLINE-4-CARBOXAMIDES (VIIIa-i). 
 
Rf Value %  of  Nitrogen Comp 
No. 
 
R 
 
R1 
Molecular 
Formula 
M.W. Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
VIIIa 4-Cl-C6H4 4-F C21H20ClFN2O 371 49 139 0.52/0.54 7.55/7.50 
VIIIb 4-Cl-C6H4 4-Cl C21H20Cl2N2O 357 56 158 0.50/0.52 7.23/7.19 
VIIIc 4-Cl-C6H4 4-NO2 C21H20ClN3O3 398 53 144 0.49/0.56 10.56/10.49 
VIIId 4-F-C6H4 4-F C21H20F2N2O 354 59 169 0.53/0.55 7.90/7.85 
VIIIe 4-F-C6H4 4-Cl C21H20ClFN2O 371 60 155 0.55/0.60 7.55/7.51 
VIIIf 4-F-C6H4 4-NO2 C21H20FN3O3 351 60 189 0.47/0.57 11.02/10.96 
VIIIg 4-CH3-C6H4 4-F C22H23FN2O 350 48 130 0.48/0.50 7.99/7.92 
VIIIh 4-CH3-C6H4 4-Cl C22H23ClN2O 367 54 151 0.52/0.58 7.64/7.60 
VIIIi 4-CH3-C6H4 4-NO2 C22H23N3O3 347 52 178 0.54/0.50 11.13/11.07 
 
   TLC solvent system Rf1: Ethyl acetate: Hexane        
   TLC solvent system Rf2: Methanol      : Chloroform 
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IR SPECTRAL STUDY OF 6-FLUORO-N-PENTYL-2-(p-FLUOROPHENYL)-
QUINOLINE-4-CARBOXAMIDE (VIIId). 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference
Alkane 
(Methyl and  
 Methylene) 
 
 
Aromatic and  
ring skeleton 
vibration 
 
 
 
Amine 
 
 
Amide 
(Ketone) 
 
Halogen  
Substitution 
 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
C-N (str., v) 
 
N-H (str., b) 
 
N-H (def., s,m) 
 
C=O (str., s) 
 
C-F (str., b) 
2954.08 
2902.00 
1459.50 
1354.08 
 
2996.52 
1656.72 
1080.17 
799.52 
1252.29 
 
3284.88-
3059.20 
1559.50 
 
1656.72 
 
1354.08-
1080.17 
2950-2875 
2900-2800 
1460-1400 
1385-1300 
 
3080-3010 
1600-1450 
1150-1050 
 825-800 
1340-1250 
 
3400-3000 
 
1650-1550 
 
1740-1650 
 
1400-1080 
235 
235 
235 
235 
 
236 
236 
236 
236 
      236 
 
237 
 
237 
 
237 
 
238 
 
O
N
F
F
NH
CH3
VIIId
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NMR SPECTRAL STUDY OF 6-FLUORO-N-PENTYL-2-(p-FLUOROPHENY-
L)-QUINOLINE-4-CARBOXAMIDE (VIIId). 
 
Signal No. Signal Position 
(δ ppm) 
 
Relative No. 
of Protons 
Multiplicity Inference 
1. 1.1573-1.2520 3H triplet -CH3(a) 
2. 1.9202-1.9751 4H multiplet -CH2(b,c) 
3. 2.5940-2.6627 2H multiplet -CH2(d) 
4. 3.5524-3.5873 2H multiplet -CH2(e) 
5. 7.8252-7.8292 2H doublet -Ar-H(f) 
6. 8.0719-8.1466 1H multiplet -Ar-H(g) 
7. 8.1919-8.2138 1H singlet -Ar-H(h) 
8. 8.5912-8.6304 2H doublet -Ar-H(i) 
9. 8.8354 1H multiplet -Ar-H(j) 
10. 8.9513-8.9765 1H        triplet -NH(k) 
11. 9.5000 1H singlet -Ar-H(l) 
O
N
F
F
NH
CH3
a
b
c
d
f
f
g
h
i
i
k
e
j
l
VIIId
 
 
MASS SPECTRAL STUDY OF 6-FLUORO-N-PENTYL-2-(4-FLUOROPHENYL)QUINOLINE-4-CARBOXAMIDES (VIIId). 
 
 
O
N
F
F
NH
CH3
(VIIId)
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TABLE NO. 8A: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 6-CHLORO/FLUORO/NITRO-N-PENTYL-2-(p-CHLORO/FLU-
ORO/METHYLPHENYL)-QUINOLINE-4-CARBOXAMIDES (VIIIa-i). (Different Inhibition Concentration in µg/ml). 
 
 
Antibacterial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Com. No. R R
1 
5 25 50 100 250 5 25 50 100 250 
VIIa 4-Cl-C6H4 4-F - 12 12 15 18 - 12 13 14 19 
VIIb 4-Cl-C6H4 4-Cl - 13 15 16 17 - 11 14 16 18 
VIIc 4-Cl-C6H4 4-NO2 - 12 13 16 19 - 13 12 15 17 
VIId 4-F-C6H4 4-F - 12 13 14 17 - 10       13 15 16 
VIIe 4-F-C6H4 4-Cl - 10 12 15 19 - 12 13 15 19 
VIIf 4-F-C6H4 4-NO2 - 12 14 17 18 - 12 13 14 17 
VIIg 4-CH3-C6H4 4-F - 12 14 15 18 - 11 13 14 16 
VIIh 4-CH3-C6H4 4-Cl - 10 13 15 17 - 10 14 17 18 
VIIi 4-CH3-C6H4 4-NO2 - 10 12 15 18 - 12 13 15 16 
Comparative activity of (VIIIa-i) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
  VIIIb   
VIIIc, 
VIIIe 
 VIIIc 
VIIIb, 
VIIIh 
VIIIb, 
VIIIh 
VIIIa, 
VIIIb, 
VIIIe, 
VIIIh 
Ampicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
 
 
TABLE NO. 8B: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 6-CHLORO/FLUORO/NITRO-N-PENTYL-2-(p-CHLORO/FLU-
ORO/METHYLPHENYL)-QUINOLINE-4-CARBOXAMIDES (VIIIa-i). (Different Inhibition Concentration in µg/ml). 
Antibacterial activity (Zones of inhibition in m.m.) 
E.coli MTCC-443 P.aeruginosa MTCC-424 Com.  No. R R
1 
5 25 50 100 250 5 25 50 100 250 
VIIa 4-Cl-C6H4 4-F - 14 15 17 20 - 11 12 15 17 
VIIb 4-Cl-C6H4 4-Cl - 13 14 17 19 - 14 15 17 20 
VIIc 4-Cl-C6H4 4-NO2 - 12 14 17 20 - 13 15 19 21 
VIId 4-F-C6H4 4-F - 14 15 17 19 - 14 17 18 20 
VIIe 4-F-C6H4 4-Cl - 12 14 15 19 - 13 15 16 19 
VIIf 4-F-C6H4 4-NO2 - 15 16 18 20 - 12 14 15 17 
VIIg 4-CH3-C6H4 4-F - 13 15 17 18 - 11 12 14 17 
VIIh 4-CH3-C6H4 4-Cl - 14 17 18 21 - 12 16 17 20 
VIIi 4-CH3-C6H4 4-NO2 - 13 15 17 20 - 13 15 17 18 
Comparative activity of (VIIIa-i) with known chosen standard drugs 
Standard drug                              Antibacterial activity 
  VIIIf 
VIIIf, 
VIIIh 
 
VIIIa, 
VIIIc, 
VIIIf, 
VIIIh, 
VIIIi 
  
VIIIb, 
VIIIc, 
VIIId, 
VIIIe, 
VIIIh, 
VIIIi 
VIIIc, 
VIIId 
VIIIb, 
VIIIc, 
VIIId, 
VIIIh 
Ampicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
TABLE NO. 8C: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 6-CHLORO/FLUORO/NITRO-N-PENTYL-2-(p-CHLORO/FLU-
ORO/METHYLPHENYL)-QUINOLINE-4-CARBOXAMIDES (VIIIa-i). (Different Inhibition Concentration in µg/ml).      
 
Antifungal activity (Zones of inhibition in m.m.) 
A.niger MTCC-282 A.clavatus MTCC-1323 
Comp
. 
 No. 
R R1 
5 25 50 100 250 5 25 50 100 250 
VIIa 4-Cl-C6H4 4-F - 18 19 21 24 - 19 21 24 25 
VIIb 4-Cl-C6H4 4-Cl - 17 19 20 22 - 18 20 23 25 
VIIc 4-Cl-C6H4 4-NO2 - 16 19 21 23 - 20 22 23 24 
VIId 4-F-C6H4 4-F - 18 20 23 25 - 21 22 22 24 
VIIe 4-F-C6H4 4-Cl - 20 21 23 24 - 18 20 22 23 
VIIf 4-F-C6H4 4-NO2 - 18 20 22 23 - 20 22 22 24 
VIIg 4-CH3-C6H4 4-F - 18 21 22 25 - 19 22 23 24 
VIIh 4-CH3-C6H4 4-Cl - 16 17 20 23 - 20 21 24 25 
VIIi 4-CH3-C6H4 4-NO2 - 18 19 21 24 - 20 23 24 25 
Comparative activity of (VIIa-i) with known chosen standard drugs 
Standard drug                             Antifungal activity 
  VIIIe     
 
VIIId 
 
VIIId, 
VIIIc, 
VIIIf, 
VIIIg, 
VIIIi 
VIIIa, 
VIIIb, 
VIIIc, 
VIIId, 
VIIIe, 
VIIIf, 
VIIIg, 
VIIIh, 
VIIIi 
VIIIa, 
VIIIb, 
VIIIc, 
VIIId, 
VIIIf, 
VIIIg, 
VIIIh, 
VIIIi 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
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SECTION-III 
PREPARATION AND BIOLOGICAL EVALUATION OF DI-(AMINOBUTYL)/ 
DI-(AMINO PROPYNYL)/  N,N-DIETHYL/  N-ETHYL PIPERAZINYL/ N-
METHYL PIPERAZINYL/ MORPHONILYL/ PIPERIDINYL / N-PHENYL 
PIPERIZINYL/PYROLIDINYL-6-FLUORO-2-(p-FLUOROPHENYL)-QUINOLI-
NE-4-CARBOXAMIDES. 
  
Keeping in view of wide spectrum biodynamic activities173-224 of 
Quinolines and with a view to have potent therapeutic agents, the synthesis 
of Di-(amino butyl)/ di-(amino propynyl) / N,N-diethyl/ N-ethyl piperazinyl/ 
N-methyl piperazinyl/ morphonilyl/ piperidinyl/ N-phenyl piperizinyl/                    
/pyrrolidinyl-6-fluro-2-(4-fluorophenyl)-quinoline-4-carboxamides(IXa-i) 
have  been synthesized by the condensation of 6-Fluoro-2-(p-fluoro)-
quinoline-4-carbonyl chloride and Di-n-butylamine/ di-propyllamine/ N,N-
diethyl amine/   N-ethyl piperazine/ N-methyl piperazine/ morpholi-ne/  
piperadine/  N-benzyl piperazine/ pyrrolidine. 
 
N
F
O
F
R
 
                                                  (IXa-i) 
                                      R=Substituted phenyl 
 
The constitutions of the products (IXa-i) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (IXa-i) 
were assayed for their in vitro biological assay. 
 
The products (IXa-i) were assayed for their in vitro biological assay like 
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96  
and B.subtillis MTCC-441 (Gram positive) and E. coli MTCC- 443 (Gram 
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negative) bacterial strain and antifungal activity towards A. niger MTCC-
282 and A. clavatus  MTCC-1323 at different concentrations: i.e. 0 (control), 
5, 25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory Concentration) 
values. The biological activities of the synthesized compounds (IXa-i) were 
compared with standard drugs viz., Ampicilline, Chloramphenicol, 
Ciprofloxacin, Norfloxacin, Griseofulvin and Nystatin. 
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REACTION SCHEME 
 
 
NH2
F
+ CH3
O
COOH +
OHC
F
-H2O -2H
COOH
N
F
F
SOCl2
COCl
N
F
F
O
N
F
F
R
Secondary amine
3 hrs.
,
(IXa-i)
/
 
 
R = Di-(amino butyl)/ di-(amino propynyl)/ N,N-diethyl/  N-ethyl piperazinyl/ N-
methyl piperazinyl/ Morphonilyl/ piperidinyl/ N-phenyl piperizinyl/              
pyrrolidinyl 
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EXPERIMENTAL 
PREPARATION AND BIOLOGICAL EVALUATION OF DI-(AMINO 
PROPYNYL)/ DI-(AMINOBUTYL)/ N,N-DIETHYL/  N-ETHYL PIPERAZINYL/ 
N-METHYL PIPERAZINYL/ MORPHONILYL/ PIPERIDINYL / N-PHENYL 
PIPERIZINYL/PYROLIDINYL-6-FLUORO-2-(p-FLUOROPHENYL)QUINOLI-
NE-4-CARBOXAMIDES (IXa-i). 
 
(A) Preparation of 6-Fluoro-2-(p-flurophenyl)-quinoline-4-carboxylic 
acid. 
For preparation, refer Part-II, Section-I, Page No. 143. 
 
(B) Preparation of N,N-diethyl-6-fluoro-2-(p-fluorophenyl)quinoline-4-
carboxamide (IXc). 
  
A mixture of 6-Fluoro-2-(p-flurophenyl)-quinoline-4-carboxylic acid 
(0.001 mole; 3.01 g) in dioxan (40 ml) and thionyl chloride (10 ml) was 
refluxed at 60 to 700 C for 3 hours. Excess of thionyl chloride was removed by 
distillation and product obtained was kept at 00C, add 2-3 drops of pyridine 
and refluxed with N,N-diethyl amine (0.01 mole; 0.73 ml) using dioxan (15 
ml) as solvent for further 6 hours. The resulting mixture was poured on to ice, 
filtered, washed with water and dried at 40 to 450C. The product was 
crystallized from ethanol. Yield: 54%, M.P.: 2700C, (Required: C, 70.58%; H, 
5.33%; N, 8.23% for C20H18F2N2O Found: C, 70.52%; H, 5.28%; N, 8.19%). 
 
TLC solvent system Rf1: Ethyl acetate: Hexane       (5.0:5.0) = 0.60. 
TLC solvent system Rf2: Methanol      : Chloroform (0.5:1.0) = 0.53. 
 
Similarly other compounds (IXa-i) were synthesized. The physical data 
are recorded in Table No. 9. 
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(C) Antimicrobial activity of Di-(amino butyl)/ di-(amino propynyl)/ 
N,N-diethyl/ N-ethyl piperazinyl/ N-methyl piperazinyl/ morphonilyl/ 
piperidinyl/ N-phenyl-piperizinyl/ pyrrolidinyl-6-fluoro-2-(p-fluorophenyl)-
quinoline-4-carboxamides (IXa-i). 
 
Antimicrobial activity testing was carried out as described in Part-I,  
Section-I, Page No. 40. The MIC values of test solution are recorded in 
Table No. 9A, 9B and 9C. 
 
Result and Discussion:- 
 
 The products (VIIIa-i) have been subjected to antibacterial activity 
towards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTC-
C-441 (Gram positive) and E. coli MTCC- 443 and (Gram negative) bacterial 
strain and antifungal activity towards Aspergillus niger MTCC-282 and 
Candida albicans MTCC-227 at same concentration . The results of antimicr-
obial activity have been depicted on Page No. 176-178.  
 
TABLE NO. 9: PHYSICAL CONSTANT OF DI-(AMINO BUTYL)/ DI-(AMINO PROPYNYL)/ N,N-DIETHYL/ N-ETHYL PIPERAZIN-
YL/ N-METHYL PIPERAZINYL/ MORPHONILYL/ PIPERIDINYL / N-PHENYL PIPERIZINYL/ PYRROLIDINYL-6-FLUORO-2-(4-
FLUOROPHENYL)QUINOLINE-4-CARBOXAMIDES (IXa-i). 
 
     Rf Value  %  of  Nitrogen Comp. No. R Molecular 
Formula 
M.W. Yield 
% 
M.P. 
0C           Rf1/Rf2 Calcd./Found 
IXa NH-(C4H9)2 C24H26F2N2O 396 49 237 0.55/0.48 7.07/7.02 
IXb NH-(C3H7)2 C22H22F2N2O 368 44 247 0.57/0.50 7.60/7.54 
IXc NH-(C2H5)2 C20H18F2N2O 340 54 270 0.60/0.53 8.23/8.19 
IXd N-Et-C4H9N C22H21F2N3O 381 57 221 0.55/0.54 11.02/10.96 
IXe N-Me-C4H9N C21H19F2N3O 367 51 278 0.57/0.51 11.44/11.38 
IXf N-(C2H4)2O C20H16F2N2O2 354 47 197 0.59/0.55 7.91/7.86 
IXg NH-(CH2)5 C21H18F2N2O 352 59 303 0.49/0.45 7.95/7.91 
IXh N-C6H4-C4H9N C26H21F2N3O 429 53 290 0.58/0.52 9.78/9.74 
IXi NH-(C2H4)2 C20H16F2N2O 338 48 227 0.56/0.49 8.28/8.22 
 
TLC solvent system Rf1: Ethyl acetate: Hexane       
TLC solvent system Rf2: Methanol      : Chloroform 
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IR SPECTRAL STUDY OF N,N-DIETHYL-6-FLUORO-2-(p-FLUOROPHENY-
L)-QUINOLINE-4-CARBOXAMIDE (IXc). 
 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference 
Alkane 
(Methyl and  
 Methylene) 
 
 
Aromatic and  
ring skeleton 
vibration and 
Quinoline 
moiety 
 
 
Ketone 
(Amide) 
 
 
 
Halogen  
Substitution 
 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
C-N (str., v) 
C=N (str., v) 
 
C=O (str., s) 
 
 
 
C-F (str., b) 
2939.61 
2879.82 
1433.16 
1369.50 
 
2969.51 
1481.38 
1114.89 
808.20 
1299.10 
1696.45 
 
1696.45 
 
 
 
1391.39 
2950-2875 
2900-2800 
1460-1400 
1385-1300 
 
3080-3010 
1600-1450 
1150-1050 
 825-800 
1340-1250 
1690-1650 
 
1740-1650 
 
 
 
1400-1080 
235 
235 
235 
235 
 
236 
236 
236 
236 
236 
236 
 
237 
 
 
 
238 
 
O
N
F
F
N CH3
CH3
IXc
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NMR SPECTRAL STUDY OF N,N-DIETHYL-6-FLUORO-2-(p-FLUOROPHE-
NYL)-QUINOLINE-4-CARBOXAMIDE (IXc). 
 
Signal No. Signal Position 
(δ ppm) 
 
Relative No. 
of Protons 
Multiplicity Inference 
1. 
 
1.1825-1.1878 6H triplet -CH3(a) 
2. 
 
2.9111-2.9180 4H quartet -CH2(b) 
3. 
 
7.2442-7.2549 2H doublet -Ar-H(c) 
4. 
 
7.4174-7.4385 1H doublet -Ar-H(d) 
5. 
 
7.5395-7.6508 1H multiplet -Ar-H(e) 
6. 
 
7.9627-7.9657 2H doublet -Ar-H(f) 
7. 
 
8.1486-8.2043 1H multiplet -Ar-H(g) 
8. 9.8569 1H singlet -Ar-H(h) 
O
N
F
F
N CH3
CH3
a
a
b
b
c
c
d
e
f
f
g
h
IXc
 
MASS SPECTRAL STUDY OF N,N-DIETHYL-6-FLUORO-2-(4-FLUOROPHENYL)QUINOLINE-4-CARBOXAMIDE (IXc). 
 
O
N
F
F
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CH3
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 TABLE NO. 9A: COMPRITIVE ACTIVITY OF DI-(AMINO BUTYL)/ DI-(AMINO PROPYNYL)/ N,N-DIETHYL/ N-ETHYL 
PIPERAZINYL/ N-METHYL PIPERAZINYL/ MORPHONILYL/ PIPERIDINYL / N-PHENYL PIPERIZINYL/ PYROLIDINYL-6-
FLUORO-2-(p-FLUOROPHENYL)-QUINOLINE-4-CARBOXAMIDES (IXa-i).(Different Inhibition Concentration in µg/ml). 
 
Antibacterial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Com.  No. R 5 25 50 100 250 5 25 50 100 250 
IXa NH-(C4H9)2 - 13 14 15 19 - 13 14 15 18 
IXb NH-(C3H7)2 - 11 13 16 17 - 11 13 16 17 
IXc NH-(C2H5)2 - 12 13 15 19 - 11 14 15 19 
IXd N-Et-C4H9N - 13 14 15 20 - 13 14 17 18 
IXe N-Me-C4H9N - 12 13 14 16 - 12 13 16 17 
IXf N-(C2H4)2O - 13 14 15 18 - 10 12 15 18 
IXg NH-(CH2)5 - 10 13 15 16 - 13 14 15 20 
IXh N-C6H4-C4H9N - 12 14 16 17 - 12 13 14 16 
IXi NH-(C2H4)2 - 10 12 16 18 - 12 13 15 19 
Comparative activity of (IXa-i) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
  IXa, IXd, IXf 
  IXa, IXc, IXd 
 IXa, IXd, IXg 
IXa, IXc, 
IXd, IXg 
IXb, IXe, 
IXd 
IXa, IXc, 
IXd, IXf, 
IXg, IXi 
Ampicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
 TABLE NO. 9B: COMPRITIVE ACTIVITY OF DI-(AMINO BUTYL)/ DI-(AMINO PROPYNYL)/ N,N-DIETHYL/ N-ETHYL 
PIPERAZINYL/ N-METHYL PIPERAZINYL/ MORPHONILYL/ PIPERIDINYL / N-PHENYL PIPERIZINYL/ PYROLIDINYL-6-
FLUORO-2-(p-FLUOROPHENYL)QUINOLINE-4-CARBOXAMIDES (IXa-i).(Different Inhibition Concentration in µg/ml). 
 
Antibacterial activity (Zones of inhibition in m.m.) 
E.coli MTCC-443 P.aeruginosa MTCC-424 Com.  No. R 5 25 50 100 250 5 25 50 100 250 
IXa - 12 15 18 19 - 10 12 15 18 
IXb - 14 16 19 21 - 10 12 15 17 
IXc - 13 15 17 20 - 11 14 15 18 
IXd - 14 15 17 21 - 10 14 16 18 
IXe - 12 13 18 19 - 13 15 18 19 
IXf - 12 15 16 20 - 10 14 16 17 
IXg - 13 15 16 19 - 12 16 17 19 
IXh - 12 13 15 21 - 11 12 17 19 
IXi 
NH-(C4H9)2 
NH-(C3H7)2 
NH-(C2H5)2 
N-Et-C4H9N 
N-Me-C4H9N 
N-(C2H4)2O 
NH-(CH2)5 
N-C6H4-C4H9N 
NH-(C2H4)2 - 10 13 15 19 - 10 12 14 20 
Comparative activity of (IXa-i) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
   IXb IXb 
IXb, IXc, 
IXd, IXf, 
IXh 
  IXe  IXe      IXi 
Ampicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
TABLE NO. 9C: COMPRITIVE ACTIVITY OF DI-(AMINO BUTYL)/ DI-(AMINO PROPYNYL)/ N,N-DIETHYL/ N-ETHYL PIPERAZ-
INYL/ N-METHYL PIPERAZINYL/ MORPHONILYL/ PIPERIDINYL / N-PHENYL PIPERIZINYL/ PYROLIDINYL-6-FLUORO-2-(p-
FLUOROPHENYL)QUINOLINE-4-CARBOXAMIDES (IXa-i).(Different Inhibition Concentration in µg/ml). 
 
Antifungal activity (Zones of inhibition in m.m.) 
A.niger MTCC-282 A.clavatus MTCC-1323 Com. No. R 5 25 50 100 250 5 25 50 100 250 
IXa NH-(C4H9)2 - 18 21 22 24 - 19 21 22 24 
IXb       NH-(C3H7)2 - 18 21 23 25 - 18 21 23 24 
IXc NH-(C2H5)2 - 17 20 23 24 - 19 20 23 24 
IXd N-Et-C4H9N - 16 18 20 21 - 18 20 22 23 
IXe N-Me-C4H9N - 15 16 17 23 - 18 19 22 25 
IXf N-(C2H4)2O - 18 20 22 23 - 21 22 23 24 
IXg NH-(CH2)5 - 18 19 21 22 - 22 22 23 25 
IXh N-C6H4-C4H9N - 18 20 22 23 - 18 20 21 22 
IXi NH-(C2H4)2 - 17 19 20 23 - 18 18 20 22 
Comparative activity of (IXa-i) with known chosen standard drugs 
Standard drug                             Antifungal activity 
       IXg, IXf IXf, IXg 
 IXa, 
 IXb,  
IXc, 
IXd, 
IXe, 
IXf, 
IXg 
     IXa, 
  IXb, 
  IXc, 
 IXe, 
IXf, 
IXg 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
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SECTION-IV 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-(6-CHLORO/FLU-
ORO/NITRO-2-(p-CHLORO/FLUORO/METHYLPHENYL)-QUINOLIN-4-YL)-
1,3,4-OXADIAZOLE-2-THIOLS. 
 
Keeping in view of wide spectrum biodynamic activities116-174 of 
Quinolines and with a view to have potent therapeutic agents, the synthesis 
of 5-[6-Chloro/fluoro/nitro-2-(p-chloro/fluoro/methylphenyl)-quinolin-4-
yl]-1,3,4-oxadiazole-2-thiols have  been synthesized by the condensation of 
6-chloro/fluoro/nitro-2-(p-chloro/fluoro/methylphenyl)-quinolin-4-carboh-
ydrazides and a mixture of Carbon disulphide and potassium hydroxide. 
N O
N
N
SH
R1
R
 
                                                        (Xa-i) 
                                R, R1 = Substituted Phenyl 
The constitutions of the products (Xa-i) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (Xa-i) 
were assayed for their in vitro biological assay. 
The products (Xa-i) were assayed for their in vitro biological assay like 
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96 
(Gram positive) and E. coli MTCC- 443 , P. aeruginosa MTCC-424 (Gram 
negative) bacterial strain and antifungal activity towards A. niger MTCC-282 
and A. clavatus  MTCC-1323 at different concentrations: i.e. 0 (control), 5, 
25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory Concentration) 
values. The biological activities of the synthesized compounds (Xa-i) were 
compared with standard drugs viz., Ampicilline, Chloramphenicol, 
Ciprofloxacin, Norfloxacin, Griseofulvin and Nystatin.  
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REACTION SCHEME 
 
 
SOCl2
R1
CONHNH2
N R
(10a-i)
NH2.NH2.2H2O
R1
COOH
N R
COCl
N R
R1
KOH, CS2
(Xa-i)
N O
N
N R
SH
R1
 
R, R1 = Substituted Phenyl 
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EXPERIMENTAL 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 5-[6-CHLORO/FLU-
ORO/NITRO-2-(p-CHLORO/FLUORO/METHYL PHENYL)-QUINOLIN-4-YL]-
1,3,4-OXADIAZOLE-2-THIOLS. 
 
(A) Preparation of 6-Fluoro-2-(p-fluorophenyl)-quinoline-4-carboxylic  
acid. 
For preparation, refer Part-II, Section-I, Page No. 143. 
 
(B) Preparation of 6-Fluoro-2-(p-fluorophenyl)-quinoline-4-carbohyd-
razide (10d). 
  
A mixture of 6-Fluoro-2-(p-fluorophenyl)-quinoline-4-carboxylic 
acid (0.01 mole; 2.84 g) in dioxan (40 ml) in and thionyl chloride (10 ml) was 
refluxed at 60-700C for 3 hours. Excess of thionyl chloride was removed by 
distillation and product obtained was kept at 00C,add 2 to 3 drops of pyridine 
and further refluxed with hydrazine hydrate 99% (0.1 mole; 4 ml) for 6 hours. 
The contents were poured in to ice-cold water. The resulting product was 
filtered, dried and crystallised from dimethyl formamide.Yield: 68%, M.P.: 
2170C, (Required: C, 64.21%, H, 3.70%, N, 14.04% for C16H11F2N3O, Found: 
C, 64.16%, H, 3.66%, N, 13.99%). 
 
TLC solvent system Rf1 : Ethyl acetate: Hexane (5.5: 4.5) = 0.45. 
TLC solvent system Rf2 : Methanol      : Toluene (4.0: 6.0) = 0.53. 
  
 Similarly other compounds (10a-i) were synthesized. The physical data 
are recorded in Table No. 10 A. 
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(C) Preparation of 5-[6-Fluoro-2-(p-fluorophenyl)-quinolin-4-yl]-1,3,4- 
oxadiazole-2-thiol (Xd). 
  
  A mixture of 6-Fluoro-2-(4-fluorophenyl)-quinoline-4-carboh-
ydrazide (0.01 mole; 2.67 g), potassium hydroxide (0.01 mole; 0.4 g), 
carbon disulphide (4 ml) and ethanol (15 ml) was heated under reflux until 
the evolution of H2S ceases. The reaction mixture was concentrated, 
dissolved in water and acidified with HCl. The resulting product was 
recrystallised from methanol. Yield: 59%, M.P.: 1380C, (Required: C, 59.82%, 
H, 2.66%, N, 12.31% for C17H9F2N3OS, Found: C, 59.76%, H, 2.61%, N, 
12.27%). 
 
TLC solvent system Rf1: Ethyl acetate: Hexane (2.0:8.0) = 0.55 
TLC solvent system Rf2: Methanol      : Toluene (0.5:9.5) = 0.60 
 
 Similarly, other compounds (Xa-i) were synthesized. The physical data 
are recorded in Table No. 10. 
 
(D) Antimicrobial activity of 5-[6-Chloro/fluoro/nitro-2-(p-chloro/fluoro-
/methylphenyl)-quinolin-4-yl)-1,3,4-oxadiazole-2-thiols (Xa-i). 
 
Antimicrobial activity testing was carried out as described in Part-I, 
Section-I, Page No. 40.   The MIC values of test solution are recorded in 
Table no. 10B, 10C and 10D. 
 
Result and Discussion:- 
 
 The products (Xa-i) have been subjected to antibacterial activity 
towards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTC-
C-441 (Gram positive) and E. coli MTCC- 443 and (Gram negative) bacterial 
strain and antifungal activity towards Aspergillus niger MTCC-282 and 
Candida albicans MTCC-227 at same concentration . The results of 
antimicrobial activity have been depicted on Page No. 189-191.  
 
 
 
TABLE NO. 10A: PHYSICAL CONSTANTS OF 6-CHLORO/FLUORO/NITRO-2-(4-CHLORO/FLUORO/METHYLPHENYL)-
QUINOLINE-4-CARBOHYDRAZIDES (10a-i). 
 
Rf Value %  of  Nitrogen Comp. 
No. 
 
R 
 
R1 
Molecular 
Formula 
M.W. Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
10a. 4-Cl-C6H4 4-F C16H11ClFN3O 358 50 180 0.56/0.62 11.74/11.68 
10b. 4-Cl-C6H4 4-Cl C16H11Cl2N3O 374 49 175 0.50/0.54 11.23/11.18 
10c. 4-Cl-C6H4 4-NO2 C16H11ClN4O3 343 47 139 0.47/0.58 14.56/14.51 
10d. 4-F-C6H4 4-F C16H11F2N3O 341 68 217 0.55/0.60 14.04/13.99 
10e. 4-F-C6H4 4-Cl C16H11ClFN3O 358 53 168 0.51/0.57 11.74/11.69 
10f. 4-F-C6H4 4-NO2 C16H11FN4O3 368 56 197 0.49/0.50 15.21/15.16 
10g. 4-CH3-C6H4 4-F C18H12FN3OS 295 52 144 0.44/0.53 14.23/14.18 
10h. 4-CH3-C6H4 4-Cl C18H12ClN3OS 312 53 161 0.40/0.62 13.48/13.42 
10i. 4-CH3-C6H4 4-NO2 C18H12N4O3S 347 50 170 0.45/0.52 17.38/17.32 
 
   TLC solvent system Rf1: Ethyl acetate: Hexane  
   TLC solvent system Rf2: Methanol      : Toluene 
 
 
 
TABLE NO. 10: PHYSICAL CONSTANTS OF 5-[6-CHLORO/FLUORO/NITRO-2-(4-CHLORO/FLUORO/METHYLPHENYL)-
QUINOLIN-4-YL)-1,3,4- OXADIAZOLE-2-THIOLS (Xa-i). 
 
Rf Value %  of  Nitrogen Comp.
No. 
 
R 
 
R1 
Molecular 
Formula 
M.W. Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
Xa. 4-Cl-C6H4 4-F C17H9ClFN3OS 316 60 198 0.49/0.52 13.31/13.28 
Xb. 4-Cl-C6H4 4-Cl C17H9Cl2N3OS 332 58 174 0.50/0.53 12.65/12.60 
Xc. 4-Cl-C6H4 4-NO2 C17H9ClN4O3S 343 61 169 0.51/0.54 16.35/16.30 
Xd. 4-F-C6H4 4-F C17H9F2N3OS 299 59 138 0.45/0.53 12.31/12.27 
Xe. 4-F-C6H4 4-Cl C17H9ClFN3OS 316 68 178 0.51/0.50 13.31/13.27 
Xf. 4-F-C6H4 4-NO2 C17H9FN4O3S 326 63 133 0.44/0.49 17.17/17.12 
Xg. 4-CH3-C6H4 4-F C17H14FN3O 337 60 153 0.47/0.50 12.46/14.42 
Xh. 4-CH3-C6H4 4-Cl C17H14ClN3O 354 59 155 0.51/0.58 11.88/11.83 
Xi. 4-CH3-C6H4 4-NO2 C17H14N4O3 347 56 161 0.46/0.51 15.38/15.32 
 
   TLC solvent system Rf1: Ethyl acetate: Hexane  
   TLC solvent system Rf2: Methanol      : Toluene                       
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IR SPECTRAL STUDY OF 5-[6-FLUORO-2-(p-FLUOROPHENYL)-QUINOLI-
N-4-YL]-1,3,4-OXADIAZOLE-2-THIOL (Xd). 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference 
Alkane 
(Methyl and  
 Methylene) 
 
 
Aromatic and  
ring skeleton 
vibration 
and Quinoline 
moiety 
 
 
 
 
Ether 
 
 
Halogen  
Substitution 
 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
C-N (str., v) 
C=N (str., v) 
N-N (def., v) 
C-S (str., m) 
 
C-O-C (asym.str.,s) 
C-O-C (sym.str.,s) 
 
 
C-F (str., b) 
2936.72 
2902.00 
1458.23 
1344.25 
 
3054.38 
1458.23 
1117.24 
807.60 
1305.05 
1674.27 
1027.61 
644.25 
 
1207.60 
1027.61 
 
1344.25-
1117.24 
2950-2875 
2900-2800 
1460-1400 
1385-1300 
 
3080-3010 
1600-1450 
1150-1050 
 825-800 
1340-1250 
1690-1650 
1220-1020 
700-650 
 
1275-1200 
1075-1000 
 
1400-1080 
235 
235 
235 
235 
 
236 
236 
236 
236 
236 
236 
236 
236 
 
237 
237 
 
238 
 
 
N O
N
N
SH
F
F
Xd
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NMR SPECTRAL STUDY OF 5-[6-FLUORO-2-(p-FLUOROPHENYL)-
QUINOLIN-4-YL]-1,3,4-OXADIAZOLE-2-THIOL (Xd). 
 
 
 
Signal No. Signal Position 
(δ ppm) 
 
Relative No. of 
Protons 
Multiplicity Inference 
1. 3.1360 1H singlet -SH(a) 
2. 6.8186-6.8202 2H doublet -Ar-H(b) 
3. 6.8891-6.9100 1H multiplet -Ar-H(c) 
4. 6.9128-6.9821 1H multiplet -Ar-H(d) 
5. 7.0408-7.0844 1H singlet -Ar-H(e) 
6. 7.5708-7.8256 3H multiplet -Ar-H(f,g,h) 
N O
N
N
SH
F
F
a
b
b
c
d
e
f
g
hXd
 
MASS SPECTRAL STUDY OF 5-[6-FLUORO-2-(4-FLUOROPHENYL)QUINOLIN-4-YL]-1,3,4-OXADIAZOLE-2-THIOL (Xd). 
 
N O
N
N
SH
F
F
(Xd)
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N O
N
N
SH
F
F
N O
N
N
F
F
N O
N
N
SH
F
F
N O
N
N
F
N
NH2
N
F
F
N O
N
N
SH
m/z = 229 (M+1) m/z = 309m/z = 341
N
m/z = 205 (M+1)
N O
N
N
SH
m/z = 255 (M+1)
m/z = 291
N O
N
N
F
m/z = 243
N
m/z = 129 (M+1)
N
F
F
m/z = 241 (M-2)
m/z = 283 (M+1)
CH3 N
F
m/z = 227 (M-1)
m/z = 341
Xd
  
TABLE NO. 10B: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[6-CHLORO/FLUORO/NITRO-2-(4-CHLORO/FLUORO/ME-
THYLPHENYL)QUINOLIN-4- YL]-1,3,4-OXADIAZOLE-2-THIOLS (Xa-j). (Different Inhibition Concentration in µg/ml). 
 
 
Antibacterial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Com.  No. R R
1 
5 25 50 100 250 5 25 50 100 250 
Xa 4-Cl-C6H4 4-F - 09 14 17 19 - 13 14 15 19 
Xb 4-Cl-C6H4 4-Cl - 10 13 15 17 - 10 12 16 18 
Xc 4-Cl-C6H4 4-NO2 - 10 12 14 16 - 11 13 14 17 
Xd 4-F-C6H4 4-F - 11 13 14 17 - 11 13 16 17 
Xe 4-F-C6H4 4-Cl - 09 11 14 19 - 10 13 15 16 
Xf 4-F-C6H4 4-NO2 - 10 13 14 18 - 12 13 16 17 
Xg 4-CH3-C6H4 4-F - 11 13 15 18 - 09 11 14 19 
Xh 4-CH3-C6H4 4-Cl - 10 14 17 20 - 10 13 14 18 
Xi 4-CH3-C6H4 4-NO2 - 11 14 18 20 - 09 14 17 20 
Comparative activity of (Xa-i) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
     Xa,   Xe,   Xh,   Xi 
      Xa 
   Xa, 
  Xi 
   Xb, 
   Xd, 
  Xf 
   Xa, 
   Xg, 
  Xi 
Ampicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
 TABLE NO. 10C: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-[6-CHLORO/FLUORO/NITRO-2-(CHLORO/FLUORO/MET-
HYLPHENYL)QUINOLIN-4-YL]-1,3,4-OXADIAZOLE-2-THIOLS (Xa-j). (Different Inhibition Concentration in µg/ml). 
Antibacterial activity (Zones of inhibition in m.m.) 
E.coli MTCC-443 P.aeruginosa MTCC-424 Com.  No. R R
1 
5 25 50 100 250 5 25 50 100 250 
Xa 4-Cl-C6H4 4-F - 15 17 20 21 - 12 13 14 15 
Xb 4-Cl-C6H4 4-Cl - 12 13 17 19 - 13 15 18 19 
Xc 4-Cl-C6H4 4-NO2 - 14 16 17 21 - 10 12 13 15 
Xd 4-F-C6H4 4-F - 11 12 15 21 - 10 13 15 17 
Xe 4-F-C6H4 4-Cl - 12 15 19 21 - 12 14 16 19 
Xf 4-F-C6H4 4-NO2 - 14 16 17 18 - 11 15 16 18 
Xg 4-CH3-C6H4 4-F - 12 13 15 17 - 12 14 16 18 
Xh 4-CH3-C6H4 4-Cl - 15 17 18 20 - 11 14 16 19 
Xi 4-CH3-C6H4 4-NO2 - 15 17 19 22 - 10 12 16 17 
Comparative activity of (Xa-i) with known chosen standard drugs 
Standard drug                              Antibacterial activity 
  
Xa, 
Xh, 
Xi 
 
Xa, 
Xc, 
Xf, 
Xh, 
Xi 
Xa, 
Xe, 
Xi 
Xa, 
Xc, 
Xd, 
Xe, 
Xh, 
Xi 
  Xb, Xf 
Xb  
Ampicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
 TABLE NO. 10D: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 5-(6-HALO/NITRO-2-SUBSTITUTEDPHENYLQUINOLIN-4- 
YL)-1,3,4-OXADIAZOLE-2-THIOLS (Xa-j). (Different Inhibition Concentration in µg/ml). 
Antifungal activity (Zones of inhibition in m.m.) 
A.niger MTCC-282 A.clavatus MTCC-1323 Com.  No. R R
1 
5 25 50 100 250 5 25 50 100 250 
Xa 4-Cl-C6H4 4-F - 19 21 24 25 - 19 21 22 24 
Xb 4-Cl-C6H4 4-Cl - 18 20 23 24 - 18 20 22 23 
Xc 4-Cl-C6H4 4-NO2 - 20 22 23 25 - 18 19 22 24 
Xd 4-F-C6H4 4-F - 16 17 20 23 - 10 20 21 24 
Xe 4-F-C6H4 4-Cl - 18 19 22 25 - 18 20 22 24 
Xf 4-F-C6H4 4-NO2 - 17 19 22 24 - 21 22 23 25 
Xg 4-CH3-C6H4 4-F - 19 22 23 24 - 21 22 23 25 
Xh 4-CH3-C6H4 4-Cl - 18 21 22 24 - 19 20 22 24 
Xi 4-CH3-C6H4 4-NO2 - 19 20 21 23 - 18 18 21 22 
Comparative activity of (Xa-i) with known chosen standard drugs 
Standard drug                             Antifungal activity 
  
Xa, 
Xc, 
Xg, 
   Xi 
    Xf, Xg 
Xf, 
Xg 
Xa, 
Xb, 
Xc, 
Xe, 
Xf, 
Xg, 
Xh, 
 
Xa, 
Xc, 
Xd, 
Xe, 
Xf, 
Xg, 
Xh, 
 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
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SECTION-V 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 4-AMINO-5-[6-
CHLORO/FLUORO/NITRO-2-(p-CHLORO/FLUORO/METHYLPHENYL)-QU-
INOLIN-4-YL]-4H-1,2,4-TRIAZOLE-3-THIOLS. 
 
Keeping in view of wide spectrum biodynamic activities173-224 of 
Quinolines and with a view to have potent therapeutic agents, the synthesis 
of 4-Amino-5-[6-chloro/fluoro/nitro-2-(p-chloro/fluoro/methylphenyl)-qui-
nolin-4-yl]-4H-1,2,4-triazole-3-thiols have been synthesized by the 
cyclocondensation of 6-chloro/fluoro/nitro-2-(p-chloro/fluoro/methylphen-
yl)quinoline-4-carbohydrazides, carbon disulphide and potassium hydro-
xide followed by the action of hydrazine hydrate. 
N N
N
N
SH
R1
NH2
R
 
    (XIa-i) 
                                R, R1 = Substituted Phenyl 
 
The constitutions of the products (XIa-i) have been delineated by 
elemental analyses, IR, PMR and Mass spectral data. The products (XIa-i) 
were assayed for their in vitro biological assay. 
 
The products (XIa-i) were assayed for their in vitro biological assay like 
antibacterial activity towards S. pyogens MTCC-442, S. aureus MTCC-96 
(Gram positive) and E. coli MTCC- 443 , P. aeruginosa MTCC-424 (Gram 
negative) bacterial strain and antifungal activity towards A. niger MTCC-282 
and A. clavatus  MTCC-1323 at different concentrations: i.e. 0 (control), 5, 
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25, 50, 100, 250 (μg/ml) for their MIC (Minimum Inhibitory Concentration) 
values. The biological activities of the synthesized compounds (IVa-i) were 
compared with standard drugs viz., Ampicilline, Chloramphenicol, 
Ciprofloxacin, Norfloxacin, Griseofulvin and Nystatin. 
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REACTION SCHEME 
 
 
 
 
 
 
 
 
 
 
                                                              
R, R1 = Subtituted Phenyl
R1
R
CONHNH2
N
N N
N
N
SH
R1
NH2
R
(1) KOH, CS2
(2) NH2 - NH2 2H20
(10a-i)
(XIa-j)
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EXPERIMENTAL 
 
PREPARATION AND BIOLOGICAL EVALUATION OF 4-AMINO-5-[6-
CHLORO/FLUORO/NITRO-2-(p-SUBSTITUTEDPHENYL)-QUINOLIN-4-YL]-
4H-1,2,4-TRIAZ-OLE-3-THIOLS. 
 
(A) Preparation of 6-Fluoro-2-(p-fulorophenyl)-quinoline-4-carboxylic 
acid.  
For preparation, refer Part-II, Section-I, Page No. 143. 
 
(B) Preparation of 6-Fluoro-2-(p-fluorophenyl)-quinoline-4-carbohyd-
razide. 
For preparation, refer Part-II Section-IV, Page No. 181. 
 
(C)  Preparation of 5-[6-Fluoro-2-(p-fluorophenyl)-quinolin-4-yl]-1,3,4- 
oxadiazole-2-thiol (Xa). 
For preparation, refer Part-II Section-IV, Page No. 182. 
 
(D) Preparation of 4-Amino-5-[6-fluoro-2-(p-fluorophenyl)-quinolin-4-
yl]-4H-1,2,4-triazole-3-thiol (XId). 
   
  A mixture of 5-[6-Fluoro-2-(p-fluoropheny)-quinolin-4-yl]-
1,3,4-oxadizole-2-thiol (Xd) (3.41 gm, 0.01M) in hydrazine hydrate 80% 
(10ml) was heated under reflux for 8 hrs.The reaction mixture was allowed  to 
cool at room temperature.The reaction mixture was poured on to crushed ice. 
The reaction mixture was neutralized with gl. acetic acid. The reaction mixture 
was filtered, washed with water and recrystallized from ethanol. Yield: 55%, 
M.P.:2450C, (Required: C, 57.46%; H, 3.12%; N, 19.71% for C17H11F2N5S, 
Found :C, 57.40%; H, 3.08%; N, 19.66%) 
 
TLC solvent system Rf1: Ethyl acetate: Hexane (2.5:7.5) = 0.50 
TLC solvent system Rf2: Methanol : Toluene      (1.0:9.0) = 0.42 
Section-IV                                                                Studies on Quinolines 
 
 
Department of Chemistry, Saurashtra University, Rajkot(Gujarat).  
 
 
196 
     Similarly, other compounds (XIa-i) were synthesized. The physical data are 
recorded in  Table No. 11. 
 
(E) Antimicrobial activity of 4-Amino-5-[6-chloro/fluoro/nitro-2-(p-sub-
stitutedphenyl)-quinolin-4-yl]-4H-1,2,4-triazole-3-thiols (XIa-i). 
 
 Antimicrobial activity testing was carried out as described in Part-I, 
Section-I, Page No. 40. The MIC values of test solution are recorded in 
Table 11A, 11B and 11C. 
 
Result and Discussion:- 
 
 The products (XIa-i) have been subjected to antibacterial activity 
towards S. pyogens MTCC-442, S. aureus MTCC-96 and B. subtillis MTC-
C-441 (Gram positive) and E. coli MTCC- 443 and (Gram negative) bacterial 
strain and antifungal activity towards Aspergillus niger MTCC-282 and 
Candida albicans MTCC-227 at same concentration . The results of antimicr-
obial activity have been depicted on Page No. 202-204.  
 
 
TABLE NO. 11: PHYSICAL CONSTANTS OF 4-AMINO-5-[6-CHLORO/FLUORO/NITRO-2-(p-SUBSTITUTEDPHENYL)-QUINO-
LIN-4-YL]-4H-1,2,4-TRIAZOLE-3-THIOLS (XIa-i). 
 
Rf Value %  of  Nitrogen Com. 
No. 
 
R 
 
R1 
Molecular 
Formula 
M.W. Yield 
% 
M.P. 
0C Rf1/Rf2 Calcd./Found 
XIa 4-Cl-C6H4 4-F C17H11ClFN5S 372 54 200 0.52/0.47 18.84/18.77 
XIb 4-Cl-C6H4 4-Cl C17H11Cl2N5S 388 56 185 0.48/0.46 18.04/18.00 
XIc 4-Cl-C6H4 4-NO2 C17H11ClN6O2S 399 60 177 0.51/0.46 21.07/21.02 
XId 4-F-C6H4 4-F C17H11F5N5S 355 55 245 0.50/0.42 19.71/19.66 
XIe 4-F-C6H4 4-Cl C17H11ClFN5S 372 48 285 0.56/0.49 18.84/18.78 
XIf 4-F-C6H4 4-NO2 C17H11FN6O2S 382 45 237 0.54/0.48 21.98/21.92 
XIg 4-CH3-C6H4 4-F C18H14FN5S 351 58 58 0.47/0.44 19.93/19.88 
XIh 4-CH3-C6H4 4-Cl C18H14ClN5S 354 52 52 0.46/0.44 19.04/18.98 
XIi 4-CH3-C6H4 4-NO2 C18H14N6O2S 347 49 49 0.57/0.49 22.41/22.36 
 
   TLC solvent system Rf1: Ethyl acetate: Hexane  
   TLC solvent system Rf2: Methanol : Toluene                              
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IR SPECTRAL STUDY OF 4-AMINO-5-[6-FLUORO-2-(p-FLUOROPH-
ENYL)-QUINOLIN-4-YL]-4H-1,2,4-TRIAZOLE-3-THIOL (XId). 
 
 
Frequency in cm-1 Type Vibration mode 
observed Reported 
Reference 
Alkane 
(methyl and 
methylene) 
 
 
 
Aromatic and  
ring skeleton 
vibration 
 
 
Quinoline 
and triazole  
moiety 
 
 
 
Halogen  
Substitution 
 
C-H(asym., str., m s) 
C-H (sym. str., m) 
C-H (asym. def., m) 
C-H (sym. def., m) 
 
 
C-H (str., v) 
C=C & C-C (str., v) 
C-H (i.p. def., m) 
C-H (o.o.p. def., m) 
 
C-N (str., v) 
C=N (str., v) 
N-N (def., v) 
C-S (str., m) 
 
 
C-F (str., b) 
2956.97 
2843.17 
1423.51 
1338.64 
 
 
3058.06 
1538.28 
1022.40 
778.01 
 
1308.75 
1672.34 
1220.07 
628.81 
 
 
1388.79 
2950-2875 
2900-2800 
1460-1400 
1385-1300 
 
 
3080-3010 
1600-1450 
1150-1050 
 825-800 
 
1340-1250 
1690-1650 
1220-1020 
700-650 
 
 
1400-1080 
235 
235 
235 
235 
 
 
236 
236 
236 
236 
       
236 
236 
236 
236 
       
 
237 
 
N N
N
N
SH
F
NH2
FXId
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NMR SPECTRAL STUDY OF 4-AMINO-5-[6-FLUORO-2-(p-FLUOROPHEN-
YL)-QUINOLIN-4-YL]-4H-1,2,4-TRIAZOLE-3-THIOL (XId). 
 
 
 
Signal No. Signal Position 
(δ ppm) 
 
Relative No. 
of Protons 
Multiplicity Inference 
1. 2.0462 2H singlet -NH2(a) 
2. 3.0508 1H singlet -SH(b) 
3. 7.4198-7.4345 2H doublet -Ar-H(c) 
4. 7.5365-7.6528 2H multiplet -Ar-H(d,e) 
5. 7.9687-7.9844 1H singlet -Ar-H(f) 
6. 8.1456-8.2743 3H multiplet -Ar-H(g,h,i) 
(XId)
(XId)
 
MASS SPECTRAL STUDY OF 4-AMINO-5-[6-FLUORO-(4-FLUOROPHENYL)QUINOLIN-4-YL]-4H-1,2,4-TRIAZOLE-3-THIOL 
(XId). 
 
N N
N
N
SH
F
NH2
F
(XId)
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N N
N
N
SH
NH2
F
F
N N
N
N
SH
NH2
F
N N
N
N
NH2
F
F
N NH
N
N
F
F
N N
N
N
SH
NH2
F
F
NH NH2
N
F
m/z = 355 m/z = 337
N NH
N
N
SH
m/z = 228 (M+1)
m/z = 323
N N
N
N
NH2
Fm/z = 257
N NH2
NH2
N
m/z = 212
m/z = 308
m/z = 265 (M-1)
NH NH2
N
F
m/z = 189 (M+1)
N
CH3
CH2
m/z = 119 (M+1)
CH3
N
m/z = 143 (M+1)
m/z = 355
XId
TABLE NO. 11A: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 4-AMINO-5-[6-CHLORO/FLUORO/NITRO-2-(p-CHLORO/-
FLUORO/METHYLPHENYL)QUINOLIN-4-YL]-4H-1,2,4-TRIAZOLE-3-THIOLS (XIa-i).                                                           
(Different Inhibition Concentration in µg/ml). 
 
 
Antibacterial activity (Zones of inhibition in m.m.) 
S.pyogens MTCC-442 S.aureus MTCC-96 Com.  No. R R
1 
5 25 50 100 250 5 25 50 100 250 
XIa 4-Cl-C6H4 4-F - 10 13 15 17 - 09 11 15 18 
XIb 4-Cl-C6H4 4-Cl - 11 13 14 17 - 12 14 16 17 
XIc 4-Cl-C6H4 4-NO2 - 12 13 15 18 - 11 14 15 18 
XId 4-F-C6H4 4-F - 12 13 14 17 - 10 13 15 17 
XIe 4-F-C6H4 4-Cl - 10 12 13 18 - 10 12 14 16 
XIf 4-F-C6H4 4-NO2 - 12 14 15 18 - 09 13 14 16 
Xg 4-CH3-C6H4 4-F - 10 12 15 17 - 13 12 15 17 
XIh 4-CH3-C6H4 4-Cl - 11 15 16 19 - 13 14 16 18 
XIi 4-CH3-C6H4 4-NO2 - 13 14 15 18 - 12 13 15 18 
Comparative activity of (XIa-i) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
          XIh     
     XIg, 
     XIh 
   XIb, 
  XIc, 
 XId 
   XIb, 
  XIh 
   XIa, 
   XIc, 
  XIh, 
XIi 
Ampicilline 11 14 16 18 19 10 13 14 16 18 
Chloramphenicol 10 13 19 20 20 12 14 19 20 21 
Ciprofloxacin 16 19 21 21 22 17 19 21 22 21 
Norfloxacin 18 19 20 21 21 19 22 25 26 28 
 
TABLE NO. 11B: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 4-AMINO-5-[6-CHLORO/FLUORO/NITRO-2-(p-CHLORO/-
FLUORO/METHYLPHENYL)QUINOLIN-4-YL]-4H-1,2,4-TRIAZOLE-3-THIOLS (XIa-i).                                                           
(Different Inhibition Concentration in µg/ml). 
  
 
Antibacterial activity (Zones of inhibition in m.m.) 
E.coli MTCC-443 P.aeruginosa MTCC-424 Com.  No. R R
1 
5 25 50 100 250 5 25 50 100 250 
XIa 4-Cl-C6H4 4-F - 12 14 16 17 - 13 14 16 19 
XIb 4-Cl-C6H4 4-Cl - 14 15 15 16 - 12 13 15 19 
XIc 4-Cl-C6H4 4-NO2 - 13 15 16 19 - 13 14 15 17 
XId 4-F-C6H4 4-F - 11 12 16 18 - 12 14 16 19 
XIe 4-F-C6H4 4-Cl - 12 14 17 19 - 10 12 13 16 
XIf 4-F-C6H4 4-NO2 - 10 14 15 16 - 12 15 16 17 
XIg 4-CH3-C6H4 4-F - 12 13 15 21 - 11 13 15 18 
XIh 4-CH3-C6H4 4-Cl - 12 15 18 19 - 10 12 13 15 
XIi 4-CH3-C6H4 4-NO2 - 10 13 15 19 - 13 14 15 19 
Comparative activity of (XIa-i) with known chosen standard drugs 
Standard drug                             Antibacterial activity 
      
 
XIg 
 
       XIf   
Ampicilline 14 15 16 19 20 14 15 15 18 20 
Chloramphenicol 14 17 23 23 23 14 17 18 19 21 
Ciprofloxacin 20 23 28 28 28 20 23 24 26 27 
Norfloxacin 22 25 26 27 29 18 19 21 23 23 
 
 
TABLE NO. 11C: COMPARITIVE ANTIMICROBIAL ACTIVITY OF 4-AMINO-5-[6-CHLORO/FLUORO/NITRO-2-(p-CHLORO/-
FLUORO/METHYLPHENYL)-QUINOLIN-4-YL]-4H-1,2,4-TRIAZOLE-3-THIOLS (XIa-i).  
(Different Inhibition Concentration in µg/ml). 
 
Antifungal activity (Zones of inhibition in m.m.) 
A.niger MTCC-282 A.clavatus MTCC-1323 Com.  No. R R
1 
5 25 50 100 250 5 25 50 100 250 
XIa 4-Cl-C6H4 4-F - 19 20 22 25 - 18 18 19 22 
XIb 4-Cl-C6H4 4-Cl - 18 20 22 23 - 18 19 21 22 
XIc 4-Cl-C6H4 4-NO2 - 18 20 21 23 - 18 20 21 23 
XId 4-F-C6H4 4-F - 18 20 22 23 - 15 17 18 21 
XIe 4-F-C6H4 4-Cl - 18 19 22 24 - 18 19 20 23 
XIf 4-F-C6H4 4-NO2 - 20 22 23 25 - 21 22 24 26 
XIg 4-CH3-C6H4 4-F - 19 20 21 24 - 21 21 23 24 
XIh 4-CH3-C6H4 4-Cl - 18 21 22 24 - 18 18 21 22 
XIi 4-CH3-C6H4 4-NO2 - 18 19 21 24 - 15 17 18 20 
Comparative activity of (XIa-i) with known chosen standard drugs 
Standard drug                             Antifungal activity 
  
XIa, 
XIf, 
XIg, 
 
    XIf, XIg 
XIf, 
 
 
XIf, 
XIg, 
 
 
XIf, 
XIg, 
 
Griseofulvin 19 23 25 25 28 18 21 22 22 24 
Nystatin 18 19 24 29 29 18 21 24 25 26 
 

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